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ABSTRACT 
 
PERFORMANCE-BASED QUALITY SPECIFICATIONS: THE LINK BETWEEN 
PRODUCT DEVELOPMENT AND CLINICAL OUTCOMES 
 
 
 
By 
Steven M. Short 
December 2009 
 
Dissertation supervised by Carl A. Anderson, Ph.D.  
The design of drug delivery systems and their corresponding dosing guidelines 
are critical product development functions supported by clinical pharmacokinetic (PK) 
and pharmacodynamic (PD) data.  Largely, the importance of variance and covariance in 
product and patient attributes is poorly understood.  The existence of PK/PD diversity 
among myriad patient sub-populations further complicates efforts to gauge the 
importance of product quality variation.  Nevertheless, a platform capable of evaluating 
the effects of product and patient variability on clinical performance was constructed.  
This dissertation was predicated on requests to re-define pharmaceutical quality in terms 
of risk by relating clinical attributes to production characteristics.    
To avoid in vivo studies, simulated experimental trials were conducted using the 
model drug, theophylline, for which data and models could be acquired from the 
 v
literature.  Where comprehensive data were unavailable (e.g., production variability 
statistics), initial estimates were acquired via laboratory-scale experiments.  Model 
asthmatic patients were generated using Monte Carlo simulation and published 
population distributions of various anothropometric measurements, disease rates, and 
lifestyle factors.  
Mathematical constructs for in vitro-in vivo correlations provide a linkage 
between Quality by Design (QbD) product and process models, PK/PD models, and 
patient population statistics.  The combined models formed the foundation for Monte 
Carlo risk assessments, which characterized the risk of inefficacy and toxicity for dosing 
of extended-release theophylline tablets.  Sensitivity analyses revealed that patient 
compliance and content uniformity significantly influenced the probability of observing 
an adverse event.   
The Monte Carlo risk assessment platform defined the link between the critical 
quality attributes (CQAs) and clinical performance (i.e., performance-based quality 
specifications (PBQS)).  The PBQS were subsequently utilized to generate process 
independent design spaces conditioned on inefficacy and toxicity risk.  These design 
spaces, which directly account for the conditional relationships between product quality 
and patient variability, can be transferred to a specific process via models that relate 
process critical control parameters to the CQAs.  Process Analytical Technology, 
therefore, can be integrated into the QbD production environment to control the safety 
and efficacy of the final product.  This work demonstrated that process and product 
knowledge can be used to estimate the risk that final product quality imparts to clinical 
performance. 
 vi
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Chapter 1: Introduction 
 
1.1 Statement of the Problem 
“Personal” computers that were once so massive they occupied more space than a 
small house have now been reduced to roughly the dimensions of a sheet of letter paper, 
yet they are orders of magnitude more powerful, not to mention less expensive, than their 
predecessors.  Automobiles, which were once so costly they were a luxury to the most 
affluent of individuals, have since been mass-produced at reasonable prices with 
increased reliability and operational efficiency, revolutionizing the means by which 
practically all people commute.  These are simple and obvious examples of the myriad 
unfathomable achievements that rest in the chronicles of history.    
 Numerous industrial sectors boast of extraordinary long-term progress regarding 
their innovative products and technological developments.  The pharmaceutical industry, 
however, might not be able to do so.  Granted, pioneering products such as osmotic 
tablets, drug eluting stents, and targeted gene delivery devices have all been developed 
near the turn of the century.  Novel goods, however, are not the exclusive gauge of 
advancement.  By and large, the pharmaceutical industry lags well behind other 
manufacturing sectors in terms of “quality.”  A study published in 2007 based on 
available benchmarks reported that pharmaceutical manufacturers operate on a level of 
approximately 35,000 defective units per 1,000,000 produced,1 which is intolerable 
considering that other sectors have already achieved Six Sigma production (i.e., 3.4 
defects for every 1,000,000 units); this is likely a function of the specifications more so 
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than the product.  Moreover, disastrous clinical outcomes, perhaps best epitomized by the 
tragic Vioxx incident, further dilute the universal standard of quality associated with the 
pharmaceutical industry. 
 The Food and Drug Administration (FDA) has candidly acknowledged the lack of 
innovation that has impeded the growth of the pharmaceutical industry.  Accepting partial 
responsibility for the current state, the FDA released a number of reports, initiatives, and 
guidances in the past decade to transform regulatory oversight and outwardly encourage 
reform, innovation, and low-risk, affordable medical products.  The modified regulatory 
architecture is risk-based; the degree of regulatory scrutiny is commensurate to the risk a 
particular product imparts to the public.  Companies that are able to adequately 
demonstrate the safety and efficacy of their products using risk- and science-based 
approaches will, therefore, be granted more regulatory flexibility.  
 In certain industries, faulty merchandise can result in mere inconvenience and 
frustration for the consumer.  Defective (i.e., substandard quality) pharmaceutical 
products, however, may be ineffective or toxic, either of which can have grave 
consequences.  The quality of medical products is typically assessed by a series of tests 
that characterize the products as acceptable or unacceptable.  Acceptability is gauged via 
lower and/or upper specification limits, thresholds set with respect to a target value, 
which are to be derived based on product safety and efficacy.  Product that is within the 
range defined by the specification(s) is deemed acceptable.  Despite all of the collective 
efforts to ensure low-risk medical products, quality in the pharmaceutical industry is 
currently evaluated in such a way that the relationship between product specifications and 
clinical performance is implicit at best.     
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Numerous controllable and uncontrollable factors affect the safety and efficacy of 
pharmaceutical products.  Pharmaceutical production involves the integration of several 
unit operations, each of which functions via a number of confounding 
parameters/variables that, if not controlled, have the potential to negatively influence 
product quality.  Manufacturing requires a thorough understanding of these 
parameters/variables, and an appreciation for their interaction.  Human variability also 
complicates safety and efficacy.  Not all humans respond identically to the same drug 
administered at an equivalent dose; numerous physiologic and pathophysiologic variables 
affect clinical performance.  Thus, these patient-specific factors also must be indentified 
and accounted for.   
Recognizing the potential severity of defective pharmaceutical products, a lack of 
understanding is typically addressed by increasing the strictness of the specification; in 
other words, the range that defines product acceptability is reduced in an attempt to 
mitigate the likelihood of an adverse event.  This, however, is often counterproductive.  
First, if the specifications are not explicitly derived in relation to the product’s safety and 
efficacy, they may be too strict.  Excessive thresholds carry the risk of not approving a 
product based on the misunderstanding the process and/or product.  Contrary, overly 
stringent specifications may result in wasted resources allocated to improve the precision 
of the manufacturing process, which unnecessarily inflates the price of the final product.  
Worse yet, the adjustments may be too lenient, especially for certain high-risk 
subpopulations that were not identified or adequately evaluated during clinical testing.  
This may be caught by the company during post-marketing surveillance, or may be 
revealed through a high-profile incident, such as a death attributed to the drug.  The 
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former would most likely mean costly re-evaluations of the dosing guidelines, the 
manufacturing process, and/or the product itself, which may even need to be temporarily 
pulled from the market.  The latter, however, would almost inevitably result in immediate 
cessation of production and sale imposed by a regulatory consent decree, and potentially 
severe legal ramifications.   
 It is evident that inaccurate or unsubstantiated specifications contradict efforts to 
provide high-quality (i.e., low-risk), affordable medical products.  The FDA, the 
pharmaceutical industry, and the general public unanimously desire safe and efficacious 
medical products.  Given that quality has not been explicitly assessed in terms of clinical 
performance, the current perception of pharmaceutical quality may very well be 
inaccurate, in part, due to the way in which quality is defined and the lack of 
understanding regarding material and process variability.  Inconsistent definitions and 
uninformative appraisals of pharmaceutical quality have initiated requests to standardize 
its definition in terms of risk to safety and efficacy.  This work demonstrates how 
pharmaceutical process and product understanding can be used to supervise 
manufacturing based on the quantifiable risk that final product quality attributes impart to 
clinical performance.   
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1.2 Hypothesis and Objectives 
This dissertation is based on the central hypothesis that pharmaceutical process 
and product understanding can be simultaneously utilized to model the risk that final 
product quality imparts to clinical performance. 
Given the central hypothesis, the objectives of this dissertation were to: 
1. Combine patient-specific factors with a pharmacokinetic model and an in vitro-in 
vivo correlation model to simulate drug plasma concentration profiles, which will 
be used in combination with a pharmacodynamic model to estimate patient risk in 
terms of inefficacy and toxicity.   
2. Utilize Monte Carlo simulation and probabilistic risk assessment modeling to 
estimate the impact that changes in pharmaceutical manufacturing variability 
impart to patients. 
3. Demonstrate how the risk simulation platform can be used to determine the 
conditional risk of product variation on clinical performance for a model solid 
oral dosage system. 
4. Generate design spaces that are conditioned on quantitative estimations of 
inefficacy and toxicity risk. 
Further, the methodologies developed in this work were used as the basis to propose a 
hypothetical scenario that couples Process Analytical Technology with Quality by Design 
such that production can be maintained in a low-risk state. 
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1.3 Literature Survey 
1.3.1 The Pharmaceutical Quality Revolution 
W. Edwards Deming, one of the forefathers of the quality revolution, once said 
that quality “… means a predictable degree of uniformity (variation) and dependability at 
low cost suited to the market.”2  Quality is unquestionably a cornerstone tenet that 
influences commerce, but what exactly is “quality” and more specifically, what does it 
mean to the pharmaceutical industry?  The International Conference on Harmonisation 
(ICH), an organization that seeks to unify the regulatory bodies of Europe, Japan, and the 
United States and their respective pharmaceutical experts in an effort to register 
pharmaceuticals for human use, has posited several definitions during the past decade.  
The ICH Harmonised Tripartite Guideline Q6A defines quality as “the suitability of 
either a drug substance or drug product for its intended use.  This term includes such 
attributes as the identity, strength, and purity.”3  The ICH Harmonised Tripartite 
Guideline Q9 offers an alternative definition: “the degree to which a set of inherent 
properties of a product, system, or process fulfills requirements.”4 
Although a standardized definition of “pharmaceutical quality” has yet to be 
acknowledged, its significance (or the lack thereof) has.  The general public is ultimately 
the customer of pharmaceutical goods (and, therefore, the ones who dictate the level of 
acceptable quality).  It is often assumed, however, that they are unable to adequately 
appraise these products.  Therefore, regulatory authorities have absorbed this function so 
that patients need not be concerned about the medications they consume.  The FDA has 
acknowledged that maintaining a scientific framework that ensures quality (low-risk), 
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innovative, pharmaceutical products is a primary public health objective.  The Agency’s 
ultimate mission (as it relates to the pharmaceutical industry) is to guarantee that the 
products available in the United States are consistently high in quality.5  
It is well understood that “quality cannot be tested into products; it should be 
built-in or should be by design.”6  As a result, numerous regulatory initiatives, reports, 
and guidances have been introduced in the past several decades to recommend (both 
binding and non-binding) procedures and precautions to help ensure quality.  In 1978, the 
FDA published 21 Code of Federal Regulations (CFR), Parts 210 and 211, which outline 
the minimum current good manufacturing practice (CGMP) methods as well as the 
facilities and controls to be implemented for the manufacturing, processing, packaging, 
and/or holding of pharmaceutical products.7  Segments of Parts 210 and 211 have since 
been revised.  Although the CGMP regulations predate ICH Q6A, the underlying 
objective is to guarantee that the final products adhere to the standards of quality set forth 
by the ICH document.  The regulations do not, however, define quality, nor do they 
adequately detail how to achieve quality during development and production.7  
The CGMPs for the 21st Century initiative was launched by the FDA in August of 
2002 to “modernize” the Agency’s role in overseeing pharmaceutical manufacturing and 
product quality.  In addition to underscoring its regulatory responsibility, the initiative 
implicitly stresses the obligatory role of all vested parties to supply quality medical 
products.  To accomplish this, the existing CGMP programs were scrutinized to help 
assemble the regulatory architecture for overseeing manufacturing quality, which 
includes the concepts of risk management and quality systems.  This clearly marked the 
beginnings of a risk-based inspection and enforcement program where regulatory 
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resources were employed in a manner commensurate with the threat to public safety.  
Eventually, the final report entitled Pharmaceutical CGMPs for the 21st Century – A 
Risk-Based Approach was released in 2004 to connect the CFR regulations and the 
Agency’s existing views regarding quality systems.5  
A formal guidance for quality systems, The Quality Systems Approach to 
Pharmaceutical CGMP Regulations, was released in 2006.8  This document introduces 
the quality system as it relates to the pharmaceutical industry, which is a strategic 
business plan that formalizes corporate functions to attain product/service (quality) 
requirements, customer approval, and continuous improvement to ultimately achieve “ … 
the public and private sectors’ mutual goal of providing high-quality drug product to 
patients and prescribers.”  Designed appropriately, a quality system mitigates the risk of 
inferior (i.e., recalled, returned, salvaged, defective) products reaching the general public.  
Consequently, it has the potential to alleviate regulatory oversight considering that the 
robustness of the system is used as a criterion for determining the necessary extent of 
supervision.5  The quality system is also advantageous in that it establishes the foundation 
for implementation of key developmental activities such as Quality by Design (QbD), 
continual improvement, and risk management.8  
Backtracking in time, the FDA introduced several influential reports/guidances 
during the 2004 calendar year.  The first of these was the Critical Path Initiative (via 
Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical 
Products), which intends to expedite the development (i.e., time-to-market) of novel, 
safe, and effective medical products.9  This is to be accomplished, in part, by taking a 
different approach to product development, which includes the use of innovative 
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techniques (e.g., computer models) to investigate the manufacturability, safety, and 
efficacy of candidate molecules and/or drug products.   
The advent of comparability protocols is also integral to the objectives of the 
Critical Path Initiative.  Comparability protocols were established via the Comparability 
Protocols Protein Drug Products and Biological Products – Chemistry, Manufacturing, 
and Controls Information draft guidance in September of 2003.10  A comparability 
protocol “is a comprehensive, detailed, written plan that describes the specific tests and 
studies, analytical procedures, and acceptance criteria to be achieved to demonstrate the 
lack of adverse effect for a specified type of CMC [chemistry, manufacturing, and 
controls] change that may relate to the safety or effectiveness of a drug product.”5  
Hence, a manufacturer can meet the criteria for a more lenient reporting category 
provided that they sufficiently demonstrate how the amendment will alter product quality 
(and, therefore, the risk to public health).  This is accomplished by exhibiting a thorough 
understanding of the drug, its manufacturing methods and controls, and the effects that 
the projected change(s) will have on clinical performance.  In certain scenarios, the 
change may actually be implemented prior to receiving regulatory approval, potentially 
decreasing the time-to-market.10 
September of 2004 brought the release of two documents that are central to the 
pharmaceutical quality revolution, the Pharmaceutical CGMPs for the 21st Century – A 
Risk-Based Approach5 and the Process Analytical Technology (PAT) guidance.6  The 
CGMPs for the 21st century was previously addressed as it relates to the CFR regulations.  
This report is also significant in that it helped launch the QbD Initiative to encourage 
sound development of (quality) pharmaceutical products.5  The QbD architecture 
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encompasses “designing and developing a product and associated manufacturing process 
that will be used during product development to ensure that the product consistently 
attains a predefined quality at the end of the manufacturing process.”8  Subsequently, the 
FDA advocated that “under the QbD paradigm, quality is built into the final product by 
understanding and controlling formulation and manufacturing variables: testing is used to 
confirm the quality of the product.”11  The ICH has also weighed in on QbD, describing it 
as “a systematic approach to development that begins with predefined objectives and 
emphasizes product and process understanding and process control, based on sound 
science and quality risk management.”12  Comprised of several factors including 
identification of critical quality attributes (CQAs), risk assessment, and continuous 
improvement,13 the most renowned component of QbD is perhaps design space.12 
The second 2004 document was the PAT guidance.6  Process Analytical 
Technology is “… a system for designing, analyzing, and controlling manufacturing 
through timely measurements (i.e., during processing) of critical quality and performance 
attributes of raw and in-process materials and processes, with the goal of ensuring final 
product quality.”  The PAT guidance details a scientific, risk-based regulatory framework 
that encourages innovative pharmaceutical development, manufacturing, and quality 
assurance through enhanced process understanding.  The intent is to instill confidence in 
those implementing novel approaches that innovation, when conducted properly, does not 
beget additional regulatory scrutiny.  In fact, manufacturing processes can be controlled 
and validated using the concepts discussed within the guidance.   
Although not a definitive indicator, validating pharmaceutical production 
processes helps to assure quality.  Given its importance, the FDA recently released a draft 
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guidance titled Process Validation: General Principles and Practices.14  Process 
validation “… is defined as the collection and evaluation of data, from the process design 
stage throughout production, which establishes scientific evidence that a process is 
capable of consistently delivering quality products.”  This assumes that (1) quality has 
been integrated into the process (recall that it cannot be tested into a product via in-
process and final-product assessments) and (2) each unit operation is under control such 
that the products adhere to all design characteristics and quality attributes, which include 
the established specifications derived from predetermined (tolerable) process average and 
dispersion estimates.7  All processes, even those founded upon risk- and science-based 
design approaches, should incorporate in-process controls to assure product quality.  
When controlled appropriately, batch-to-batch, lot-to-lot, and unit-to-unit variability is 
such that the units sampled meet or exceed the validation criteria, giving the 
manufacturer, the regulatory authorities, (and in essence, the patient) confidence that the 
distributed products accurately reflect the label claims.  Effective validation requires (1) 
an appreciation of the sources of variability, (2) detectability and sensitivity to variation, 
and  (3) the capacity to “control the variation in a manner commensurate with the risk it 
represents to the process and product.”14  With liberty, the final statement also implies 
that a certain degree of variability is tolerable; acceptability should be proportionate to 
the risk it presents to patients.  Validation also intends to confirm that the process is 
robust to factors that have the potential to stifle yield (e.g., raw material, manufacturing, 
environmental, and/or analytical method variability).  Reductions in market supply 
clearly hurt the manufacturer, but more importantly, they impact the public well-being. 
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Continuous improvement is an underlying theme in each of the aforementioned 
documents and is critical to enhancing quality.  Although the theory of continuous 
improvement is tacit within regulatory guidances, its premise is obvious.  Continuous 
improvement involves the ongoing effort to enhance the efficiency and effectiveness of 
services or manufactured goods, and, therefore, broadly encompasses efforts that 
facilitate understanding, innovation, and the availability of affordable, quality drug 
therapies.  Philosophies and initiatives such as Total Quality Management, Lean 
(Manufacturing), and Six Sigma are integral components of continuous improvement and 
should not be overlooked within the context of pharmaceutical quality (www.asq.org).  
The ultimate goal of continuous improvement is zero-defect production, where all units 
(drug products) conform to the utmost level of quality.   
1.3.1.1 A Specification-Based World 
ICH Q9 states that the “manufacturing and use of a drug product, including its 
components, necessarily entail some degree of risk.”4  It is understood that a certain level 
of variability is inherent to production.  Moreover, the potential sources of variability are 
extensive, which increases the complexity of manufacturing.  Variability, in turn, imparts 
risk to those who manufacture, regulate, prescribe, or consume medical products.  It is 
therefore necessary to account for its influence.  Variability (in essence, quality) is 
commonly evaluated via in-process and end-product tests (e.g., blend uniformity and 
content uniformity analyses, dissolution testing), which are centered on predetermined 
specifications.  A specification is “a list of tests, references to analytical procedures, and 
appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for 
the tests described.”3   
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Despite the importance of specifications, there is little guidance available 
detailing how they are to be determined.  Specifications: Test Procedures and Acceptance 
Criteria for New Drug Substances and New Drug Products: Chemical Substances Q6A3 
and Specifications: Test Procedures and Acceptance Criteria for 
Biotechnological/Biological Products Q6B15 are arguably the foremost documents on 
establishing specifications for the endorsement of non-registered new chemical and 
biological drug products, respectively; specifications for delivery systems that utilize 
well-documented active pharmaceutical ingredients (APIs) are often outlined in 
pharmacopoeias, such as the United States Pharmacopeia-National Formulary (USP-NF) 
monographs.  Within ICH Q6A and Q6B guidelines, specifications are cast as an integral 
component in the overall control strategy of ensuring the consistency and quality of drug 
products; the control strategy includes (but is not limited to) validated manufacturing 
processes and test procedures, good manufacturing practices (GMPs), and raw-material, 
in-process, and stability testing.  ICH Q6A states that the thorough understanding 
acquired during product characterization should be used to establish specifications.  
Guidances only imply that specifications should be derived with careful consideration of 
process critical control parameters (PCCPs) and product CQAs.  Critical quality 
attributes are the physical, chemical, biological, or microbiological properties or 
characteristics that are known to affect product quality whereas process critical control 
parameters are the process variables that affect product CQAs.  As such, PCCPs and 
CQAs should be identified during product development and, subsequently, should be 
controlled within tolerable operational and performance limits using data obtained during 
clinical and toxicological studies. 
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Acceptance criteria for new drug products are typically proposed, with 
accompanying rationalization, by the manufacturer and are approved by the regulatory 
agencies.  They are implemented not to fully characterize a product, but to substantiate its 
quality.  It is important to underscore, however, that testing via well-designed 
specifications is not the entirety of quality assurance.  As stated in ICH Q6A, “the quality 
of drug substances and drug products is determined by their design, development, in-
process controls, GMP controls, and process validation, and by specifications applied to 
them throughout development and manufacture.”3  
Needless to say, specifications serve as surrogates for quality within the current 
paradigm.  All marketed drug products, via representative sampling, have, therefore, 
conformed to the established specifications, providing assurance to the patients that they 
are receiving safe and efficacious products.  That is not to say, however, that the 
practitioners and patients themselves cannot impart additional risk by, for example, 
deviating from established dosing guidelines; dynamics such as this are likely to 
exacerbate risks imparted by manufacturing.  Quality assessments that utilize numerical 
acceptance ranges dichotomize quality as either acceptable or unacceptable; only samples 
that fall within the upper and lower specification limits are deemed fit-for-use.  At best, 
all marketed units of a given product are then, by default, categorized as low-risk or 
quality outputs.  This message is rather misleading given that risk can be readily 
communicated as a continuous rather than a nominal metric.  Moreover, even when all 
other factors are equitable, risk is often disparate within patient populations, which, 
although designed not to, can provide a false sense of security to patients.   
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Although not always the case, the formulae for performance measurements and 
acceptance tests often assume that the response is symmetric with respect to the target or 
average value.  This suggests that both positive and negative deviations from the target 
carry the same intrinsic risk, which, in reality, may be incorrect.  Take, for example, 
capability, which compares process performance to established specifications.  A 
common metric for estimating capability is the process capability index (Cpk) 
 ⎥⎦
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where μ and σ are the mean and standard deviation of the process, which is assumed to be 
normally distributed, and USL and LSL are the upper and lower specification limits, 
respectively.  Cpk can take on values of (-∞, ∞) and is negative only when the process 
mean is beyond the specifications.  While certain capability metrics are meaningful only 
when the process is centered (e.g., Cp or process capability), Cpk reflects that processes 
are not always on target.  
The process capability index, which assesses the specification range in relation to 
the breadth of the process, is taken as the minimum of the two estimates; the estimates 
are equal when the process is centered.  Cpk can be enhanced by (1) reducing short-term 
variability, (2) altering the mean, or (3) relaxing the USL and LSL.  Cpk and/or process 
sigma (via the Six Sigma program) estimates are often used to convey the level of 
repeatability or quality for a production process.  Cpk and process sigma differ only by a 
factor of 3.0; hence, a Cpk of 2.0 is equivalent to a process sigma of 6.0.16  Both metrics 
have statistical interpretation in that they communicate the likelihood of observing a unit 
outside of the specification limits (sometimes referred to as the defect rate), which is 
typically expressed as defects per million observations (DPMO) or defects per billion 
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observations (DPBO).  For example, a Cpk of 2.0 (i.e., process sigma of 6.0) corresponds 
to 2.0 DPBO.  It is important to note that a process sigma of 6.0 corresponds to 3.4 
DPMO when the 1.5 σ shift is applied to account for drifts in the process mean.1  The 
corresponding DPMO or DPBO for any Cpk can be determined from a z table for the 
standard normal distribution. 
Capability, therefore, addresses the issue of how well the process is controlled 
with respect to the specifications by quantifying the measurements that are within the 
limits.  Assuming that the specifications are established to mitigate risk (and that the 
more in control a process is, the less risk it poses), Cpk and risk are inversely related.  
Quality and Cpk, however, are positively correlated.  Recognizing that the USL and LSL 
are typically set equidistant from the target value, Cpk does not take into consideration 
whether the deviation is positive or negative with respect to the mean, despite the fact 
that it can analyze non-centered processes.  Given that risk is likely asymmetric with 
respect to the process mean (e.g., positive and negative deviations from the nominal API 
level may pose different risks), Cpk can be misleading if quality is interpreted, for 
instance, in terms of clinical performance.  While this is irrelevant in certain industries, 
this is critical in regards to pharmaceutical products.     
1.3.1.2 21st Century Pharmaceutical Production 
ICH recently released the Harmonised Tripartite Guideline Q8(R1) to address the 
development of pharmaceutical products and their associated manufacturing methods.12  
One of the key objectives of Q8(R1) is to offer direction for effectively reporting process 
and product knowledge obtained through risk- and science-based design and development 
efforts to regulatory officials.  Additionally, issues that often provide evidence to 
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inspectors and reviewers that the applicants have achieved an enhanced understanding are 
highlighted.  Enhanced product and process knowledge combined with effective 
reporting methods mitigate risk to public safety, which can lead to reduced regulatory 
oversight.    
ICH Q8(R1) also supports the QbD initiative.  Not only does process and product 
design help to establish specifications and manufacturing controls, they aid in the 
construction of the design space(s).  A design space is “the multidimensional 
combination and interaction of input variables (e.g., material attributes) and process 
parameters that have been demonstrated to provide assurance of quality.”12  The design 
space(s) is included in the application package and is therefore reviewable.  Since it is 
subject to approval, only intentional deviations outside of the design space constitute a 
post-approval change; inadvertent departures are potential bases for product failure. 
Appendix 1 of ICH Q8(R1) contrasts two very different approaches to 
pharmaceutical development; the minimal (sometimes referred to as the traditional)17 and 
the QbD approach.  The two methodologies are compared side by side in Table 1.1 based 
on six different categories: overall pharmaceutical development, manufacturing process, 
process controls, product specifications, control strategy, and lifecycle management.12  At 
the one extreme, the traditional methodology underscores a rather archaic approach to 
pharmaceutical production.  This approach embraces many of the practices that helped 
spur the pharmaceutical quality revolution.  On the other hand, the QbD methodology 
employs the guiding principles of the quality revolution and serves as a step towards the 
desired state (i.e., risk- and science-based design, control strategies centered on quality, 
real-time release, risk-based regulatory architecture).  While neither methodology 
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accurately summarizes the whole of pharmaceutical production, it is a safe assumption 
that the current state is more aptly outlined by the minimal approach. 
 
Table 1.1 Comparison of the minimal and QbD methodologies for pharmaceutical development.  Amended 
from ICH Q8(R1).  
Aspect Minimal … The Current 
State? 
QbD…A Trend Towards the 
Desired State 
Overall 
Pharmaceutical 
Development 
• Empirically driven 
• Inefficient experimental 
design 
• Mechanistically and 
scientifically driven 
• Multivariate experimental 
design 
• Incorporation of PAT and 
design space 
Manufacturing 
Process 
• Fixed 
• Concerned with 
reproducibility 
• Flexible (within design 
space) 
• Concerned with robustness 
and a quality control 
strategy 
Process 
Controls 
• In-process testing only 
when necessary 
• Off-line analyses 
• PAT system 
• Feed forward and feedback 
via process and control 
models 
Product 
Specifications 
• Principle method of control 
• Derived according to batch 
data 
• Integrated component of 
quality control strategy 
• Derived according to 
desired product 
performance 
Control 
Strategy 
• In-process and final 
product testing 
• Risk- and science-based 
quality control strategy 
• Real-time release 
Lifecycle 
Management 
• Reactive; action taken 
typically only when 
problems arise 
• Post-approval change 
• Continuous improvement  
 
As pharmaceutical production progresses towards the desired state, it is apparent 
that both PAT and QbD will have, at least for the foreseeable future, a central role in 
assuring product quality.  Figure 1.1 illustrates the role of design space with regard to 
risk- and science-based pharmaceutical manufacturing.  PAT is integral to designing, 
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analyzing, and controlling processes.6  As a thorough understanding of the product and 
process is acquired through the PAT system, PCCPs and CQAs are identified.  Research 
and development efforts are essential in gaining product and process knowledge.  
Additional experimentation, however, increases the manufacture’s investment, which is 
why the direction and extent of research needs to be carefully balanced with the potential 
benefits in order to provide affordable, safe, and innovative medical products to the 
public.  Experimental design, which is a key aspect of PAT, should be utilized to obtain 
the maximum amount of information in as few trials as possible.  Experimental design 
undoubtedly extends operational ranges well past that which is implemented during 
controlled production, which enhances sensitivity to the critical parameters/attributes.  
These data are then used to construct the n-dimensional design space, which is comprised 
of inter-related PCCPs (e.g., compaction pressure) and material attributes that are known 
to affect product quality.  The perimeter of the hyperspace is established according to a 
thorough understanding of the inputs and their relationship to a given performance 
metric(s).  Efficient design and modeling not only reduce the ambiguity surrounding the 
boundaries, they increase the robustness of the design space, which minimizes the 
potential for upset (i.e., product of unacceptable quality) due to unanticipated variation.  
The critical-to-quality variables are then monitored (via sensors) and controlled (via 
process and control models) to be within the limits of the design space.  This ultimately 
ensures the desired level of product quality.  Ideally, the design space would be defined 
according to clinical risk. 
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Figure 1.1. The inter-relationship between PAT, design space, and pharmaceutical manufacturing.  Adapted 
from R.C. Lyon, Process monitoring of pilot-scale pharmaceutical blends by near-infrared chemical 
imaging and spectrosocopy, Eastern Analytical Symposium (EAS), Somerset, NJ, 2006. 
Given the overall complexity of pharmaceutical manufacturing, the number of 
material, process, and product attributes/parameters that potentially influence quality is 
sizeable.  Experimental design and risk assessment can be utilized to not only help 
identify those factors that affect product CQAs, but to rank the importance of the 
individual factors based on their significance and elucidate potential confounding 
attributes/parameters.  As development efforts progress and more data become available, 
they can be incorporated to gain additional understanding.  These data also help establish 
the processing conditions under which quality product is reliably produced.  The 
corresponding operational ranges of the PCCPs (as they relate to CQAs) can then be used 
to construct the design space. 
 As ICH Q8(R1) outlines, considerable regulatory flexibility is promised to sound 
submissions that provide justification for the inputs and process parameters that were 
included in (and excluded from) the design space.12  A number of sequential design 
spaces can be generated for each unit operation within a manufacturing process.  Figure 
1.2 was reproduced from ICH Q8(R1), Appendix 2, Example 3.12  It illustrates a design 
space for drying where the target moisture content is 1-2 %.  Assuming that there were 
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additional unit operations downstream from drying, intermediate material outside the 
design space limits would not be suitable for further processing due to excessive impurity 
formation or excessive particle attrition.  Alternatively, a single design space that bridges 
all unit operations is also acceptable.  Figure 1.3, which was reproduced from ICH 
Q8(R1), Appendix 2, Example 2,12 is an example of one such overarching design space 
that was constructed from two single attribute design spaces for friability and dissolution 
testing.  The limits are simply defined as the overlapping ranges of tolerable outputs, 
which were both dependent on the two PCCPs.  Given that both friability and dissolution 
are dependent on a number of inter-related factors, for example, the type and proportion 
of excipients, the homogeneity of the blend, the radial tensile strength of the tablets 
(which itself is dependent on a number of confounding manufacturing parameters, such 
as compaction pressure, turret speed, blending speed, blending time, charge order, 
blender volume, etc.), it is easy to conceptualize how this one design space accounts for 
numerous processing parameters and product attributes.  Regardless of whether several 
consecutive hyperspaces or one overarching hyperspace is utilized, manufacturers can 
specify if they will operate within the entire design space or within some restricted area.  
Despite the flexibility, one thing should always be consistent from design space to design 
space: operation within the limits yields quality product.12 
 22
 
Figure 1.2. Example design space illustrating the moisture content as a function of time during drying.  The 
target moisture content is 1 - 2 %.  Intermediate material outside the limits would not be suitable for further 
processing.  This figure was reproduced from ICH Harmonised Tripartite Guideline Pharmaceutical 
Development Q8(R1), November, 2008. 
 
Figure 1.3. Overarching design space determined from two inter-related design spaces.  Friability and 
dissolution were identified as the CQAs while two parameters (labeled 1 and 2) of a wet granulation unit 
operation were identified as the PCCPs (e.g., excipient particle size distribution, water content, granule 
size).  The overlapping regions of the two inter-related hyperspaces are identified here as "Design Space."  
This figure was reproduced from the ICH Harmonised Tripartite Guideline Pharmaceutical Development 
Q8(R1), November, 2008. 
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Whether or not QbD concepts are integrated, the minimum compulsory 
components to be included in pharmaceutical development are:12  
1. A quality target product profile 
2. Potential product CQAs 
3. CQAs of the API, excipients, and other integral components.  This includes 
selection of the appropriate inactive ingredients and their proportions in the final 
delivery system. 
4. A suitable manufacturing route 
5. A control strategy. 
These items are necessary to control the manufacturing process such that component and 
product CQAs are suitable to yield the desired quality target product profile (QTPP).  A 
quality target product profile is “a prospective summary of the quality characteristics of a 
drug product that ideally will be achieved to ensure the desired quality, taking into 
account safety and efficacy of the drug product.”12  As such, product design and 
development efforts are structured around the QTPP.  Overall, quality can not be assured 
when one or more of these elements are, in whole or part, absent.    
While the above strategy can be followed to assure quality, the QbD initiative 
incorporates several supplementary strategies, which help lay the foundation for 
continuous improvement over the lifetime of the product.  The QbD approach 
comprises:12 
1. Systematically assessing and improving the product and process design, which 
includes 
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a. Use of a priori knowledge, experimental design, and risk assessment to 
identify material characteristics and process parameters that are potentially 
critical-to-quality 
b. Determining, either empirically or via first principles, the mechanistic 
relationships between material characteristics and process parameters to 
product CQAs   
2. Developing a control strategy founded upon process and product knowledge and 
quality risk management techniques.  The control strategy may contain design 
space(s) and/or measures for real-time release testing.    
Unlike final product testing, which as the name implies, involves assessing the product as 
or after it leaves the production line, real-time release testing is the assessment of in-
process and/or final product quality via process data, which would consist of various 
PCCPs and CQAs.  As quality is incorporated within the design, the product and its 
intermediates are assessed in real-time (i.e., during processing) to substantiate its quality.  
Real-time release therefore becomes a surrogate for the various analytical procedures 
necessary for final product release.6 
The QTPP is clearly a crucial element in pharmaceutical development whether or 
not QbD tactics are incorporated.  As consumers are more or less incapable of assessing 
quality, the manufacturer (by defining the QTPP) and the regulatory agency (by 
approving the product and its QTPP) ultimately dictate the level of quality that is 
acceptable for patients.  The QTPP should be established according to numerous product 
and performance features, which include: 
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1. “Intended use in clinical setting, route of administration, dosage form, 
delivery systems; 
2. Dosage strength(s); 
3. Container closure system;   
4. Therapeutic moiety release or delivery and attributes affecting 
pharmacokinetic characteristics (e.g., dissolution, aerodynamic performance) 
appropriate to the drug product dosage form being developed; 
5. Drug product quality criteria (e.g., sterility, purity, stability and drug release) 
appropriate for the intended marketed product.”12 
Since the QTPP specifies the desired quality and design space has a critical role in 
assuring product quality, it stands to reason that when pharmaceutical development 
involves QbD, the limits of the design space(s) can be defined by aspects of the QTPP.  
Moreover, the most important facet of the QTPP is the safety and efficacy of the drug 
product.  Therefore, efforts should be made to construct the design space according to the 
attributes and parameters that directly affect safety and efficacy.  After all, safety and 
efficacy are truly the principal benchmarks of pharmaceutical quality. 
1.3.1.3 A New Definition of “Pharmaceutical Quality” 
Quality is equally vital to the manufacturers, regulators, and consumers of 
pharmaceutical products.  Regulatory officials, researchers, and academicians alike 
appreciate the disharmony surrounding pharmaceutical quality.  In an effort to more 
effectively communicate allowable consumer risk, in part, determined through content 
uniformity testing, Williams et al.18 suggested an alternative method where (risk) 
tolerance limits (for content uniformity) would be “based on a better understanding of 
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population and individual dose/response curves for efficacy and toxicity.”  Janet 
Woodcock, Director of the Center for Drug Evaluation and Research (CDER) at the 
FDA, pushed the envelope when she summarized several of the industry’s (quality) 
shortcomings (e.g., quality assessment via end-product testing) and thus, the underlying 
frustrations of many individuals amid the “current state.”19  At the conclusion of her 
article, Dr. Woodcock purposed re-defining pharmaceutical quality in terms of risk by 
relating clinical attributes to production characteristics.  The ideas put forth by Williams 
et al. and Woodcock are, at minimum, revolutionary as they not only present the 
opportunity to directly manage production in terms of product performance, they offer 
the impetus to reform the pharmaceutical industry.  These visions have been largely 
ignored to date. 
Cogdill and Drennen took notice when they laid the foundation for relating 
manufacturing quality and clinical performance of a drug product.20  They described the 
combination of probabilistic risk assessment (PRA) and Monte Carlo simulation (MCS) 
to relate elements such as raw material quality, product design, population statistics, 
dosing guidelines, and patient compliance estimates with pharmacokinetic (PK), 
pharmacodynamic (PD), and in vitro-in vivo correlation (IVIVC) models to remold 
quality in terms of risk.  The objective was to translate manufacturing and drug product 
attributes into estimates of risk of toxicity and inefficacy.  Given the appropriate 
modeling, the interpretability of risk can be enhanced by transforming the metric from a 
nominal (i.e., acceptable or unacceptable) or categorical (i.e., low, medium, high) to a 
continuous (probabilistic) response.  Moreover, the proposed platform departs from the 
current series of univariate measures that do not effectively account for covariance 
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among observations by harnessing multivariate data to simultaneously model the 
confounding factors that influence product performance.  The model-based platform 
could then be used, for example, to define CQA hyperspaces bounded by risk or set 
manufacturing performance targets (e.g., Cpk) based on tolerable risk.  With estimates of 
risk of toxicity and inefficacy, product and process design could then focus on 
minimizing overall risk to the patient.  Risk to patients is both an effective gauge of 
quality and a more detailed means of communicating quality to consumers.  This has the 
potential to redefine the marketplace, in effect reallocating purchasing power to the true 
customer (i.e., the patient), allowing him/her to make informed, risk-based decisions with 
the guidance of clinicians. 
In addition to altering the manner in which consumers perceive pharmaceutical 
products, this novel methodology transforms the system in which products could be 
released and approved.  The current system typically requires a series of sequential tests 
(e.g., content uniformity, assay, dissolution), which if the sampled units are within the 
specifications, the product is determined to be acceptable for release to the general 
public.  Under the new paradigm, the confounding factors (e.g., uniformity, release rate, 
clinical performance) would be modeled (with respect to risk) simultaneously, effectively 
supplanting the need to set numerous specifications.  Product release and approval, 
therefore, would be based on limits of tolerable risk to patient safety.  This is consistent 
with the QbD approach of defining product specifications according the desired product 
(clinical) performance (Table 1.1). 
Dickinson et al. published an article shortly after Cogdill and Drennen concerning 
dissolution testing and its link to clinical performance within the QbD paradigm.21  The 
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objective was to demonstrate that in vitro dissolution testing is sensitive to 
manufacturing, formulation, and in vivo (bioavailability) changes such that the method 
could be used to assure that the safety and efficacy of newly tested products mirrors that 
observed in the preceding clinical assessments.  A functional relationship between the 
pharmacokinetics and pharmacodynamics of a drug is truly required to effectively model 
clinical performance.  As the authors highlighted, however, this relationship is not always 
available during the development stages.  Thus, pharmacokinetic modeling was used as a 
surrogate for analyzing safety and efficacy.  Ultimately, the relationship between 
manufacturing and composition variables and clinical performance was proposed to be 
used to set the boundaries of the operational design space for in vitro dissolution.  The in 
vitro dissolution test, therefore, would be capable of assessing the influence that product 
changes have on clinical performance.  
The authors proposed five strategic components for establishing a methodology 
capable of harnessing in vitro dissolution testing for evaluating clinical performance.21   
1. Using a priori knowledge of the product under development and/or comparable 
products, perform a risk assessment to identify the various risks to clinical quality. 
2. Develop a dissolution method that is sensitive to process and product variables 
that are expected to influence dissolution of the drug.  The method should be 
physiologically relevant.  
3. Ascertain from the in vitro and in vivo data the impact that changes to these 
variables have on clinical performance. 
4. Define the dissolution specifications that ensure clinical performance. 
5. Control dissolution within the limits of the design space to ensure clinical quality. 
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Following a risk assessment to prioritize the product and process variables most 
likely to affect safety and efficacy, four different dosage forms comprised of an 
unidentified model drug were investigated based on their likelihood to alter the 
dissolution release profile (which should affect the pharmacokinetics, and consequently, 
safety and efficacy).  Following in vitro and in vivo analyses (in human volunteers), the 
authors observed comparable in vivo performances amongst the four formulations, 
despite their dissimilar dissolution profiles.  Consequently, the authors did not attempt to 
establish an IVIVC, but concluded that it was not required to define a clinically relevant 
design space since in vitro dissolution testing was able to distinguish the formulation and 
manufacturing differences.  Several different approaches to defining the dissolution 
specifications were presented.  The first is in agreement with the FDA guidance22 for 
situations where a Level A IVIVC has been established.  When this is the case, Cmax or 
AUC should not deviate more than ± 10 %.  When the pharmacokinetics of the drug are 
not appreciably effected by variability in dissolution, as was the case for the model drug 
selected by Dickinson et al., the authors advocate that a “safe space” can be indentified 
where the change in pharmacokinetic parameters is minimal over a defined range of 
dissolution conditions (e.g., t50, t90).  Lastly, a combination of a safe space and an IVIVC 
can be specified to allow the pharmacokinetic parameters to be controlled within ± 10 % 
deviation.  Efforts such as these will reduce the burden of clinical trials, effectively 
promoting more efficient pharmaceutical development and manufacturing.21  
 30
1.3.2 Theophylline 
1.3.2.1 Background 
Theophylline (Figure 1.4) was formally introduced for the treatment of status 
asthmaticus (i.e., acute asthma) in 1937 following six years of investigational therapy 
during which Drs. Herrmann and Aynesworth observed relief in several patients.23  It 
was, however, administered to humans as early as 1904, where it was noted to cause 
acute poisoning.24  Since its introduction, theophylline has been used more frequently for 
chronic cardiorespiratory disorders25 and, to a lesser extent, for the treatment of neonatal 
apnea.26  A xanthine derivative, theophylline is prescribed for the management of acute 
and chronic bronchospasms linked to asthma and chronic obstructive pulmonary disease 
(COPD).  Despite being largely supplanted by newer bronchodilators (e.g., 
corticosteroids, beta-2 adrenergic agonists), theophylline is beneficial for certain patients, 
including those who fail to adhere to or cannot meet demanding dosing schedules, and 
those who experience inadequate relief from available alternatives.  It is one of the most 
commonly prescribed medications worldwide for the management of airway diseases due 
to its low cost.  While it is generally regarded as a third-line treatment, theophylline is 
sometimes the only affordable alternative to inhaled corticosteroids.27  Additionally, its 
anti-inflammatory and immunomodulatory effects have generated added attention to the 
drug’s clinical potential.25  Theophylline is also frequently utilized as a model drug for a 
variety of research foci, including investigations into the disparity in clearance 
mechanisms between neonates and adults28 and the evaluation of physiologically-based 
PK models. 29,30  
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Figure 1.4. Chemical structure of anhydrous theophylline, C7H8N4O2, CAS registry number 58-55-9. 
Theophylline has been almost universally classified as a bronchodilator, but its 
capacity to manage chronic asthma cannot be fully explained by its modest 
bronchodilator activity.  Although the molecular mechanisms of action for theophylline 
are still in question, the general consensus is that the immunomodulatory, anti-
inflammatory, and bronchoprotective effects collectively contribute to its pharmacologic 
actions.  Theophylline nonselectively inhibits phosphodiesterase, which is responsible for 
cleaving phosphodiester bonds, such as those found in cyclic 3’,5’-guanosine 
monophosphate (cGMP) and cyclic 3’,5’-adenosine monophosphate (cAMP).  At 
therapeutically relevant concentrations, theophylline induces an increase in intracellular 
cGMP and cAMP concentrations, which results in bronchodilation and inhibition of 
inflammatory and immune cells.  Theophylline also acts as a nonselective antagonist of 
adenosine receptors at these concentrations.  Although adenosine has virtually no effect 
on airway smooth muscle of non-asthmatic individuals, it elicits bronchoconstriction in 
asthmatic patients.  Theophylline has also been noted to reduce fatigue in diaphragmatic 
muscles, enhance mucociliary clearance, block the decrease in ventilation that occurs 
with sustained hypoxia, and lessen microvascular leakage of plasma into the 
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airways.25,27,31  Further information regarding the potential mechanisms of action is found 
in the articles by Barnes27 and Barnes and Pauwels.31 
1.3.2.2 Absorption, Distribution, Metabolism, and Excretion  
Theophylline is a water-soluble drug that is rapidly and completely absorbed 
when administered in solution or as fast dissolving uncoated tablets.25,28  Selected 
controlled- or extended-release dosage forms, however, are not 100 % bioavailable; 
certain products have reported fractions of the dose absorbed systemically of as low as 
0.42.32  Absorption occurs throughout the gastrointestinal tract, and the extent of 
absorption has been reported to be comparable in the stomach, the small intestine, and the 
colon.33  Others, however, have observed greater quantities of theophylline absorbed in 
the small intestine when compared to the stomach and colon.34  Theophylline is 
distributed primarily in extracellular fluid with a volume of distribution of approximately 
0.45 to 0.5 L/kg.  It is roughly 40 % protein bound (largely to albumin), but due to age-
related variability, the range is reported to be 40 – 60 %.35  Despite the variability, 
measurements of total serum concentrations are said to accurately reflect the unbound 
fraction.36  Theophylline is typically considered to be rapidly removed from the body; the 
plasma half-life in adults is 7 – 9 hours.35  While this may be accurate for the majority of 
the population, dramatic fluctuations in the elimination rate have been observed and the 
average half-life has been reported to be 1.2 – 65 hours.37   
It is generally accepted that serum concentrations of 10 – 20 mg/L define the 
therapeutic range of theophylline.25,38,39  Researchers, however, have observed responses 
at concentrations as low as 5 mg/L,26,31 and thus, have suggested altering the therapeutic 
window to 5 – 15 mg/L to avoid potentially toxic events,35 which are more probable at 
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higher serum concentrations.  Others are content to report the therapeutic window as 5 – 
20 mg/L.40,41  Toxic effects of theophylline include nausea, vomiting, abdominal cramps, 
diarrhea, headache, arrhythmias, tremor, agitation, hypothermia, seizures, brain damage, 
and mortality.25,42,43  Despite viewpoints that the severity of toxic events was correlated to 
the drug level, it is apparent that typical toxic symptoms associated with lower serum 
concentrations (e.g., nausea, vomiting) do not necessarily precede severe adverse 
reactions (e.g., seizure, death).38   
Although theophylline has been used to manage cardiorespiratory conditions for 
over 70 years, the dose-response relationship remains unclear.  Most references indicate 
that theophylline is primarily (~90 %) metabolized via the liver and the remainder is 
excreted unchanged in the urine.35  While this is reasonably accurate for the general 
population, certain sub-groups (e.g., neonates, those with liver diseases) eliminate 
theophylline differently.  Disposition, metabolism, and excretion of theophylline are 
dependent on a variety of factors and its metabolic pathway interacts with that of 
caffeine, which is also a xanthine derivative.  Caffeine and theophylline are structural 
analogues that differ by a single N-methyl group and both molecules undergo hepatic 
metabolism via similar saturable mechanisms.28 
The following discussion focuses on the metabolism and excretion of 
theophylline, and the relevant conversions between the two analogues.  For particulars 
regarding the elimination of caffeine, please refer to the article by Ginsberg et al.28  The 
predominant mechanism of removal for theophylline in adults is metabolism via the 
cytochrome P450 (CYP) 1A2 enzyme (Figure 1.5).  The three resultant metabolites are 3-
methylxanthine and 1-methyluric acid (via N-demethylation), and 1,3-dimethyluric acid 
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(via 8-hydroxylation); theophylline is converted to the intermediary product 1-
methylxanthine, which is ultimately oxidized (via C8-oxidation) to 1-methyluric acid by 
xanthine oxidase.  1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine 
constitute 45 – 55 %, 15 – 20 %, and 10 – 15 %, respectively, of the urinary metabolites 
in adults.35  While metabolism is almost universally attributed to CYP1A2, other CPY 
enzymes (e.g, CYP1A1, CYP2E1, CYP3A4) and flavin-containing monooxygenases 
(FMO) have been established as minor contributors to the biotransformation of 
theophylline.  For example, several studies indicated that CYP2E1 and CYP3A4, in 
addition to CYP1A2, contribute to the oxidative metabolism of theophylline to 1,3-
dimethyluric acid.44  Further, metabolism of theophylline by both CYP1A1 and CYP1A2 
has been observed.28,44  Given that only minor quantities of CYP1A1 are expressed in the 
liver, these findings suggest that a certain amount of theophylline is metabolized 
elsewhere.  It is common modeling practice, however, to restrict metabolism to the liver 
only.  Caffeine, on the other hand, counteracts the elimination of theophylline as one of 
its primary metabolic pathways yields theophylline (Figure 1.5).28  Since the metabolism 
of caffeine to theophylline elevates blood levels of the latter, consumption of caffeine is 
often times restricted or even prohibited during treatment with theophylline.  
Consumption of soda, tea, and coffee has been reported to yield theophylline serum 
concentrations of less than 3 mg/L.42 
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Figure 1.5. Diagram of the major metabolic pathways for theophylline and caffeine.  CYP represents 
cytochrome P450 and FMO is the acronym for flavin-containing monooxygenases. 
While predominant in adults, the CYP1A2 metabolic pathway is under-developed 
in neonates and infants.  Consequently, theophylline elimination is altered in newborns.  
To begin with, roughly 50 % of the theophylline dose is excreted unchanged in the urine 
of neonates.  Despite the fact that renal elimination is enhanced, it is not as efficient as 
metabolism via CYP1A2, which results in a net decrease in theophylline clearance in 
neonates as compared to adults.  This is manifest by the three- to five-fold increase in the 
half-life of theophylline in neonates (20 – 34 hours compared to 7.3 hours in adults).  
Secondly, upwards of 40 % of the theophylline is metabolized via 8-hydroxylation in 
newborns (presumably by means of CYP2E1 and/or CYP3A4), which has been reported 
to be less than that in adults.  Finally, approximately 5 – 10 % of the theophylline is 
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converted to caffeine and excreted in the urine, which has been observed in both neonates 
and infants.35  This mechanism has never been detected in adults, suggesting that it is 
perhaps a compensatory pathway found only in neonates.28,35  Metabolic enzyme activity 
comparable to that in adults is not normally observed until approximately 3 years of 
age.44     
Inter-patient variability is perhaps best epitomized by the extreme disparity in 
theophylline clearance.43,45  This is substantiated by the work of Jusko et al. who 
observed clearance values ranging from 4 – 143 mL/hr/kg in 200 individuals with diverse 
physiological, pathophysiological, environmental, and behavioral characteristics.46  
Factors other than age (e.g., sex, diet, concomitant drug therapies, recreational drug use, 
obesity, illness, pregnancy) also obfuscate the disposition and elimination of 
theophylline.26,42,43,46,47  For example, polycyclic aromatic hydrocarbons found in tobacco 
smoke have been shown to induce several drug-metabolizing enzymes (i.e., CYP1A1, 
CYP1A2, and CYP2E1), which ultimately increase the clearance rates of theophylline by 
upwards of 80 % in smokers as compared to nonsmokers.48  Elevated clearance rates 
have also been observed in smokers weeks to months following abstention.  Individuals 
subjected to second-hand smoke also have enhanced theophylline clearances.  In addition 
to the direct influence on enzymatic biotransformation, smoking has physiologic 
manifestations, such as vasoconstriction, which decreases blood perfusion to the liver, 
ultimately reducing the elimination of theophylline.  Therefore, the safety and efficacy 
profiles for smokers are distinct, and their dosage regimens must be adjusted 
accordingly.48  
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1.3.2.3 Dosing  
Numerous attempts have been made to define theophylline dosing regimens for 
given sub-populations,37,41,42,49 but none have been proven to be applicable to the general 
population; when tested in independent sub-populations, most patients required dose 
adjustments to bring their serum levels within the defined therapeutic range.43,45,47,49  
Though Bayesian forecasting methods50,51 appear to be most accurate, these dosing 
regimens do not supplant the need to closely monitor serum concentrations to ensure 
proper administration.49  To date, no universal dosing method has been generated for 
theophylline. 
Due to the unpredictable nature of dosage requirements, individualized dosage 
regimens have been posited as a reasonable method of safely dosing patients with 
theophylline.35,39,49,52  “It is important to realize that there are wide interindividual 
differences in theophylline clearance and in the degree of its interaction with other 
agents.  Therefore, data in the literature should be regarded only as a general guide, and 
careful observation for adverse drug reactions and blood level monitoring have to be 
conducted in most patients.”35  Individualized methods, however, are restrictive in that 
they necessitate estimations of serum concentration to ensure proper dosing.  Hurley et 
al. demonstrated in a randomized clinical trial that in contrast to dosages based on serum 
theophylline concentrations alone, utilizing each patient’s estimated theophylline 
clearance enhanced the accuracy of dosing.53  Irrespective of the dosing scheme, 
extensive inter-patient pharmacokinetic variability coupled with the narrow therapeutic 
window complicate the administration of theophylline. 
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Several research groups have attempted to model the clearance of theophylline as 
a result of the significant challenges that inter-patient variability poses to clinicians for its 
accurate dosing.  Chiou et al. introduced a method to rapidly estimate the total body 
clearance of theophylline following constant-rate intravenous (IV) infusion that requires 
two plasma samples and a reasonable estimate of the apparent volume of distribution.37  
This method was demonstrated using rabbits as test subjects.  Similarly, Powell et al. 
assessed three routines for modeling total body clearance in healthy volunteers and 
patients suffering from airway obstruction who were administered theophylline via 
constant-rate IV infusion.45  These methods required up to seven blood samples for the 
analysis of theophylline concentration. 
In addition to modeling the clearance, Powell et al. also studied the effects of 
various (potentially confounding) factors on the clearance and volume of distribution, 
including sex, age, race, smoking habits, bronchitis, asthma, pneumonia, congestive heart 
failure, and severity of bronchial obstruction in 31 healthy volunteers and 26 patients.  
They found that sex, age, race, and the diagnosis of asthma or chronic bronchitis per se 
had no significant effect on clearance, whereas smoking, severe congestive heart failure, 
pneumonia, and severe bronchial obstruction resulted in significant changes.  
Additionally, the authors observed that, with the exception of patients who had severe 
congestive heart failure or pneumonia, changes in theophylline clearance during the 
course of the therapy were minor; no change as a function of time was observed in the 
healthy volunteers.  In contract to clearance, the volume of distribution was not correlated 
with any of the factors examined.  The authors suggested that these data supported the 
argument that changes in half-lives for a given disease state are a result of alterations in 
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clearance rather in the volume of distribution.  Thus, with the exclusion of those patients 
whose clearance is expected to drastically change throughout the course of treatment, 
they conclude that a single theophylline concentration should be adequate for the entire 
IV theophylline therapy.45   
Jusko et al. also performed an extensive retrospective study to model the 
environmental and pathophysiologic factors that affect theophylline clearance in 200 
patients and normal volunteers, including age, sex, liver disease, congestive heart failure, 
obesity, renal function, history of drug, tobacco, marijuana, caffeine, or alcohol use, and 
pregnancy.46  The history of drug use included consideration of oral contraceptives, 
barbiturates, benzodiazepines, phenothiazines, and tricyclic antidepressants.  Clearance 
was modeled using a previously developed nonlinear algorithm.54  The authors noted that 
other factors (e.g., marked dietary changes, respiratory viral illness, thyroid dysfunction, 
acute steroid administration, low arterial PO2, recent ingestion of charcoaled foods) could 
affect the disposition of theophylline; however, they were either not acknowledged as 
factors at the time this study was performed or these data were unavailable.  All but 8 of 
the subjects were Caucasian; therefore, differences attributable to race were not 
examined.  Of the factors assessed, age, liver disease, smoking status, and congestive 
heart failure significantly altered clearance.   
Additionally, Jusko et al. sought to characterize the variability in theophylline 
clearance within the sample population.  Analysis of variance was used to determine the 
order, priority, and interactions of the factors that correlated with theophylline clearance 
to yield the maximum statistical discrimination between groups.55  Clearance estimates 
were subdivided into mutually exclusive subgroups based on the reduction of 
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unexplained variance (p < 0.01).  If a factor was previously accounted for, but had the 
potential to mediate the effects of factors yet to be considered, it could be reintroduced 
for assessment.  Ultimately, the authors generated a clearance cascade, which illustrates 
the mean and standard deviation of total body theophylline clearance for each subgroup.  
This cascade can be reduced to a linear dosing nomogram to aid physicians in effectively 
targeting steady-state theophylline serum concentrations.  The authors concluded that 
variability due to phenothiazines, tricyclic antidepressants, severe renal impairment, or 
oral contraceptives in nonsmokers could not be discounted as these categories were 
inadequately represented.  Furthermore, they cautioned that many of the 
drug/disease/history/physiologic associations had not yet been verified in a prospective 
clinical trial.46 
By means of 16 patients experiencing airway obstruction, Gilman et al.56 
compared the methods of Powel et al.45 and Jusko et al.,46 and a weighted least-squares 
Bayesian approach and the method of Chiou et al.37 for the estimation of theophylline 
clearance following administration of aminophylline via IV infusion.  Percent error was 
used to quantify the predictive error.  Patients suffering from acute congestive heart 
failure, cirrhosis of the liver, pneumonia, sepsis, or severe malnutrition, or those who had 
taken erythromycin or cimetidine were excluded.  The authors concluded that the Jusko et 
al. method out-performed that of Powel et al.; however, the patients were categorized 
into only 7 of the possible 16 terminal nodes of the Jusko et al. clearance cascade.  
Moreover, the Bayesian method was found to be more precise and less biased than the 
Chiou et al. routine; however, the requirement of selecting a prior model for the 
individualized expectations of pharmacokinetic parameters and their corresponding 
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variances limits the applicability of the Bayesian method when these models have not 
been adequately developed. 
The most accepted dosing schedules for theophylline require administration one 
(i.e., q.d.), two (i.e., b.i.d.), or three (i.e., t.i.d.) times per day; however, regimens that 
necessitate multiple daily dosages are believed to exacerbate patient non-compliance.  
However, previous reports have shown that once-daily dosing of theophylline increases 
the likelihood of observing serum concentrations outside the therapeutic window.32,57-59  
This finding has lead researchers to advise twice-daily dosing, which has been shown to 
result in less extensive peak/trough fluctuations, thus increasing the probability of 
maintaining concentrations within the desired range.  Despite the (supposed) reduced risk 
of an inefficacious or toxic event associated with twice-daily dosing, researchers contend 
that higher clinical efficacy is attained with once-daily dosing.58,60,61  Additionally, it has 
been stressed that fluctuations in clinical effects that closely parallel the oscillations in 
serum concentration, which would advocate twice-daily dosing, have not been 
substantiated in published studies.58  
1.3.3 Mathematical Modeling and Numerical Simulation 
The terminology modeling (or model) and simulation are occasionally used 
interchangeably so as to suggest they share a common definition.  While they both are 
abstract representations of real-world systems, each has a distinct meaning and it is 
important to differentiate between them.  These terms are used throughout the remainder 
of this dissertation according to the definitions provided by Peter Bonate, noting that the 
original definition of simulation is expanded.62  A model signifies any mathematical 
construct generated using fundamental processes or data that relates inputs to outputs, 
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whereas simulation is the exploitation of models to examine the long-term impact that 
variability [or uncertainty], treated as an input to the model, has on a system.  The term 
simulation is broadened to include assessments of uncertainty.  Table 1.2, which was 
adapted from Bonate’s work, contrasts the two expressions.62 
 
Table 1.2. Comparison and contrast of the terms modeling and simulation.  Adapted from Bonate, PL. 
2000. Clinical trial simulation in drug development. Pharmaceutical Research 17(3):252 – 256.   
Modeling Simulation 
Sensitive to assumptions Sensitive to assumptions  
Sensitive to black-box criticisms  Sensitive to black-box criticisms 
Uses data Builds upon models based on data 
Useful method for data summarization Useful method to summarize complex 
inter-relationships between variables 
Relates inputs to outputs Incorporates random variability [or 
uncertainty] into a model and assesses its 
effects long-term 
Random variability is a nuisance variable Random variability can be incorporated 
in the simulation 
Looks back in time Looks forward in time 
Can identify which variables are more 
important than others 
Can indentify which variables are more 
important than others 
Cannot be replicated Can be replicated 
 
1.3.3.1 Monte Carlo Simulation 
Mathematical models provide users the opportunity to manipulate inputs to 
examine outputs, which offers greater insight into the functionality of processes and 
systems.  Models are categorized according to the flexibility of their inputs; when all are 
fixed, the model is said to be deterministic, whereas when some or all of the terms are 
characterized by a certain level of random variability, the model is stochastic.  Simulation 
harnesses models to observe an outcome or a prediction based on a given set of 
parameters (i.e., inputs).  Stochastic modeling techniques that utilize random variability 
are typically referred to as MCS.  Stanislaw Ulam and John von Neumann are credited 
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with coining the expression Monte Carlo, which came during their work on the atomic 
bomb at Los Alamos in 1946.  Rugen and Callahan make the distinction, however, that 
Ulam developed the approach earlier while playing solitaire.63  Though the phrase is a 
reference to the gambling casinos in Monaco, it was initially used to simulate random 
neutron diffusion in fissile material.63-65   
The Monte Carlo method is a numerical technique used to solve mathematical 
functions by random sampling.  Although the theory of random sampling was established 
long before the Monte Carlo method, MCS was not practical until the advent of 
computers.  The universal approach of the Monte Carlo method is simple; MCS 
iteratively samples a set of random model parameters from their underlying distributions 
(which are generated a priori), performs a number of deterministic computations using 
the inputs, and stores the resultant outputs.  Thus, a program is constructed to conduct a 
number of independent, random trials, the results of which are accumulated at the 
conclusion of each iteration.  The Monte Carlo method is applicable to any system that is 
affected by random factors.  Unlike deterministic functions, MCS has the distinct 
advantage of estimating the sensitivity or robustness of a system to random variation or 
error through the propagation of uncertainty.  This uncertainty allows stochastic elements 
of a system to better represent practical observations, which can lead to more precise 
conclusions and/or actions.64,65   
 The Monte Carlo method utilizes random variables, which implies that for any 
given trial, the value assumed for a given input is unknown.  The term “random,” 
however, has a more specific meaning in the context of MCS in that the range of 
potential values the variable can assume, along with the probabilities of these values are 
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known a priori.  Truly random numbers or distributions are cumbersome since it is often 
desirable to reproduce calculations performed on a computer; in order to repeat trials 
using random numbers, the numbers would need to be stored during each trial.  Thus, 
MCS is typically conducted with what are known as pseudo-random numbers, which are 
values generated to approximate a particular distribution (e.g., uniform, normal) using 
mathematical formulae that simulate random numbers.  Rather than having to test the 
validity (or randomness) of the random numbers at the start of each trial, pseudo-random 
number generators need only be tested once to confirm their ability to generate a 
sequence of numbers that approximates the properties of random values.  The pseudo-
random numbers can then be re-generated if need be using the same “seed” or point at 
which the algorithm began generating values.64,66  
Pseudo-random number generators do have one significant limitation; the total 
number of values that can be generated using any given seed is finite.  Eventually, 
identical values will be re-generated as the pseudo-random number generator cycles.  
Therefore, the user must verify that the sequence of pseudo-random values generated is 
large enough for the specific application such that earlier trials do not become correlated 
with later trials as a result of re-sampling.  This ensures that the simulation is truly 
stochastic.  Pseudo-random number generators are restricted by the number of bits (n) the 
computer possesses such that a sequence, often times referred to as the period, of pseudo-
random numbers can be no longer than 2n.  Newer algorithms, however, have 
circumvented this issue, utilizing numerous generators for the seed and the integer 
generator such that periods of 264 (Marsaglia's Ziggurat algorithm) and 219,937 – 1 
(Mersenne Twister algorithm) are attainable.64,66  
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The results of any MCS trial are dependent upon the number of times the system 
is perturbed.  The model(s) must be tested a sufficient number of times such that the 
parameters sampled are representative of the general population.  If the sampling is 
inadequate, the output will be misleading since certain input conditions that are likely to 
occur will not have been considered.  While it is not possible to offer a general rule of 
thumb as to the required number of iterations, the simulation should iterate enough times 
to allow the output to stabilize.  Ensuring that the change in the estimate drops below a 
defined threshold for a set number of consecutive iterations is one approach to verifying 
stabilization.64,65 
1.3.3.2 Pharmaceutical Applications of Monte Carlo Simulation 
 Since its formal introduction, the number of applications that harness MCS has 
grown substantially.  Monte Carlo simulation is utilized in many scenarios, including the 
general fields of manufacturing, economics, and science.63  While a thorough review of 
all the applications of MCS is well outside the focus of this dissertation, the following 
discussion offers a brief overview of its major uses within the pharmaceutical industry.  
Additional detail regarding MCS is provided in section 1.3.7.     
 Monte Carlo simulation is a versatile tool that supports numerous aspects of the 
drug discovery and development process.  The preliminary tasks of generating models 
and defining simulation inputs a priori force companies to identify the components that 
are well understood and, likewise, the elements that are uncertain or missing altogether.  
Although MCS is used throughout the drug discovery and development process,67 its 
greatest impact as it relates to pharmaceutics is perhaps in the area of clinical trials, 
commonly referred to as clinical trial simulation.67,68  To start with, MCS can be used to 
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study the economic investments necessary to conduct these trials, with the obvious 
objective of minimizing the total cost.62  Poland and Wada utilized PK, PD, and 
economic models along with MCS to study the effects of the dosing regimen (i.e., once- 
versus twice-daily administration) and patient compliance on the efficacy of an 
antiretroviral drug in Phase II trials.69  The authors concluded that despite enhanced 
patient adherence to the once-a-day dosing schedule, the marginal increase in long-term 
efficacy did not warrant the change from twice- to once-daily administration in view of 
the delayed time-to-market, additional monetary investments, and technical uncertainties 
associated with the new product.  This is an excellent example of how MCS helped 
circumvent additional clinical trials that would have undoubtedly increased development 
expenses.      
Many other facets of clinical trials can benefit from MCS.  Although their explicit 
objectives may not have included minimizing financial investments, there is a consistent 
economic implication in the following cases.  For example, MCS is used to approximate 
the initial dose in humans for phase I studies.  This can be of particular benefit in 
allometric scaling efforts where PK parameters have been well-characterized (typically as 
averages) within the confines of animals, but transferability to humans is uncertain.  
Simulation can help elucidate which parameters have the largest effect on scaling the 
dose to humans by propagating variability through the models.  Moreover, MCS is 
beneficial for determining the dose for phase II and III studies where the test subjects are 
typically patients rather than healthy volunteers.  Therefore, fewer adverse events are 
anticipated from optimizing the dose in silico rather than in vivo, which inevitably 
increases the likelihood that the particular drug will receive approval for marketing.62       
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With a predictive PK model, single- and multiple-dose plasma versus time 
profiles can be generated with the aid of MCS, which can then be used to optimize the 
dose and the dosing schedule to ensure plasma concentrations are within the desired 
therapeutic range.  Gomeni et al. took a similar (but extended) approach where they used 
PK and PD modeling in conjunction with MCS to assess the effects of PK absorption and 
disposition parameters (e.g., fraction of dose available), and inter-individual variability 
on percent receptor occupancy, which had been identified as a surrogate for efficacy.70  
The authors were able to identify the variables that had the largest influence on receptor 
occupancy, which enhanced their company’s understanding of the unidentified drug and 
helped direct future development efforts.    
As evidenced by the work of Poland and Wada, and Gomeni et al., models 
representing various components fundamental to clinical trials (e.g., PK and PD) can be 
integrated with MCS to investigate the effects of various inputs (e.g., patient compliance, 
inter-individual variability) on the clinical effectiveness of a given treatment.  This offers 
the user the unique opportunity to explore numerous circumstances, some of which are 
not ethical in a clinical trial setting.  For instance, MCS can be used to investigate the 
therapeutic outcome of patients missing a given percentage of their doses, which is not 
acceptable in situations where the patient would potentially experience significant 
discomfort or harm.  The ability of simulation to efficiently address the “What if” 
questions in silico rather than in vivo underscores its utility.   
Dutta and Reed utilized MCS to investigate the effects of patient compliance on 
plasma concentrations of valproic acid during treatment with 12-hour enteric-coated 
divalproex sodium tablets.71  PK simulation is an ideal platform to assess the effects of 
 48
missed doses, and patient/clinician compensations for the omissions, seeing as how 
withholding medication from patients suffering from epilepsy or acute mania is unethical.  
Valproic acid, one of the two APIs in divalproex sodium tablets, has a narrow therapeutic 
window of plasma concentrations of 50 – 100 mg/L.  Given its narrow therapeutic range 
and short elimination half-life of 6 – 16 hours, patient compliance is critical to the safety 
and effectiveness of this modality; low plasma concentrations can result in seizures 
whereas high plasma levels run the risk of inducing clinical toxicity.   
  The authors wanted to examine the PK effects of missing one or two doses in 
conjunction with three different temporary dosing regimen adjustments: (1) one missed 
divalproex dose compensated for by doubling the dose at the next scheduled dose 
administration (12-hour replacement), (2) two consecutive missed divalproex doses offset 
by administering a doubled dose 6 hours following the first missed dose (18-hour 
replacement), and (3) two consecutive missed divalproex doses counteracted by tripling 
the dose at the next scheduled dose administration (24-hour replacement).  Moreover, 
they were interested in the confounding effects (i.e., drug-drug interactions) of hepatic 
enzyme-inducing antiepileptic drugs on valproic acid plasma concentrations.  To 
accomplish this, adjustments were made for certain individuals to simulate the shortened 
elimination half-lives and elevated clearances observed for patients taking antiepileptic 
medications.   
Population mean PK parameters for dose, bioavailability, absorption lag-time, 
first-order absorption rate constant, steady-state volume of distribution of unbound drug, 
protein binding parameters (i.e., the number of binding sites for the two classes of 
binding sites and their corresponding binding association constants), elimination half-life, 
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and clearance of free drug were taken from the literature.  Different doses, elimination 
half-lives, and clearances were implemented for patients with enzyme induction versus 
those uninduced.  The age range of the hypothetical patients was restricted to 11 – 64 
years and body weight was assumed to be 70 kg.  Patients not taking other enzyme-
inducing antiepileptic drugs were administered 562.5 mg every 12 hours (i.e., 16 
mg/kg/day), whereas induced subjects were administered 1125 mg (i.e., 32 mg/kg/day).  
Log-normal distributions representing 20 % inter-patient variability were generated for 
clearance, volume of distribution, albumin concentration, and the protein binding 
parameters using the population averages.  Patients, in effect, were generated by 
randomly sampling the underlying distributions for the parameters estimates, which were 
then used to simulate plasma concentration-time profiles.  Predicted plasma 
concentrations were subjected to 10 % residual error to include real-world variability.  A 
total of 1000 patients were tested.   
The resultant valproic acid plasma concentration-time profiles (Figure 1.6) were 
analyzed to quantify the effects of the missed doses and hepatic enzyme induction in 
terms of the change in steady-state maximum and minimum concentrations (Cmax and 
Cmin, respectively).  The simulated profiles illustrate the dramatic fluctuations in valproic 
acid plasma levels that accompany one or two missed doses and the three temporary 
dosing regimen adjustments.  Although there was no actual link to the PD outcomes, the 
authors assumed that the lower limit for clinical efficacy was 50 mg/L, below which the 
likelihood of a breakthrough seizure is greatly enhanced, and that plasma concentrations 
greater than 100 mg/L increased the probability of toxicity.  Using these criteria, the 
authors concluded that the probability of inefficacy (i.e., seizing) is greatly enhanced 
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when as little as one dose is omitted, especially for those taking antiepileptic medications.  
Uninduced patients are at low to modest risk for toxic events, even when the dose is 
tripled.  Induced patients, however, are likely to experience transient toxicity due to 
elevated plasma concentrations.  Given their observations, Dutta and Reed recommended 
a modified dosing regimen for non-compliant patients who miss one or two divalproex 
doses.  For patients treated with concomitant antiepileptic medications, an omitted dose 
should be offset if the individual recalls the miss up to 12 hours later, noting the risk of 
adverse events.  If the same patient recalls the omission 18 or 24 hours later, the 
patient/clinician is advised against full-dose compensation (i.e., either doubling or 
tripling the dose depending on the time) due to risk of clinical toxicity.  In these 
instances, the clinician is encouraged to consider a partial dose replacement approach in 
conjunction with a return to the scheduled dosing regimen.  As for uninduced patients, 
they should replace the dose upon recalling the miss, even if two consecutive doses are 
omitted.  The authors also pointed out that the simulation could be revised to model 
young pediatric and/or geriatric patients with better estimates of their PK parameters (i.e., 
population-specific variability).71 
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Figure 1.6. Simulated valproic acid (VPA) plasma concentration-time profiles of epileptic patients at 
steady-state (SS) following the miss of one or two scheduled divalproex doses, with replacement 12, 18, or 
24 hours later followed by continuation of scheduled dosing regimen.  (a) VPA concentration-time profiles 
in the mean simulated patient administered 562.5 mg q 12 hours.  (b) and (c) VPA concentration-time 
profiles in the mean simulated patient administered 1125 mg q 12 hours with hepatic enzyme-inducing 
medication.  Panel (c) is the same data shown in (b) with the addition of the inter-patient and residual 
variabilities in VPA concentration-time curves.  The error bars of (c) represent standard deviation (SD).  
Solid line (0-24 h) to dotted line represents baseline steady-state profile (no missed doses) for the mean 
simulated patient, and the solid line (24-72 h) represents the predicted mean change after omitting two 
doses, with replacement 24 h later and resumption of scheduled dosing (triple dose). 
Watanalumlerd et al. employed MCS and PK modeling to study the effects of 
gastrointestinal transit on plasma concentration-time profiles of an orally administered 
combined immediate-release and enteric-coated amphetamine pellet formulation in the 
fed and fasted states.72  Compartmental PK were assumed with first-order absorption of 
the immediate-release pellets, zero-order gastric emptying rate in the fed condition or 
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first-order gastric emptying rate in the fasted condition of enteric-coated pellets into the 
intestine, first-order absorption of the drug after being released from the enteric-coated 
pellets, and first-order elimination.  Once absorption occurs, it is assumed that the PK can 
be described by a one-compartment model.  The PK equations included terms for the 
gastric emptying time as well as the lag time of gastric emptying.  The PK parameters for 
amphetamine (i.e., absorption rate constant, elimination rate constant, apparent volume of 
distribution, and the fraction of the drug absorbed) were obtained by fitting plasma 
concentration data obtained from the available literature.  Constant doses of 20 and 30 
mg were administered for the fed and fasted states, respectively.   
Given that the primary focus of this work was to investigate the effects of gastric 
emptying, only the terms for gastric emptying time and the lag time of gastric emptying 
were varied during the simulations.  The means and standard deviations for gastric 
emptying time and lag time of emptying were also taken from literature.  Separate 
estimates were available for the fed and fasted states, and a total of four lognormal 
distributions were generated for the time parameters.  Variability of 30 % was 
implemented for lag time in the fasted state since an estimate was not accessible; this 
resulted in a range comparable to the other gastrointestinal transit parameters.  Each 
simulated plasma concentration-time curve portrayed the mean of 500 trials, and the 
variability was captured in one of two ways: (1) by displaying standard deviation error 
bars or (2) by plotting the 25th, 50th, and 75th percentiles, for each simulated time point.  
Two lines representing the minimum and maximum simulated concentrations for each 
time point were also provided.72    
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The accuracy of the simulated plasma concentration-time profiles was assessed by 
comparing the percent difference between the actual and predicted time to the maximum 
concentration (Cmax).  A difference of 2.8 % was observed in the fed state, while an 8.4 % 
difference was observed for the fasted condition.  The simulations confirmed the authors’ 
suspicion that the combined formulation, in both the fed and fasted states, would not 
yield a double-pulsed release profile typical for two immediate-release doses 
administered at different times because the dosage system remained intact as it passed 
through the gastrointestinal tract.  Rather, the profiles were characteristic of a typical per-
oral sustained release formulation.  This work confirmed that PK modeling of combined 
immediate-release and enteric-coated pellets should consider the effects of gastric 
emptying and gastrointestinal transit.72   
While the majority of the above examples incorporate several components of the 
drug development process as they relate to clinical trials, the work of Watanalumlerd et 
al.72 exemplifies that any given element can be studied independent of its counterparts.  
Integration is, however, a logical extension of studying each component independently.  
Simulation is expected to enhance the efficiency of the drug development process by 
generating a greater understanding of the drug itself and its safety and efficacy within 
patients.  In doing so, the significant cost associated with producing innovative medical 
products is likely to be reduced.  Simulation can also be harnessed to analyze and reduce 
the intrinsic risk of pharmaceutical products.     
1.3.3.3 Probabilistic Risk Assessment 
Probabilistic risk assessment is a systematic method to quantitatively characterize 
the risk of a given system.  Assuming the risk is detectable, it consists of two 
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components, probability and severity.  Probability describes the likelihood of occurrence 
for an adverse event, whereas severity expresses the magnitude of the outcome.  When 
conducting a PRA, risk is expressed through a risk model, a function comprised of the 
various terms known or thought to impact adverse events.  At least one of the inputs to 
the risk function is described by its probability distribution as opposed to a scalar (e.g., 
central tendency); methods that only use single values as inputs are referred to as point 
estimate techniques.65   
Depending on the underlying objectives, PRA is used to evaluate the variability 
and/or uncertainty of risk estimates.  Variability is defined as the true heterogeneity of a 
variable or a response for a sample or population, while uncertainty is the error associated 
with the parameters or models.  For example, parameter uncertainty may arise due to 
questionable model inputs, which may be a consequence of the representativeness of the 
data for a given sample population.  Model uncertainty could be a result of ambiguity in 
the estimated model coefficients or perhaps the structure of the model used for the risk 
function (e.g., linear versus nonlinear).  It is important to note that uncertainty can be 
reduced (e.g., acquire additional or improved data), whereas variability is inherent to a 
population.  Variability, however, can be better characterized with more data, but cannot 
be reduced or eliminated.  The output of a given PRA trial is the observed range of 
probability distributions, which, depending on the input distributions, characterize 
variability or uncertainty.  The results of PRA can be used to better allocate resources 
(e.g., personnel, finances) and establish performance objectives to mitigate risk.  Thus, 
PRA is an effective means of weighting initial investments based on potential returns.65 
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One of the main objectives when conducting a PRA is to determine the 
distribution(s) of possible risk scores.  This illustrates the range of threats the assessor 
can expect.  It is also essential to understand which factors have the largest impact on 
risk.  This is accomplished through a sensitivity analysis, which is a systematic method to 
delineate the dependency of the risk estimates on variability or uncertainty in the risk 
factors.  It is used to quantify the relative contribution of each model input to risk and to 
understand important sources of variability or uncertainty.  This is imperative since subtle 
changes to one factor may have a significant effect on the risk estimate, whereas other 
factors may be relatively insensitive to large fluctuations.65 
Sensitivity analyses can range from extremely simple techniques to those that 
utilize relatively complex mathematical and statistical approaches.  The latter are more 
common since numerous sources of variability and uncertainty tend to simultaneously 
affect the risk estimate.  Simple techniques might include determining the range of 
possible values or quantifying the percent of total risk for each factor.  More complex 
approaches might include multiple linear regression or some other statistical analysis to 
assess the percent variance in the risk estimate explained by each factor.65   
A common metric used in sensitivity analyses is the sensitivity ratio, which is 
sometimes referred to as the elasticity equation.  The sensitivity ratio (SR) is expressed as  
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where Y1 is the baseline output obtained using baseline values for the input variables, X1 
is the baseline point estimate for the input variable X, X2 is the new value of the input 
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variable X after the change, and Y2 is the new output after changing the value of one of 
the input variables X to X2.  For PRA, the input is a specific value for a given risk factor 
and the output is the risk estimate.  Risk estimates are most sensitive to factors that yield 
the highest absolute value of the SR and least sensitive to those with the lowest absolute 
value of the SR.  Although popular and instructive, the SR has limited applicability.  The 
SR approach assumes independence of the input variables.  Therefore, if two or more 
inputs interact, varying one input while another is held constant can misrepresent the 
actual impact on risk.  When this is the case, confounding variables must be allowed to 
vary simultaneously.65   
Another metric commonly used in sensitivity analyses is the coefficient of 
determination (R2).  With this method (i.e., simple linear regression), the square of the 
correlation coefficient (r) between the various input values for a given factor and the 
result risk estimates is reported; the correlation coefficient itself is powerful because it 
indicates whether the factor is positively or inversely correlated to risk.  Factors with an 
R2 close to 1.0 have are highly sensitive whereas those close 0.0 are nearly insensitive.  
The coefficient of determination for the risk factors can also be represented as the 
percentage contribution to total variance of risk.  Numerous other statistical approaches, 
such as the Spearman rank correlation and multiple linear regression, are also valid for 
performing sensitivity analyses.  The sensitivity analysis methods ultimately employed 
will depend on the level (i.e., discrete or continuous) of the input and output variables and 
the form of the underlying risk model (i.e., linear or nonlinear).65 
Sensitivity analyses performed on inputs to certain risk models, in particular those 
that are nonlinear, have the potential to be highly dependent upon the values used to 
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perturb the model.  For that reason, it is beneficial to examine a broad range of values for 
the inputs to delineate their impact on risk.  Inputs characterized as random variables can 
be described by a specified probability distribution.  As such, the inputs can assume 
values within this distribution and, therefore, can be easily studied using MCS.65  
Likewise, MCS can be used to evaluate the uncertainty in input variables or model 
parameters.   
1.3.3.4 Monte Carlo Simulation and Probabilistic Risk Assessment  
Probabilistic risk assessment has long been used as a standalone gauge of adverse 
events.  Wreathall and Nemeth suggest that this technique has (conceivably) been used 
most frequently within the commercial nuclear power industry;73 this is not to say, 
however, that PRA was not used earlier by other industries.  Beginning in the early 
1970s, the US Atomic Energy Commission sought to estimate the number of accidents 
that could potentially result in the discharge of radioactive materials.  While PRA itself 
can be used to analyze a system (as can MCS), several guidance documents underscore 
the utility of employing it with MCS.  The National Aeronautics and Space 
Administration (NASA) details their use of PRA in conjunction with MCS to help direct 
decisions to ultimately augment safety and program performance.74  Similarly, the 
Environmental Protection Agency (EPA) has applied PRA and MCS to analyze 
ecological risk for the support of risk-based decisions since 199775 and proposed 
equivalent approaches for analyzing risk to human health in 2001.65  The 2001 EPA 
Superfund guidance illustrates how to use MCS to estimate exposure and risk, and 
discusses the role of PRA in their decision making process.  The time, resources, and 
expertise required to effectively perform PRA are noted as drawbacks to this technique.  
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While this may be true, the potential benefits and savings realized by such a program well 
outweigh these requirements. 
Inputs to PRA risk expressions can assume different values based on their locale 
within the population; as such, these inputs are said to be random variables.  A 
continuous variable can be described by its associated probability density function or 
cumulative distribution function, whereas a discrete variable can be characterized by its 
corresponding probability mass function.  These functions describe the probability of the 
parameter assuming a given value.  When defining or selecting the appropriate values or 
distributions for input parameters, there often is an underlying level of ambiguity 
regarding these data.  For example, in situations where data either do not exist or have yet 
to be collected, estimates are often drawn from previous assessments or suitable 
literature.  More appropriate data can be incorporated into the PRA if and when they 
become available.  Thus, it is the responsibility of the individual(s) executing the 
assessment to defend the assumptions that were made and properly communicate their 
implications and constraints.65   
Once the risk equation(s) have been defined and the corresponding input 
distributions have been characterized, MCS can be used to repeatedly extract input 
parameters at random to evaluate their influence on risk.  In other words, each iteration 
tests a potential real-world scenario (e.g., 80 kg, 65 year old asthmatic male with 
congestive heart failure dosed with a theophylline tablet coming from a batch that was 
found to have unacceptable content uniformity) to better understand the risk associated 
with the particular set of conditions.  With the estimated risk distribution, it is then 
possible to determine if appropriate action is necessary.  Results of PRA trials and the 
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actions that follow are dependent on not only the individual or organization conducting 
the assessment, but also the rationale behind its initiation.  For example, the output may 
indicate that the underlying distribution for a given parameter (e.g., content uniformity of 
an active pharmaceutical ingredient) needs to be narrowed to lower the probability of 
observing toxicity in patients.64,65 
 Risk assessment is frequently used to estimate the potential hazards associated 
with various substances, including pharmaceutical compounds.  For example, molecules 
that are identified as potentially carcinogenic, mutagenic, and/or teratogenic are typically 
entered into a risk assessment program to characterize the relative risk between dose and 
response (e.g., development of a tumor).  In order to accomplish this, it is necessary to 
estimate the probability of the expected outcome as a function of the dose administered.  
The elucidation of this relationship, however, fails to deconvolve the underlying 
pharmacokinetic and pharmacodynamic mechanisms that contribute to the undesirable 
response.  Therefore, integration of PK knowledge has been proposed as a means to 
enhance the power of the risk assessment.76   
Kodell et al. conducted a probabilistic dose-response assessment using tumor 
dose-response data from a 2-year rodent bioassay to investigate several methods of 
integrating PK and PD knowledge within a dose-response model.76  The authors used 
MCS to study the impact of linking various combinations of PK and PD models on the 
assessment of risk.  Further, MCS was exploited to randomly generate rodent tumor 
responses based on doses sampled from an assumed PK dose distribution.  They 
concluded that the use of PK data, which related administered dose to in vivo levels, 
reduced the uncertainty associated with assessment of tumor risk.  They also determined 
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the PK models of various complexities did not affect the variability in the risk estimate.  
This was attributed to the binary model for tumor response (i.e., tumor or no tumor). 
 Although the study by Buur et al. does not involve the administration of a drug 
with the intent to treat humans, many of the concepts and methods utilized within are 
directly applicable to the pharmaceutical industry.77  The authors performed a risk 
assessment when they used probabilistic modeling and MCS in conjunction with a 
physiologically-based PK model to predict the withdrawal times of sulfamethazine 
residues in swine tissue.  The FDA regulates the period of time that must elapse before 
feed animals can be harvested for consumption following the administration of certain 
agents to mitigate the risk of adverse reactions in humans (i.e., withdrawal time).  
Sulfamethazine is an antibiotic used for the treatment and prevention of several diseases 
commonly contracted by pigs.  Sulfonamide drugs are of significant interest to regulatory 
officials since they are known to cause a variety of allergic reactions in humans.   
The authors utilized a published physiologically-based PK model and numerous 
published values for the parameters of interest (e.g., hepatic clearance rates, rate of 
absorption, percent plasma protein binding).  A sensitivity analysis was conducted to 
determine the parameters that significantly affected the pharmacokinetics of 
sulfamethazine; specific details regarding the statistical approaches employed were not 
provided.  Lognormal distributions for the statistically significant parameters (inputs to 
the PK model used to predict tissue and plasma concentration) were generated using the 
widest dispersion estimates published so as to output the most conservative withdrawal 
time estimates.  These distributions, therefore, represented the variability within the 
general swine population.  Insensitive parameters were not utilized during the subsequent 
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MCS analyses.  Each MCS trial iterated 1000 times to yield a single withdrawal time.  
The withdrawal time was estimated as the upper limit of the 95th percent confidence 
interval of the time necessary for 99 % of all tissue and plasma concentrations of the 
1000 trials to decrease below the specified threshold.  A series of 100 trials were 
conducted for specific tissues of interest.  The validity of the simulation architecture was 
assessed by comparing the predicted plasma and tissue concentration profiles to 
published mean concentration-time data sets; it was determined that the predicted 
concentrations corresponded well with the reported values.  The authors concluded that 
the mandated withdrawal time of 15 days should be revisited in lieu of the considerable 
public health risk that persists well after this time window.  Although the authors 
acknowledge that their methodology most likely yields more conservative estimates than 
those that might actually be observed, they underscore the fact that their simulation 
architecture can be updated as additional data which better approximate the true 
parameter distributions are acquired.77        
1.3.4 In Vitro-In Vivo Correlation (IVIVC)  
1.3.4.1 Background 
Pharmacokinetic and pharmacodynamic models are generated using clinical data 
acquired with the assistance of healthy volunteers and ailing patients.  While testing in 
humans is a critical component of the drug development process for a new drug 
application (NDA), there is a distinct need for a method capable of assessing the clinical 
effectiveness and reproducibility of medical products within an artificial environment.  
This is especially relevant in the case of abbreviated new drug applications (ANDAs) for 
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generic drugs, where clinical studies to establish safety and effectiveness are generally 
not required.  Knowledge obtained during pharmacokinetic, and to a certain extent 
pharmacodynamic, modeling is used to help establish a relationship between in vitro and 
in vivo performance.  Predictive relationships between in vitro and in vivo product 
performance decrease development costs, reduce unnecessary burden to test subjects, and 
expedite product release, all of which underpin public health objectives of the FDA. 
 In vitro-in vivo correlation is the mathematical architecture for relating in vitro 
drug release profiles to absorption in vivo.  The main purpose of IVIVC is to demonstrate 
in vivo bioavailability through in vitro analyses.  Dissolution testing is the conventional in 
vitro test employed by the pharmaceutical industry to assess drug release profiles in view 
of the fact that drug dissolution and release from the dosage form are acknowledged as 
key elements to clinical performance; dissolution was formally recognized as a sensitive 
and reproducible surrogate for assessing bioequivalence in 1993.  Dissolution testing 
supports manufacturing quality control programs, the determination of product release 
characteristics, and certain regulatory considerations.22,78,79   
Dissolution testing monitors the extent or rate of drug release as a function of 
time.  The United States Pharmacopeia (USP) defines 4 different apparatus (1 – 4), the 
basket apparatus, the paddle apparatus, the reciprocating cylinder, and the flow-through 
cell, for general dissolution testing.80  For certain compounds, individual monographs 
dictate the specific requirements for dissolution analyses.  The FDA encourages the use 
of apparatus 1 or 2 for the establishment of an IVIVC; however, apparatus 3 and 4 may 
be employed when the dissolution properties cannot be ascertained with the former 
setups.  Equally important to the setup is the analytical method utilized to monitor drug 
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release.  Ultraviolet-visible (UV/Vis) spectroscopy or high pressure liquid 
chromatography (HPLC) are the two most common analytical techniques used to 
measure API concentration within the dissolution media.  Given the overall significance 
of dissolution testing, the methodology and its associated specifications are often justified 
through IVIVC efforts.  In addition to its role in instituting scale-up and postapproval 
changes (SUPAC), establishing biowavers, and setting dissolution specifications,79 
IVIVC has also been associated with enhanced product quality.78   
 Clinical data are traditionally available early on in the drug design and 
development process.  IVIVC efforts commence during the initial stages of development 
and can continue late into the life cycle of a product.  Numerous prototype formulations 
and dosage forms, with various in vitro and in vivo characteristics, are typically 
considered during product development.  Although the majority of IVIVCs reported in 
literature are for per oral dosage forms, research is underway to establish correlations for 
other delivery vehicles (e.g., transdermal patches, biodegradable parenteral depot 
systems).78,79  The IVIVC begins by proposing an in vitro target to meet a desired in vivo 
performance profile or specification; the targets are subject to change, however, as the 
product characteristics are finalized to achieve the intended performance.  The desired 
performance profile may also be modified.  As more and more data are generated, the 
IVIVC is refined to accurately reflect the relationship it seeks to describe. 
1.3.4.2 Classification of IVIVCs 
Numerous approaches to IVIVC modeling are defensible.  Moreover, IVIVCs of 
disparate complexities are suitable depending on the given application.  Both the USP 
and the FDA have released documents intended to help direct participants in constructing 
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an IVIVC appropriate to their needs.  The FDA published a guidance on IVIVC in 1997 
entitled Extended Release Oral Dosage Forms: Development, Evaluation, and 
Application of In Vitro/In Vivo Correlations.22  Likewise, a chapter titled In vitro and In 
vivo Evaluations of Dosage Forms can be found within the USP.81  Within these 
documents, four different levels of IVIVC are acknowledged: A, B, C, and Multiple 
Level C (certain articles recognize a fifth level, D;78 however, since it is a rank ordering 
and, therefore, not a true correlation, level D will not be considered within this work).  
The levels are defined based on the amount of data used to establish the relationship, 
which directly determines the interpretability of the IVIVC function. 
Level A correlations are the most powerful IVIVC and are advocated by the 
FDA.22  As Level A correlations use all in vitro and in vivo data, they represent a point-
to-point relationship between the in vitro dissolution response and the in vivo input rate, 
where the latter is typically expressed as the in vivo release of the drug from the delivery 
vehicle.  Linear correlations, regardless of whether the in vitro and in vivo curves are 
directly superimposable or are rendered so by the implementation of a scaling factor, are 
the most common Level A correlations.  Nonlinear solutions, however, are not incorrect 
and therefore, should not be overlooked in situations where linear correlations are 
infeasible.  Once the association between the in vitro dissolution rate and the in vivo input 
rate is understood, the relationship must be extended to include the portion of drug 
absorbed in vivo (the relationship is not, however, extended to the therapeutic outcome).  
Ultimately, Level A correlations should be completely predictive of a drug’s in vivo 
performance (e.g., plasma drug concentration).  This type of correlation can be used to 
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justify a change in the manufacturing route, site of production, incoming raw materials, 
and/or for certain minor formulation amendments. 
Level B correlations are similar to Level A in that they use all in vitro and in vivo 
data; however, they are not defined point-by-point.  Rather, Level B correlations are 
based on statistical moment analyses, particularly the first moment.  For Level B 
correlations, the mean in vitro dissolution time is related to the mean in vivo residence 
time or the mean in vivo dissolution time.  It is critical to note that dissimilar in vivo 
curves can produce comparable mean residence times.  Since Level B correlations do not 
model absolute plasma time curves, they alone cannot be used to justify the same changes 
that can be addressed with Level A correlations. 
   Level C correlations relate one dissolution metric (e.g., t50%, t90%) to one 
pharmacokinetic parameter (e.g., Cmax, Tmax, AUC).  Considering that a Level C is a 
single point correlation, it does not communicate the complete in vivo plasma profile.  
Since only a partial relationship between dissolution and absorption is ascertained, a 
Level C is the weakest of all the correlation levels.  The applicability of a Level C 
correlation is analogous to a Level B correlation.  While neither establish bioequivalence, 
both may be useful in product design, particularly in optimizing formulations.78 
Multiple Level C correlations relate several dissolution time points, preferably a 
minimum of three representing initial, intermediate, and ending time values, to one or 
more pharmacokinetic parameters.  Each time point should be related to the same 
variable when more than one pharmacokinetic parameter is implemented.  A multiple 
Level C correlation established using time points representative of the entire dissolution 
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profile can serve as evidence for a biowaver.  More often than not, a Level A correlation 
is feasible if a Level C correlation has been established.   
1.3.4.3 Approaches to IVIVC Modeling 
Deconvolution and convolution are two common methodologies employed to 
construct IVIVCs.  The former is a two-stage modeling technique, whereas the latter 
involves a single stage.  The first stage of deconvolution entails modeling of the in vivo 
absorption or dissolution time profile.  This can be accomplished using a number of 
pharmacokinetic techniques such as the Wagner-Nelson or Loo-Riegelman methods, or 
general non-compartmental schemes.82  Once the in vivo time profile has been estimated, 
the second stage of the deconvolution method is to determine the relationship between 
the in vivo profile and the in vitro dissolution profile.  The goal is to establish a point-to-
point relationship between the corresponding in vitro and in vivo parameters acquired at 
the same time.  This can be done by way of a simple linear relationship or a more 
intricate sigmoidal (e.g., Hill) function.  Deconvolution methods suffer from restricted 
modeling flexibility (due to the numerous constraints imposed by the methods of stage 
one) and do not convey drug plasma concentrations (as they model fraction dissolved 
versus fraction absorbed), which severely limit the interpretability of the IVIVC.22,83 
Conversely, convolution directly relates the in vitro dissolution profile to the in 
vivo drug plasma concentration time profile through a convolution integral  
 ( ) ( ) ( ) ( ) ( )∫ −=∗=
t
drtCtCtrtC
0
τττδδ     (1.3) 
where C represents the drug plasma concentration, r is the in vivo input rate, τ is the 
dosing time, t is the current time, and Cδ is the instantaneous absorption of a unit quantity 
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of drug, which can be estimated from IV bolus, oral solution, suspension, or rapidly 
releasing (in vivo) immediate release dosage forms.  In other words, total plasma 
concentration C(t) is the summation (i.e., integral) of the remaining fractions Cδ(t-τ) of 
the infinitesimal contributions r(τ)dτ occuring at time τ.22,83  The fundamental objective 
of convolution-based IVIVC methods is to determine the functional relationship that 
connects the in vivo input rate (r) to the in vitro dissolution rate (rdis) such that 
 ( )trfr dis ,=   (1.4) 
The most parsimonious convolution-based IVIVC model involves a linear relationship 
 ( ) ( )traatr dis⋅+= 10   (1.5) 
where the scale (a1) and offset (a0) coefficients are 1 and 0, respectively.  This has been 
termed the basic convolution-based IVIVC method.83  While this is an ideal scenario, the 
scale and offset coefficients may often be different than 1 and 0, respectively.  Due to 
factors that frequently prohibit instantaneous uptake in vivo (e.g., time necessary to 
transport to absorption site) and factors that yield differences in units of measurement 
(e.g., fraction of the dose absorbed), time and amplitude scaling in addition to lag-time 
coefficients are often beneficial to model performance, which can be achieved using the 
equation 
 ( ) ( )tstrstr disr ⋅+⋅= 10   (1.6) 
where s1 and sr are the time and amplitude scaling factors, respectively, and t0 is the 
absorption lag-time term, or the time at which the drug is first absorbed systemically.  
Scaling and offset coefficients should only be applied in situations where they can be 
justified mechanistically and enhance the predictive power of the model.83 
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While deconvolution- and convolution-based methods have been applied for some 
time,22 a novel method known as direct, differential-equation-based IVIVC was proposed 
by Peter Buchwald in 2003.83  Although the direct, differential-equation-based IVIVC 
method is analogous in many ways to the convolution technique, it is unique in that it 
harnesses differential equations, which are linked to a basic pharmacokinetic model that 
describes the system under consideration.  Plasma concentration, therefore, is 
mathematically expressed by a functional pharmacokinetic model that describes the effect 
of the body on the drug itself.  The assumption is made that absorption, distribution, and 
elimination of the drug can best be modeled using compartmentalized pharmacokinetics.  
For ease of demonstration, the following discussion will assume a one-compartment 
model; however, multi-compartment models can be used during differential-equation-
based IVIVC.  
The fundamental architecture of differential-equation-based IVIVC expresses in 
vivo drug plasma concentration as  
 ( ) kCtr
dt
dC −=   (1.7) 
where k represents the elimination rate constant, and C, r, and t are as were previously 
defined.  In terms of pharmacokinetic modeling, the in vivo input rate (concentration per 
time) for a one-compartment open model with, for example, exponentially decreasing 
input with an absorption rate κ, can be expressed using the common formulae  
 ( ) ( )tktt ee
kV
DCe
V
Dtr κκ κκ
κκκ −⋅−=⇒⋅=
−− 00   (1.8) 
where D0 represents the initial dose and V is the volume term.  For the purposes of 
IVIVC, however, the in vivo input rate (r) is related to rdis through a function analogous to 
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that used in the convolution method (Equation 1.4).  This assumes, however, that 
dissolution, not absorption, is the rate limiting step. 
 Buchwald83 proposed an amended model that includes φabs, a time-dependent 
absorption factor that takes into consideration fluctuations in absorbance as the dosage 
system traverses the gastrointestinal tract 
 ( ) ( ) ( )tstrsttr disrabs ⋅+⋅⋅= 10ϕ   (1.9) 
The time-dependent absorption factor can be as straightforward as a low-pass filter (φabs 
= 1 if t ≤ tcut ; φabs = 0 if t > tcut) or can be something more complex such as a sigmoidal 
step-down function 
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1
  (1.10) 
where η is the steepness of the cut-off and tcut is the last time point at which absorption 
occurs.  To minimize the number of parameters that must be optimized, η can be set to a 
constant value.  Due to its extensive surface area, the small intestine is the primary site of 
absorption for many drugs.  The mean small intestine transit time has been reported to be 
3 (±1) hours.84-87  Taking into consideration the range of gastric emptying times, minimal 
systemic uptake would be expected beyond 4 to 10 hours post administration; drugs that 
absorb well within the colon (i.e., certain highly-permeable molecules) would extend the 
aforementioned absorption window.  Thus, the application of a time-dependent 
absorption factor is justifiable for many controlled release delivery systems.  Buchwald 
reported enhanced IVIVC performance when a sigmoidal absorption function (tcut = 6.4 
hours) was used in conjunction with scaling and offset factors.83   
 A total of two equations are necessary to establish an IVIVC for a one-
compartment pharmacokinetic model (Equations 1.7 and 1.9).  Each additional 
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compartment incorporated in the pharmacokinetic model will require one additional 
differential equation to describe the change in concentration as a function of time within 
that compartment.  Estimations of rdis at numerous time points are required to numerically 
solve the IVIVC equations.  The dissolution rate can be estimated by fitting the in vitro 
dissolution profiles with a flexible, continuous function, such as a sigmoidal, quadratic, 
or exponential (e.g., Weibull) expression.  The instantaneous dissolution rates are then 
acquired via the analytical derivative of the fitted function.83   
 The direct, differential-equation-based IVIVC method is restrictive in that it 
assumes compartmental-based pharmacokinetics.  It does, however, yield an estimation 
of the elimination rate constant (k), which can be verified for accuracy using clinical data.  
Moreover, it circumvents the need to convolve or deconvolve mathematical expressions, 
and it directly relates the in vitro dissolution profile to the in vivo drug plasma 
concentration time profile. 
1.3.4.4 Predictability of IVIVCs 
The validity of an IVIVC is demonstrated by its predictability.  Recalling that the 
key objective of an IVIVC is to generate a predictive mathematical function that relates 
in vitro and in vivo performance, validity is centered on the degree of prediction error.  
Validity can be assessed via the data used to construct the IVIVC (referred to as internal 
predictability) or data independent of those used to generate the model (referred to as 
external predictability).  Predictability assessments via internal and/or external methods 
are dependent on the intended use of the IVIVC and the therapeutic index of the drug; 
estimations of internal variability should be performed for all IVIVCs.  Narrow 
therapeutic index drugs require external estimations of prediction error.  Greater detail 
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regarding the requirements of internal versus external predictability can be found in the 
FDA guidance.22  Regardless of the method used, predictability must demonstrate that the 
IVIVC model can accurately predict in vivo performance from in vitro data comprised of 
various release rates and manufacturing conditions.  Generally, this should be 
accomplished using a minimum of three different formulations with release rates that 
vary by, for example, 10 % for each formulation, which should yield a commensurate 
distinction in in vivo performance.  Prediction error can be assessed as the average 
absolute prediction error (% PE) and typically must be less than 10 % to demonstrate 
predictability for both internal and external estimations.  An adequate number of subjects 
should be studied to effectively characterize in vivo performance.  This has been 
accomplished with as few as 6 and as many as 36 individuals, but this is not to say that 
more cannot be evaluated.22  Jaber Emami conducted a thorough review of IVIVC in 
2006 and noted that the majority of the literature articles failed to report (or perhaps even 
assess) predictability.78   
 Dissolution is often used as a quality control gauge to assess batch-to-batch or lot-
to-lot similarity/dissimilarity.  The variability of release at a given time point(s) is 
commonly assessed, where the acceptance specification could be set as ± 10 % deviation 
from the average profile of the clinical/bioavailability samples.  The power of the 
analysis is amplified if a predictive IVIVC has been established.  Given that dissolution 
now conveys in vivo performance, the dissolution release specifications can be 
established with aid from the IVIVC to mitigate in vivo variability.22,79 
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1.3.4.5 IVIVC for Theophylline Dosage Systems 
 Theophylline is categorized as a class I compound according to the 
Biopharmaceutics Classification System (BCS).88  As a class I molecule, theophylline 
exhibits high solubility and high permeability.  Drug dissolution, not absorption, is the 
rate-limiting step to the bioavailability of theophylline;89 when dissolution occurs rapidly, 
however, the rate of absorption is then determined by the frequency of gastric emptying.  
Therefore, an IVIVC is not unexpected for theophylline dosage systems, especially for 
controlled release products where dissolution, not absorption, is the rate-limiting step.    
 El-Yazigi and Sawchuk remarked that even though the bioavailability of 
theophylline had been thoroughly investigated, the potential of establishing a quantitative 
IVIVC had yet to be reported as of 1985.90  This finding was the impetus for 
investigating the effects of pH, apparatus, and stirring speed on the dissolution rate of 
theophylline from assorted commercially available products.  In doing so, the authors 
modeled the cumulative percent theophylline dissolved using a first-order equation.  The 
covariation between the cumulative percent dissolved at various times or the first-order 
rate constant was assessed against different pharmacokinetic parameters (e.g., the fraction 
of the dose absorbed at a given time, dose-normalized area under the curve, peak serum 
levels).  Pharmacokinetic parameters were estimated from the in vivo data, which were 
collected in male New Zealand white rabbits.  At the time of publication, a coefficient of 
determination of 0.9 or greater backed by reproducible predictions of the modeled 
bioavailability parameters signified a good IVIVC.  The authors reported strong Level C 
correlations amongst in vitro and in vivo parameters for the dosage forms assessed under 
a myriad of experimental conditions.  Moreover, good agreement between the actual and 
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predicted pharmacokinetic parameters was reported (for one apparatus at a specified pH 
and a constant stirring rate).90   
 Munday and Fassihi generated IVIVCs for the commercially available controlled 
release product Theo-Dur as well as their own novel controlled release delivery system 
Mintab.89  All in vivo data was collected in canines.  The authors used the rudimentary 
deconvolution-based approach to IVIVC modeling where a one-to-one correspondence 
between the in vitro and in vivo data is desired.  Although the Theo-Dur tablets 
demonstrated good IVIVC, poor correlation between the in vitro dissolution and in vivo 
absorption of the Mintab system was observed.  This was attributed to the incongruent 
dissolution profiles observed across the various dissolution conditions.  The authors did 
not investigate alternative approaches to modeling the Mintab data.  Moreover, they 
neglected to comment on the predictability of the IVIVCs.89   
 Yu et al. investigated the in vitro and in vivo characteristics of four experimental 
oral controlled release theophylline dosage systems (three different hard gelatin capsule 
formulations and one tablet).91  Healthy male beagles were used to collect the in vivo 
data.  The in vitro dissolution profiles of the four different delivery vehicles where shown 
to be unique across the various formulations and dissolution conditions.  Using a 
deconvolution-based IVIVC approach, the authors established a point-to-point (ratio) 
relationship between the cumulative percent theophylline released in vitro and in vivo.  
Although no predictability estimates were determined, the authors concluded that the 
correlation between the in vitro and in vivo data was good based on the visual congruence 
of the point-to-point (ratio) time profiles.91  
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 While the previous investigations utilized animals for the in vivo analyses, 
Hussein and Friedman conducted an IVIVC study of various theophylline formulations in 
both canines and humans.92  Five experimental sustained release theophylline 
formulations and two commercial sustained release products (i.e., Theotrim and Theo-
Dur) were selected.  Two different dissolution media were used to model conditions 
within the gastrointestinal environment.  Distinct mean dissolution profiles were obtained 
for each dosage system using the specified dissolution methodology.  Three male and two 
female dogs and six healthy humans (gender not indicated) were studied to obtain the in 
vivo absorption data.  The percent theophylline absorbed in both humans and canines was 
estimated using the Wagner-Nelson method.  Mean in vitro release and individual in vivo 
absorption profiles were used in conjunction with linear regression to relate the 
percentage released to the percentage absorbed at each time point sampled.  The slopes (± 
standard deviation) and the coefficients of determination for three of the experimental 
formulations and both commercial products were reported; the remaining two 
experimental formulations were only tested in vitro (no explanation provided).  Based on 
the variance explained through linear regression, the authors concluded that IVIVC was 
feasible using bioavailability data obtained both in canines and humans.  No estimates of 
prediction error were reported.92   
1.3.5 Pharmacokinetics 
1.3.5.1 Background 
 The study and understanding of in vivo drug (and metabolite) levels over the 
duration of treatment are key functions in the drug development process.  These 
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concentrations, in turn, influence the clinical outcomes of the therapy and, therefore, must 
be managed so as to be both safe and effective.  Aside from the intricacies of drug 
delivery systems, numerous variables, including behavioral, environmental, physiologic, 
and pathophysiologic factors, can influence the uptake and disposition of medical 
substances.  For example, concomitant drug therapies via drug-drug interactions 
commonly modify the rate of removal of one or several of the drugs from the body, 
which has the potential to drastically affect patient well-being.  Furthermore, many drugs 
perform differently when administered to infant, adolescent, adult, or geriatric patients 
due to changes in organ size and function.  As such, extensive studies must be undertaken 
to identify these factors, as well as those associated with the intricacies of the delivery 
system, and appreciate how (mechanistically) they alter the management of disease.  
More often than not, these studies yield quantitative empirical models that predict drug 
serum/plasma levels for groups of patients under a specific set of conditions.   
Pharmacokinetics denotes the examination of the time course of drug absorption, 
distribution, metabolism, and excretion (ADME) to ultimately elucidate the relationship 
between dose and exposure.  Pharmacokinetics can be grossly divided into two 
components, an experimental and a theoretical element.  The former involves the 
collection and analyses of data, and the methods describing these practices, while the 
latter entails the generation and validation of physiologically-based or empirical models 
that express drug levels following administration.  The pharmacokinetic focus of this 
dissertation is predominantly on the theoretical component.  Thus, the background and 
application of experimental pharmacokinetics, which includes topics such as sampling of 
biological fluids/tissues and the analytical methodologies for measuring drug 
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concentration, will not be addressed.  This work will, however, model plasma rather than 
serum concentrations given that plasma has the ability to perfuse through all tissues in the 
body.  If a dynamic equilibrium is assumed to exist between plasma and the body tissues, 
changes in drug plasma concentration thereby mirror those in the tissues.82,93   
 One of the major outcomes of experimental pharmacokinetics that subsequently 
becomes the impetus for theoretical modeling is the drug concentration time profile, 
which is an illustration of the concentration of drug in the serum/plasma determined at 
precise sampling time points following the administration of one or more doses (Figure 
1.7).  Drug concentration time profiles reflect the substance’s absorption into systemic 
circulation, distribution to the various tissues in the body, and elimination via 
biotransformation and/or excretion, all of which take place simultaneously during 
treatment.  Countless variables affect the shape of these profiles, including the route of 
administration, the dosing intervals, the amount of drug administered, the rate of gastric 
emptying, and the fitness of the individual and the clearing organ(s).  The profiles, or 
more precisely, the data upon which the profiles were generated, are then used as inputs 
to various numerical models that seek to accurately express the change in drug 
concentration as a function of time.  Otherwise, they can be described by scalar metrics 
such as the maximum concentration (Cmax), the time necessary to reach the maximum 
concentration (Tmax), the area under the curve (AUC), and/or the drug clearance rate, all 
of which have particular PK significance.82,93     
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Figure 1.7. Plasma concentration time profile for a dose administered every 12 hours for 15 days simulated 
in silico. 
 The underlying PK are typically described as liner or nonlinear.  Linear kinetics 
are characteristic for a drug whose PK parameters are invariant with the administration of 
different doses.  For example, first-order kinetic equations might adequately describe the 
time course of drug ADME; a plot of the AUC for the plasma concentration-time curve 
versus dose would be linear.  Some drugs, however, display dose-dependent (i.e., 
nonlinear) PK, and the same AUC versus dose plot would be nonlinear over certain 
ranges.  Many of the physiological processes responsible for ADME are conducted by 
carrier-mediated or enzymatic systems, both of which are subject to saturation.  
Additionally, the drug (or other concomitant drugs) may induce a physiologic or 
pathophysiologic change that transforms the kinetics of the drug of interest from linear to 
nonlinear.  These situations are exemplified by a change in the rate of drug elimination.   
For instance, the elimination rate may decrease due to the saturation of metabolic 
enzymes or may increase due to the induction of metabolic enzymes.  Regardless of the 
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directionality, dramatic inaccuracies in the plasma levels may occur if the change is 
inaccurately modeled.82  
As stated, pharmacokinetic models can be empirical or physiologically-based.  
Empirical models are applied to a set of data based solely on their ability to 
mathematically describe the information, regardless of the underlying physiological and 
pathophysiological mechanics.  Alternatively, physiologically-based pharmacokinetic 
models encompass the physical and biochemical functions of the body with respect to 
ADME of drugs and metabolites.  These models may incorporate knowledge regarding 
the rate of blood perfusion for a particular organ or the various types of cells that 
constitute the major organ systems that interact with the drug substance.82,93   
In theory, an infinite number of models can be ascribed to the complex kinetic 
processes of ADME if they are scrutinized on a cellular or sub-cellular level.  
Approaches to modeling, however, normally employ a number of assumptions to 
simplify these processes while concurrently retaining physiological relevance or 
numerical applicability.  The two most notable categories of pharmacokinetic modeling 
are compartmental and non-compartmental models.  Compartmental models reduce the 
body down into a number of systematic or serially-related compartments that reversibly 
interact with one another.  Compartments are hypothetical regions that represent a tissue, 
an organ, or a collection of tissues/organs that display comparable blood flow and affinity 
for a given drug.  Compartmental models assume that the drug is rapidly mixed and is 
homogenously distributed within a compartment of a definite volume.  Moreover, each 
drug molecule has the same likelihood of exiting the compartment.  Rate constants are 
used to express the transfer of drug between compartments and differential equations 
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describe the change in drug concentration over time.  The instantaneous concentration of 
drug in the body is, therefore, the summation of concentrations in each of the contributing 
compartments.  Compartment models are open in view of the fact that drug can be 
eliminated from the system.82,93   
There are two general forms of compartmental pharmacokinetics.  The first is 
known as the catenary system, which is structured as a series of coupled compartments 
(analogous to box cars on a train) where input occurs in the first compartment and drug 
can only be transferred to and from adjacent compartments.  Since this format does not 
effectively characterize the manner in which plasma interacts with tissues/organs, 
catenary models are used infrequently.  The other form of compartmental 
pharmacokinetics is referred to as the mammillary system, which consists of, at a 
minimum, one central compartment.  They can also incorporate numerous peripheral 
compartments, all of which have direct (and potentially coincident) access to the central 
compartment.  Mammillary models are the most common structure for compartmental 
pharmacokinetics.82,93 
Non-compartmental pharmacokinetics makes no assumption regarding the nature 
of the distribution of a drug, whereas compartmental modeling presumes that substances 
are distributed amongst one or more compartments.  Non-compartmental PK makes use 
of statistical moments (e.g., area under the moment curve (AUMC), AUC), which are 
mathematical descriptions of a discrete distribution of data.  A statistical moment of 
concentration-time data describes the probability density function, which represents the 
true relationship between concentration and time.  A non-compartmental approach to 
modeling is preferred by some as it is not centered on the same assumptions as 
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compartmental pharmacokinetics, which traditionally applies empirical models that have 
no physiologic relevance.  Non-compartmental modeling can be of particular benefit in 
situations where a single compartment model fails to adequately characterize an entire 
population (e.g., a fraction of the patients are characterized by a two-compartment model, 
while the remainder are more accurately described by a three-compartment model).  
Nevertheless, non-compartmental models use differential equations to express the change 
in concentration (in the body as a whole) over time. 
 The following discussion and accompanying formulae are a straightforward 
example of a one-compartment open model.  While more complex functions, some of 
which are nonlinear (e.g., Michaelis-Menten kinetics), exist, the reader is referred to any 
advanced pharmacokinetic textbook for greater detail.  One-compartment open models 
are particularly useful for drugs administered via IV bolus injection, where the drug is 
introduced into systemic circulation (nearly) instantaneously.  A one-compartment model 
following IV bolus administration is fundamentally characterized by three terms, the drug 
in the body (DB), the apparent volume of distribution (VD), and the elimination rate 
constant (k).  The apparent volume of distribution is the volume in which the drug is 
assumed to be homogeneously distributed, and the elimination rate is the collective total 
of the joint processes of biotransformation and excretion.  The apparent volume of 
distribution does not correspond to a true anatomic space; rather, it signifies the volume 
of the sampling compartment used to estimate the amount of drug in the body, hence the 
annex “apparent.”  Since the human body is more or less at constant volume, it is 
common practice to use an invariable estimate for the VD.  However, certain physiologic 
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conditions, such as edema, which results in increases to total body water, can invalidate 
this assumption.82,93 
 The differential equation that describes a one-compartment model with 
instantaneous uptake is 
 BB kDdt
dD −=   (1.11) 
where DB and k are as previously defined.  Following integration, the drug in the body at 
any time (t) is expressed as 
 ktBB eDD
−= 0   (1.12) 
where 0BD  is the amount of drug in the body at time t = 0.  Mathematically, DB is 
estimated as  
 pDB CVD =   (1.13) 
where Cp represents the concentration of drug in the plasma.  Given these relationships, 
the first-order decrease in plasma drug concentration is expressed as 
 ktpp eCC
−= 0   (1.14) 
where 0pC  is the concentration of drug in the plasma at time t = 0 once the drug has 
equilibrated within the body.  The VD is estimated using the expression 
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where the dose is administered via IV bolus injection and 0pC  is estimated by 
extrapolating the plasma concentration versus time curve back to the y axis.82,93   
 Clearance is the pharmacokinetic term for the overall rate of removal of drug 
from the body.  It does not identify the underlying elimination mechanism(s); rather, 
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clearance is purely a numerical expression of the volume of fluid containing drug that is 
removed from the body per unit time.  Although clearance is typically expressed with 
respect to volume, removal can also be conveyed in terms of mass, fraction, or 
concentration per unit time.  Many drugs are removed from the body via a first-order 
process (i.e., the rate of removal is only dependent upon the plasma concentration).  
When expressed as volume per unit time, clearance is assumed to be constant for a first-
order process, which is a direct result of assuming a constant VD; just as was true for VD, 
certain physiologic circumstances can invalidate this assumption.  As such, clearance (Cl) 
from the body is expressed as 
 DkVCl −=   (1.16) 
where k is the first-order elimination rate constant.  The negative sign indicates that drug 
is being removed from the body.  Although the instantaneous rate of drug removal from 
the body (i.e., amount per unit time) will decrease as concentration declines, clearance 
(i.e., volume per unit time) will remain constant so long as elimination is characterized by 
first-order kinetics.  The concept of clearance can be incorporated within the expression 
of plasma concentration for a one-compartment open model to yield 
 ( ) ( )tVClDp DeVDC /0 / −=   (1.17) 
where D0 denotes the initial IV dose.  Analogous equations exist for alternative routes of 
administration and for multi-compartment models.  Moreover, the concept of clearance is 
also applicable in non-compartmental pharmacokinetics.82,93  Extensive discussion 
regarding the estimation of clearance (e.g., renal excretion and biotransformation rate 
constants) can be found in pharmacokinetic textbooks and the literature.  The reader is 
referred to these general references for greater detail.     
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1.3.5.2 Pharmacokinetic Models of Theophylline 
Accurate dosing of theophylline has remained a significant challenge since its 
first applications in the early 20th century.  Imprecision can largely be attributed the 
extensive inter-patient variability for the PK of theophylline.  Consequently, substantial 
effort has been devoted to better understanding the underlying relationship between dose 
and exposure. 
Ginsberg et al. investigated the utility of a physiologically-based PK model for 
discriminating PK differences in neonates and adults.  This study was performed using 
two model drugs, caffeine and theophylline, both of which are know to have disparate PK 
in neonates and adults.  Both drugs were selected since caffeine demonstrates a more 
dramatic difference as a function of age, despite the fact that caffeine and theophylline 
are eliminated via similar pathways (refer to section 1.3.2.2).  Since the underlying PK 
mechanisms and the significant confounding factors are, by and large, poorly established 
for neonates when compared to adults, the authors were particularly interested in 
investigating the transferability of in vitro metabolic parameters determined in 
mammalian cells transfected with CYP c-DNAs to whole liver metrics.  This is an 
attractive method since the whole liver metrics can then be adjusted for the differential 
expression levels observed between neonates and adults.   
To accomplish this objective, a 5-compartment physiologically-based PK model 
was generated (i.e., liver, kidney, fat, and rapidly and slowly perfused tissues).  Hepatic 
metabolism was modeled using published in vitro Michaelis-Menten constants (i.e., Vmax 
and Km) for the major metabolic pathways of caffeine and theophylline (i.e., CYP1A1, 
CYP1A2, CYP2E1); all other transfer equations were linear.  The Michaelis-Menten 
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constants were scaled to account for the size of the liver, the amount of microsomal 
protein per gram of liver tissue, the aggregate concentration of CYP enzymes per 
microgram of microsomal protein isolated from the tissue, and the relative amount of 
each CYP enzyme to the total microsomal CYP quantity for a specific age range.  
Metabolism in organs other than the liver was not modeled and the fate of the 
metabolites, with the exception of conversion of theophylline to caffeine in neonates 
(assumed to be first-order), was not considered.  Renal elimination was expressed as a 
first-order process.  Although several of the model coefficients (i.e., the Michaelis-
Menten constants) were adjusted from the published values to optimize model 
performance, the authors concluded that the model described the differential PK 
reasonably well based on the comparison of predicted metabolite and drug levels with 
urinary excretion data.  Adjustments were deemed necessary since the in vitro system did 
not mimic the compensatory pathways that are present in vivo (e.g, conversion of 
theophylline to caffeine, no incorporation of FMO).  The authors also noted that 
metabolism in newborns should be adjusted for gestational variations and postnatal age 
during the first weeks of life.  This study underscores the importance of neonatal PK data.  
Scaling of theophylline data from adults to newborns would overlook the conversion of 
theophylline to caffeine that takes place in this age group.28 
 Bjorkman exercised a similar set of objectives when he generated a generalized 
physiologically-based PK model applicable across a broad range of ages.30  Unlike the 
work of Ginsberg et al.,28 however, all relevant PK parameters (i.e., model inputs) were 
scaled using data obtained from adults as opposed to estimating the parameters from in 
vitro metabolic data.  The physiologically-based model was evaluated with theophylline 
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and midazolam, two drugs that display dissimilar physiochemical and PK attributes (e.g., 
lipophilicity, predominant CYP metabolic enzymes).  As the unbound (i.e., free) fraction 
of theophylline is known to vary with age, a constant unbound fraction of 0.56 was 
assumed for adults, while plasma protein binding for infants and children was modeled 
according to the age-related variability is serum albumin concentration (equation not 
given in original article).  Total theophylline clearance was partitioned to be 85 % hepatic 
and 15 % renal, and clearance was assumed to be linear (i.e., first-order) across all age 
ranges studied.  For subjects from 0 – 9 years, a bi-exponential growth function was used 
to assign the relative contributions of CYP enzymes to the hepatic metabolism of 
theophylline, while 92 % was attributed to CYP1A2 and 8 % to CYP2E1 for individuals 
10 years or older.  Renal clearance for infants of 6-months was increased by 10 % owing 
to the methylation of theophylline to caffeine.   
The model was validated using amassed literature data.  Model performance was 
assessed according to the percent prediction error for the estimation of clearance (Cl), 
volume of distribution at steady state (Vdss), and terminal half-life (t1/2).  The median 
prediction errors for Cl, Vdss, and t1/2 of theophylline were -4.0 %, 3.4 %, and 24 %, 
respectively.  Bjorkman concluded that the model predicted Vdss and Cl well, but noted 
that inter-subject variability of the actual clearance data was considerable.  This is not 
surprising given the findings of studies such as Jusko et al.46 and Chiou et al.37  The error 
of prediction for t1/2 was appreciably larger; inaccuracies in Cl and Vdss, however, are 
compounded in half-life estimations.  Additionally, Bjorkman questioned the legitimacy 
of several reported half-life values cited for neonates and infants, which may be more 
inexact than the predicted values.  While clearance, and to a much lesser extent, terminal 
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half-life of theophylline changed as a function of age, the volume of distribution was 
relatively invariant.30   
 While these examples are far more complex than a linear one-compartment open 
model, several studies have demonstrated reasonable predictive power using this 
technique.  Many of the following articles have been previously addressed in literature 
survey (refer to section 1.3.2) and, therefore, will not be expounded upon other than to 
specify the PK modeling assumptions that were implemented.  The studies conducted by 
Powell et al.45 and Chiou et al.37 utilized a linear one-compartment open model to 
describe theophylline concentrations.  Powell et al. also assumed that clearance and 
volume of distribution were constant for any given individual regardless of the 
theophylline level.  The authors defended their assumptions by referencing the empirical 
observations of a few studies published prior to their work.  The article by Gilman et 
al.,56 which compared the methods of Powel et al.45 and Jusko et al.,46 and a weighted 
least-squares Bayesian approach and the method of Chiou et al.37 for the estimation of 
theophylline clearance, employed a one-compartment open model and assumed linear 
elimination of theophylline.  The authors justified the use of linear elimination based on 
the several reports that theophylline failed to demonstrate saturable elimination in adults.  
The mean age of the patients utilized in the Gilman et al. study was 43.5 ± 15.8 years.  A 
constant volume of distribution of 0.5 L/kg was implemented.   
Brocks et al. performed a PK study in 34 pediatric patients ranging in age from 4 
months to 14 years of age using a one-compartment open model for orally administered 
theophylline.94  The authors generated predicted theophylline serum concentrations using 
both the patient’s individualized volume of distribution (0.3 – 1.54 L/kg) and a 
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standardized value of 0.5 L/kg, and two blood samples.  The mean prediction errors 
between the observed and predicted serum concentrations using the individualized and 
standardized volumes of distribution were -0.509 mg/L and 1.27 mg/L, respectively.  The 
authors concluded that their method can be used to accurately estimate theophylline 
dosages for pediatric patients, despite the fact that it does not require IV data.   
Casner et al. conducted a randomized trial during which the accuracy of a PK 
model for IV theophylline dosing was compared to physician dosing.95  A total of 35 
asthmatic or COPD patients were followed throughout the trial (several were excluded 
due to incomplete data) in one of two randomized groups; the kinetic group was dosed 
according to a computerized version of the Chiou et al. method,37 while the empirical 
group was dosed by physicians instructed to obtain a target concentration of 15 mg/L.  
The physiologic and pathophysiologic characteristics of the two groups were comparable.  
Three serum theophylline levels were determined from blood samples for each patient.  
Prediction error for the two groups was estimated by subtracting the third serum level 
from the target concentration.  The mean absolute values were 14.8 ± 4.4 and 12.6 ± 4.1 
mg/L for the kinetic and empirical groups, respectively.  Despite the fact that the 
computer predicted dosing was closer to the target value, the difference was not 
statistically significant.  Moreover, none of the clinical outcomes (e.g., number of 
subtherapeutic or toxic levels, duration of time in hospital) were statistically different 
between groups.  The authors concluded that PK model for theophylline dosing was of no 
additional clinical benefit.  It is noteworthy, however, that a linear, one-compartment PK 
model was able to match the skill of trained physicians.   
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The investigation of Hurley et al. was similar to the preceding study of Casner et 
al.; Hurley et al. conducted a randomized trial to assess the clinical differences of 
computerized versus physician dosing in 91 asthmatic or COPD patients upon admission 
to the hospital with acute air-flow obstruction.53  The authors also implemented a one-
compartment open model; however, the physicians were not advised to attain a target 
theophylline level.  Patients were initially dosed according to total body weight and then 
their doses were adjusted either by a computerized model (i.e., monitored group) or by a 
physician (i.e., control group).  Hurley et al. observed no statistically significant 
difference in theophylline serum concentrations between the two groups, nor in the 
number of subtherapeutic or superpotent levels.  They did, however, observe a 
statistically significant difference in the lower number of reported subjective side effects 
(i.e., breathlessness, palpitations) in the kinetic (or monitored) group as well as a 
statistically shorter hospital stay in the kinetic group (6.3 days) compared to the empirical 
(or control) groups (8.7 days).  Unlike Casner et al., the authors concluded that “using a 
pharmacokinetic method to determine theophylline dosage for the patient with acute air-
flow obstruction improves the likelihood of achieving a theophylline concentration in the 
therapeutic range, and may hasten the patient’s recovery.”  
 These are but a few of the examples of the PK models that have been generated to 
study theophylline.  Other researchers have also advocated the use of linear, one-
compartment models for the analyses of theophylline delivery systems.32,35,41,51,52,96,97  
Such models are purported to be applicable for both IV and orally administered dosage 
systems.       
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1.3.6 Pharmacodynamics 
1.3.6.1 Background 
A thorough understanding of the physiochemical properties of a drug and how 
they control its ADME is imperative.  Such knowledge, however, offers little insight as to 
how the molecule interacts with the targeted pharmacophore to elicit a physiologic 
response.  Although a mechanistic understanding of the manner in which a drug docks 
with the molecular target is not essential early in the development process, a sponsor 
must quickly identify how patients respond to the drug at a specified dose.  Likewise, it is 
important to understand how the safety and effectiveness of a drug delivery system 
change as it is optimized with respect to a desired exposure-response profile.  Within this, 
it is important to recognize that optimization will most likely affect the onset, magnitude, 
and duration of drug action.       
Once the pharmacokinetics of a drug are reasonably well understood, it is 
important to define the minimum effective concentration (MEC) that results in the 
desired endpoint and the minimum toxic concentration (MTC) that results in any adverse 
(i.e., toxic) event; concentrations between the MEC and MTC delineate the therapeutic 
window.  Numerous drugs exhibit a proportional relationship between the administered 
dose and the observed outcome.  Many individuals, however, respond differently 
(although not necessarily unfavorably) to the same drug administered at equivalent doses 
and it is this inter-individual variability that obfuscates the underlying exposure-response 
relationship.  Moreover, small fractions of the population can respond negatively to a 
given substance at a specified dose, despite the fact that the majority of individuals 
tolerate the treatment.  It is therefore important to integrate pre-clinical data with clinical 
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observations, as they become available, to better understand the relationship between 
exposure and pharmacologic outcome.  A thorough appreciation of the exposure-response 
relationship can help to better pinpoint successful management practices for individual 
patients or sub-populations a priori.48   
Pharmacodynamics is the field of study devoted to the onset, intensity, and 
duration of drug action following exposure.  In other words, PD is a supplement to PK 
that draws a parallel between the drug concentration time profile and pharmacologic 
endpoints to ultimately elucidate the relationship between exposure and response.  This 
bridge between PK and PD helps define the optimum dosing regimen to achieve the 
intended result.  It follows, therefore, that the same intricacies that affect the PK of a drug 
have the potential to influence the PD.  More importantly, these variables can act 
independently on the PD, despite the fact they showed no observable effect on the PK.  
Thus, it is necessary to investigate the potential demographic, physiologic, and pathologic 
factors that affect the exposure-response relationship.48 
Pharmacodynamic research often involves extensive investigations into the 
genetic factors that predispose individuals to respond favorably or unfavorably to a given 
drug.  Even in instances where the response is efficacious per se, pharmacologic 
outcomes that deviate from the projected exposure-response profiles are sometimes 
attributable to genetic polymorphisims of genes that encode receptors specific to the 
drugs and/or metabolites.  Such genetic variations have been known to alter the response 
independent of any change in the PK curve.48   
Adding to the significant challenge of defining an exposure-response profile is 
tolerance.  In certain cases, the observed pharmacologic outcome is modulated as a 
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function of time, despite maintaining the same dosing regimen.  This can be attributed to 
several physiologic or pathophysiologic factors, including an increase or decrease in the 
quantity of receptors, or an alteration in receptor affinity or signal transduction.  Thus, the 
exposure-response profile can be severely misconstrued if these time-dependent effects 
are overlooked.48 
Numerous other phenomena mask the underlying relationship between the PK and 
PD of a particular drug.  For instance, certain molecules elicit no effect below the MEC, 
while others yield a response distinctive from that observed within the therapeutic 
window; these effects are thereby exacerbated by sub-potent dosing and/or patient 
incompliance.  In such instances, a single exposure-response curve inadequately 
characterizes the causal relationship.  Furthermore, although many exposure-response 
curves are linear (or can be transformed to be so) over extended ranges, others are more 
appropriately described by an alternate function (e.g., sigmoid) due to disproportionate 
increases or decreases in response at extreme concentrations.  Selection of an 
inappropriate mathematical function to characterize the exposure response relationship 
can yield an erroneous PD model.     
The ability to ascertain the true exposure-response relationship is dependent upon 
the accuracy of the response estimate.  For example, subjective endpoints (e.g., decrease 
in pain) have higher degrees of uncertainty than measurable responses (e.g., decrease in 
blood pressure).  Responses that are dependent on an individual’s or a physician’s 
perception can complicate efforts to generate an accurate PD curve.  Further, certain 
pharmacologic endpoints are not feasible to measure.  Therefore, to increase the 
practicality or lower the associated risk, surrogate PD endpoints are employed under the 
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assumption that they are predictive of the actual clinical response.  For example, analyses 
of the antitumor effects of chemotherapeutic agents would require routine biopsies, which 
pose too high of a risk to the patient.  To circumvent this risk, clinicians often monitor 
expression levels of white blood cells to gauge patient response.98  Use of surrogate 
endpoints requires an additional level of validation to ensure that they are indeed 
representative of the true pharmacologic outcome.  Regardless of the endpoint employed, 
the success of any therapy is dependent upon, along with other critical links, a precise 
relationship between exposure and response.  
1.3.6.2 Pharmacodynamic Models of Theophylline 
 While numerous studies have focused on understanding the complex relationship 
between theophylline dose and exposure, less research has been devoted to developing 
pharmacodynamic models expressing the link between exposure and response.  This may 
be, to some extent, justified by the fact that researchers generally agree upon the 
therapeutic window that characterizes theophylline and the inefficacious and toxic events 
that occur outside this range.  Consistently dosing within this range, however, has proven 
to be a challenge.  
 The pharmacologic outcomes of theophylline closely parallel serum or plasma 
concentrations.  Both the degree of bronchodilation and the decrease in airway 
responsiveness trend with theophylline concentration.25  In fact, bronchodilation 
increases linearly with logarithmic increases in theophylline concentration, within the 
therapeutic range.35  Over the years of treatment with theophylline, researchers and 
clinicians have concluded that theophylline concentrations of 10 – 20 mg/L are most 
likely to safely provide clinical benefit, although it should be noted that levels as low as 5 
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mg/L are efficacious in certain cases.  Others, however, have campaigned for the lower 
limit of efficacy to be established as 5 mg/L (refer to section 1.3.2).  Thus, the MEC is 
not unanimously acknowledged as 5 or 10 mg/L, or some concentration in between.   
Concentrations in excess of 20 mg/L compromise the safety of treatment as the 
likelihood of toxic side effects increase dramatically above this level.  This is 
demonstrated in Figure 1.8 where the toxic outcomes of 50 adult patients treated with 
theophylline were documented.39  Unfortunately, the occurrence of more severe side 
effects is not always preceded by mild toxic events.  While certain mild side effects (e.g., 
headache nausea) may be offset by the potential clinical benefit, the fact that the onset of 
more severe side effects cannot be accurately predicted has firmly established the MTC at 
20 mg/L, although some have suggested this value should be reduced to 15 mg/L (refer to 
section 1.3.2).  Severe side effects are consistently observed at concentrations well in 
excess of 20 mg/L.   
 
Figure 1.8. Mean theophylline serum concentrations versus the frequency and severity of toxic effects in 50 
adult patients.  Mild toxic events included nausea, vomiting, headache, and insomnia.  Potentially serious 
toxic effects were limited to sinus tachycardia.  Severe toxic side effects included life-threatening cardiac 
arrhythmias and seizures. 
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 A number of studies have evaluated the effects of concomitant therapies on the 
pharmacologic outcome of theophylline, but they are specific to a single drug effect and 
sample population, and thus, have limited applicability.  For example, Hoffman et al. 
investigated the effects of total body gamma irradiation on several drugs in rats.99  They 
concluded that gamma radiation did not affect the theophylline dose necessary to induce 
seizures.  Similarly, Hoffman et al. explored the potential for cyclosporine to potentiate 
the effects of theophylline in rats.100  They observed that administration of cyclosporine 
reduced the theophylline concentration required to induce seizures and suggested that 
cyclosporine may increase the risk for generalized seizures during treatment with 
theophylline.        
A survey of the literature reveals that the majority of PD studies involving 
theophylline focus on bronchodilation in asthmatic patients.  One of the criteria used to 
diagnose asthma as well as monitor its condition is forced expiratory volume in one 
second (FEV1), which is the amount of air that an individual can forcibly expire in one 
second.  FEV1 is typically measured in liters using a spirometer and is reported as a 
percentage of the amount of air that can be forcibly expired after full inspiration.          
 It has long been reported that the degree of bronchodilation (or percentage change 
in FEV1) is linearly related to theophylline concentration when the concentration axis is 
log-transformed.  Indeed, Mitenko et al. observed this relationship in six hospitalized 
asthmatic patients who were administered theophylline IV; no mathematical relationship 
defining the PD model was offered.41  More recently, however, researchers have 
observed findings that challenge this correlation.   
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Flores-Murrieta et al. reported in 1999 that previous researchers had failed to 
model the PD outcomes of theophylline in asthmatic patients presenting with different 
degrees of airway obstruction.101  The authors conducted a study in 15 asthmatic patients 
who were cleared of all confounding diseases.  Patients were divided into two groups, the 
first consisting of 2 males and 6 females (mean age 40 ± 11 years) who displayed FEV1 
values of less than 50 % and the second comprised of 7 females (mean age 30 ± 12 years) 
with FEV1 values between 50 and 70 % of ideal.  A single 250 mg dose of theophylline 
was administered via IV infusion over 30 minutes and plasma drug concentration as well 
as FEV1 was measured for a total of 12 hours.  Plasma concentration-time data were 
modeled using a two-compartment open model consisting of a central and an effect 
compartment.  A two-compartment model was determined to be optimal due to the delay 
between the appearance of theophylline in the plasma and bronchodilation.  Plasma 
concentration in the effect compartment was correlated to FEV1 via a sigmoidal Emax 
expression  
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where E is the pharmacologic response, E0 signifies the baseline response, Emax 
represents the theoretical maximum effect that can be attained, EC50 symbolizes the drug 
concentration at 50 % of the maximum effect, C is concentration at the effect site, and γ 
is the sigmoidicity constant, which dictates the steepness of the curve.  The optimal fits 
for the response curves were determined using nonlinear regression.  Emax 
pharmacodynamic models were previously demonstrated to be practical for correlating 
FEV1 to theophylline concentration.102   
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The authors observed counterclockwise hysteresis loops in both groups when 
FEV1 values were plotted against theophylline plasma concentration (Figure 1.9).  This 
phenomenon suggests that the relationship between bronchodilation and theophylline 
concentration is indirect, possibly due to a delay in the equilibrium between plasma 
concentration and the site of drug action.  Both groups were able to achieve comparable 
FEV1 values when treated with theophylline; however, the EC50 value was higher for the 
severe patients, which increases their risk of experiencing a toxic event.  The PK of the 
two groups were comparable.  While these results confirm the indirect relationship 
observed by two other research groups,103,104 they contradict the general viewpoint that 
the extent of bronchodilation is directly related to theophylline concentration.  The 
authors concluded that by failing to segregate patients according to baseline airway 
function, earlier investigations may have overlooked the true exposure-response 
relationship for theophylline.101   
 
Figure 1.9. Plots of FEV1 verses theophylline plasma concentration to patients with severe (left) and 
moderate (right) airway obstruction.  The arrows indicate the counterclockwise hysteresis. 
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             Despite years of research and a substantial number of literature publications, it is 
evident that the PD, much the same as the PK, of theophylline has yet to be fully 
elucidated.  The author is unaware of any large-scale study assessing the safety and 
effectiveness of theophylline in a broad population encompassing the various 
physiologic, pathophysiologic, and other factors known to influence its action.  As a 
result of these voids, theophylline remains a viable research candidate for PK and PD 
investigations.     
1.3.7 Pharmacokinetic/Pharmacodynamic Simulation 
The individual disciplines of PK and PD are merely two of the many discrete 
components situated on the continuum known as the drug discovery and development 
process.  Integration of these components, however, convolves their contributions and 
offers knowledge that transcends each discipline to provide a more complete picture of 
the drug delivery system and its impact on patient well-being.  Integrated PK and PD 
models bridge the relationship between dose and response.  These models can then be 
used to better guide the development and ultimate utility of a drug delivery system.  For 
example, integrated PK/PD models can be used to minimize the likelihood that a patient 
will experience an adverse event following commencement of a therapy.  The same 
models can be used to understand how response changes between fed and fasted states or 
how the pharmacologic outcomes might be affected as a result of drug-drug interactions 
that alter the ADME of one or several of the concomitant drug therapies.48 
Modern-day computers augment the arsenal of research tools available to 
scientists and clinicians.  Technological advances in the areas of hardware and software 
have nearly eliminated computational deficiencies that were limiting factors several 
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decades ago.  Thus, personal computers are powerful enough to conduct a variety of in 
silico simulations with varying underlying objectives.  Numerical simulation can be 
expected to take a more prominent role in the drug discovery and development process as 
it compliments the FDA’s Critical Path Initiative by utilizing innovative techniques to 
study the manufacturability, safety, and efficacy of candidate molecules and/or drug 
products.9  Pharmacokinetics and pharmacodynamics are two pharmaceutical disciplines 
that utilize computer simulation extensively.   
Once a PK model has been generated, a simulation platform can be constructed to 
assess the impact that random variation to the inputs has on the PK model output(s) (e.g., 
plasma concentration).  The article by Gomeni et al. was previously introduced as it 
pertains to MCS.70  Regarding the details of their PK modeling and simulation, the 
authors first implemented a convolution approach to estimate plasma concentration.  
Specifically, the in vivo delivery rate, which was modeled using the Weibull function, 
and the disposition and elimination time course, which was described by a two-
compartment linear model, were convolved to predict plasma concentration.  The authors 
then perturbed this model via MCS by randomly sampling values for the inputs (e.g., 
fraction of the dose absorbed, Weibull shape and time parameters) to better understand 
their influence on plasma concentration, and subsequently, receptor occupancy.  Log-
normal distributions for each input parameter were generated according to a 
predetermined coefficient of variation for that particular trial.  The simulation evaluated 
plasma concentration for a given patient 24 hours after the 7th dose to better understand 
how variability of the inputs affected receptor occupancy. 
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Alternatively, Peters recently illustrated how physiologically-based PK simulation 
can be used to estimate PK model coefficients with two model drugs, verapamil and a 
proprietary compound no longer in development, in both rats and humans.105  The 
primary objective was to demonstrate that physiologically-based PK simulation of plasma 
concentration-time profiles can reliably differentiate the underlying PK mechanisms, 
most notably the intestinal loss of orally administered drugs from first-pass hepatic 
metabolism, which are more often than not modeled in the same compartment as they are 
difficult to separate within clinical data.  A generalized physiologically-based PK model 
comprised of a 9-compartment absorption model and a 14-compartment (i.e., 14-organ) 
somatic model was constructed to account for factors such the first-pass effect, intestinal 
loss, renal and biliary elimination, enterohepatic recirculation, and conversion of the 
metabolites back to the parent compound.   
For a given drug, the first phase began by iteratively optimizing the estimates of 
clearance and the tissue partitioning coefficients of the 14 organs for IV administration 
using known physiochemical properties of the drug (i.e., permeability and solubility).  
Model performance was evaluated by assessing the goodness of fit for the predicted AUC 
with the mean of the actual AUC values.  Once the predicted profile closely mirrored the 
actual IV plasma curve, the next step used the optimized clearance and distribution 
parameters to simulate the plasma concentration-time profile for oral administration.  
Assuming that solubility and permeability are the only two properties that determine the 
shape of the profile (i.e., that clearance and tissue distribution coefficients are not 
dependent upon the route of administration), differences between the actual and predicted 
concentration-time curves for oral administration should be attributable to intestinal loss 
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factors such as drug-induced gastric emptying delay, enterohepatic recirculation, gut wall 
metabolism, chemical degration, P-glycoprotein efflux, and/or variable absorption across 
the gut.  These model parameters can then be modulated to reveal which factors are more 
than likely responsible for any differences between profiles.  Peters emphasized that this 
method is functional even with inaccurate estimates of clearance and/or tissue 
partitioning coefficients.  Further, she highlighted that physiologically-based PK 
modeling is a suitable approach for deconvolving absorption from distribution, 
metabolism, and excretion phenomena for orally administered drugs.  The specific factors 
affecting the pharmacokinetics of the oral dosage form can then be differentiated through 
additional laboratory experimentation.105  
It is evident that as physiologically-based modeling and simulation progresses, the 
concept of compartments is continually advancing from bodily systems or organs to 
cellular structures (e.g., enzymes, transporters).  This presents the opportunity to model 
and simulate population variability on a cellular level, which will better elucidate how 
these disparities, which could be attributed to numerous factors (e.g., genetics, disease 
states, concomitant drug therapies), affect drug kinetics and action.67   
A quantitative PK model is a prerequisite for predicting the clinical effectiveness 
of a given drug.  Once such a model is available, it can be integrated with 
pharmacodynamic knowledge to study the safety and efficacy of treatment.  Often times, 
simulation utilizes PK and PD models simultaneously to accelerate the drug development 
process.  Such models are typically referred to as PK/PD models, which attempt to link 
the drug dosages to the clinical outcomes.  The value of a PD model is dependent upon 
the merit of the corresponding PK model; a PD model that cannot accurately predict 
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pharmacologic response as a function of drug concentration has limited utility.  Several 
case studies that investigated the potential impact of certain variables (e.g., dosing 
schedule, PK parameters, patient compliance) on the effectiveness of treatment were 
reviewed earlier.   
Another important advantage of PK/PD simulation is its ability to help identify 
specific sub-populations that will benefit from treatment with the compound under 
investigation.  As a rule of thumb, any compound that lacks efficacy will fail in clinical 
trials.  Likewise, categorizing patients who will not respond safely or effectively to a 
given therapy is vital for the sponsor, the regulatory agencies, and the general public.  
With knowledge of a substance’s ADME along with explicit inter-patient characteristics, 
simulation can elucidate specific patient conditions that preclude individuals from 
treatment.  In silico investigations of patient variability in diverse populations has been 
coined population pharmacodynamics.  As Michelson et al. indicates, responder 
populations can be identified using simulated patients generated from hypotheses or by 
fitting observed data to dose-response curves using any number of mathematical 
functions that account for covariates (e.g., age, gender, health factors).106  Tools that 
identify responder populations should not only increase the number of available 
therapies, but should enhance the efficiency and effectiveness of clinical trials, which will 
ultimately hasten the time-to-market.      
Eddy and Schlessinger published what is perhaps one of the most comprehensive 
examples of a simulation platform constructed to study a disease state.107  The authors 
generated an extensive diabetes model and simulation platform referred to as the 
Archimedes model.  While the Archimedes model transcends the classification of PK/PD 
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simulation, it is purposefully offered as a summary to the literature survey since it 
integrates many of the elements addressed thus far.  The authors indicated that the model 
was too large to detail in a single manuscript, but the equations and corresponding 
assumptions are available in an online appendix (http://care.diabetesjournals.org).  The 
Archimedes model was generated according to 3 basic criteria: (1) the model was to 
include all facets of the disease or its management that were considered valuable for 
investigating areas of interest, (2) the model was to be able to delineate clinically relevant 
features of the disease and its management, and (3) the level of detail incorporated was to 
be commensurate with its importance in the design of clinical trials.  The Archimedes 
model was sequentially constructed and utilized in the following five stages: (1) develop 
a nonquantitative or conceptual description of the pertinent biology and pathology of 
diabetes (i.e., the variables and their relationships), (2) identify studies that focused on 
these variables and their underlying connection, (3) use the knowledge found in those 
investigations to link these variables via mathematical functions, (4) program these 
models into the simulation platform, and (5) perform numerical simulation using the 
platform.  Individual models were tested and debugged during phase (4) of this series.  
Although the development criteria and phases were originally couched in terms of the 
Archimedes model, it should be noted that they are directly applicable to alternative 
simulation systems. 
The Archimedes model was constructed using a system of differential equations 
and was coded using an object-oriented language known as Smalltalk.  At the time of 
publication, it included numerous physiologic, pathologic, logistical, administrative, and 
economic factors including disease risk factors, incidence and progression of the disease, 
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glucose metabolism, symptoms, treatments, complications (e.g., coronary artery disease, 
congestive heart failure, deaths from diabetes and its associated complications, 
physiological dysfunctions as a result of disease (change in production of glucose as a 
result of an increase or decrease in insulin, etc.)), and differences amongst health care 
facilities (e.g., tests for pathophysiology of diabetes, re-admission rates).  The structural 
relationship of the variables included in the diabetes model is summarized in Figure 1.10.  
The Archimedes model has the flexibility to assess three different treatment regimes (i.e., 
IV insulin, oral drugs, diet and exercise).  Response to, for example, insulin is initially 
modeled by an individual’s insulin factor from a distribution that characterizes the 
variation of the general population.  This effect is then propagated through the various 
expressions that comprise the Archimedes model to account for confounding factors.  
The authors validated the Archimedes model in a subsequent article using actual clinical 
data from 18 trials.  They concluded that the platform has the capacity to realistically 
model and simulate anatomic and pathophysiologic changes, treatments, and outcomes 
relevant to diabetes and its complications within the context of the available trial data.108  
They also indicated that the Archimedes model has the inherent flexibility to incorporate 
additional underlying knowledge regarding this disease state as it becomes available.107     
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Figure 1.10. Schematic diagram detailing the structural relationship of the factors included in the 
Archimedes model of diabetes.  Circles represent variables and lines indicate relationships.  In general, the 
arrows directed into a variable represent one equation.  Squares indicate other components of the model 
that are too complex to be shown here and have their own corresponding diagrams consisting of tens of 
variables and relationships.  UKPDS and DCCT are acronyms for actual clinical trails and appear as circles 
with dashed boarders.  These two trails were used to help construct the elements of the model illustrated in 
the figure.  Reproduced from the work of Eddy and Schlessinger. 
 This work was founded on the central hypothesis that pharmaceutical process and 
product understanding can be simultaneously utilized to model the risk that final product 
quality imparts to clinical performance.  The subsequent chapters, whole and in part, 
address one or more of the objectives stated in section 1.2.  Chapter 2 describes the 
particular data, models, and assumptions used to construct the risk simulation platform, 
which is the medium used to redefine pharmaceutical quality in terms of risk by linking 
clinical attributes to production characteristics.  Subsequently, the determination of the 
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conditional risk of product variation on clinical performance for the model drug delivery 
system is detailed.  Chapter 3 builds upon the underlying relationships between product 
variation and clinical performance to generate design spaces conditioned on quantitative 
estimates of inefficacy and toxicity risk. 
Multivariate data analysis and calibration are important elements of PAT and 
QbD as spectroscopic techniques are often used to acquire and/or enhance product and 
process knowledge.  Chapter 4, therefore, demonstrates the utility of multivariate data 
analysis for elucidating the effects of various product and process variables on 
spectroscopic measurements.  The influence of experimental design on spectroscopic 
variance is also considered.  Chapters 5 and 6 described the role of net analyte signal 
theory and figures of merit in gauging the performance of calibration models, which will 
likely be integral components of future risk simulation efforts.  Not only is it important to 
understand the performance of calibrations, it is critical to identify how their performance 
influences the prediction of factors that ultimately affect risk.   
The penultimate chapter (7) seeks to unify the preceding topics via a hypothetical 
example revolving around the incorporation of PAT into a QbD production environment 
to ultimately control the clinical performance of the final product.  Here, non-invasive 
spectroscopic techniques are strategically integrated prior to final product release to 
monitor those attributes which are potentially critical to quality.  The corresponding role 
of process and control models in managing inefficacy and toxicity risk of the model drug 
delivery system is also addressed.  Lastly, Chapter 8 provides a summary of the 
aforementioned work. 
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 This dissertation explicitly links product characteristics to clinical performance 
using the proposed methodology.  It is important to emphasize that these theophylline 
data were used to demonstrate one (of potentially several) approaches to directly relating 
product and patient characteristics.  The clinical risk data were not, however, generated 
with the intent to suggest that theophylline regimens should or should not be altered.   
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Chapter 2: A New Definition of Pharmaceutical Quality: Assembly 
of a Risk Simulation Platform to Investigate the Impact of 
Manufacturing/Product Variability on Clinical Performance of a 
Model Theophylline Solid Oral Dosage System 
 
2.1 Introduction 
 Around the turn of the 21st century, an informal retrospective survey of the 
pharmaceutical industry revealed that its progress (particularly with regard to 
manufacturing) was essentially stagnant and paled in comparison to other industrial 
sectors.  Some individuals contend this was obvious and discussed within intellectual 
circles ad nauseum.  Countless more, however, were reluctant to admit or failed to detect 
the issue at hand, and yet others who begrudgingly acknowledged the problem hurriedly 
placed blame on an overly restrictive regulatory system that penalized innovation.  This 
was all set to change.   
Taking initiative and holding themselves partially responsible, the FDA launched 
the CGMPs for the 21st Century campaign in 2002 to, in effect, “modernize” the 
pharmaceutical industry.  The modernization commenced internally, and a new, risk-
based regulatory architecture was created to refocus resources where they were needed 
most; areas that posed the greatest risk to the public.  In turn, pharmaceutical companies 
were encouraged to adopt risk- and science-based approaches for drug discovery and 
development.  Numerous initiatives, reports, and guidances followed (e.g., PAT, QbD), 
many of which promoted innovation and offered examples as to how the associated 
changes fit within the contemporary regulatory environment.  These documents 
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underscore the need for collective change and emphasize several benefits that 
manufactures would reap from innovation.    
“Quality” is explicitly or implicitly addressed in all of these documents.  To date, 
the exact definition of quality in the pharmaceutical industry is unresolved, which is 
burdensome given that one of the primary objectives of the modernization initiative is to 
spur innovation to ultimately enhance pharmaceutical product quality.  This uncertainty 
culminated in 2004 when Dr. Janet Woodcock, Director of the CDER at the FDA 
proposed re-defining pharmaceutical quality with regards to risk by linking production 
characteristics to clinical attributes.19 
It is well understood that the clinical performance of any therapeutic regimen is 
dependent on a number of factors.  For example, patient compliance dramatically 
influences safety and efficacy profiles.  Consequently, researchers and clinicians invest 
time and energy to understand and control compliance rates.  Manufacturing of the drug 
products also imposes a certain degree of risk on clinical performance.  Despite its 
influence, little (if any) effort is devoted to quantifying the risk associated with 
manufacturing processes.  If quality is to be re-defined in terms of risk, probabilistic 
relationships between production and clinical attributes must be established.       
Cogdill and Drennen described an approach for relating manufacturing 
characteristics and clinical performance of a drug product.20  They proposed the 
combination of probabilistic risk assessment (PRA) and Monte Carlo simulation (MCS) 
to relate elements such as raw material quality, product design, population statistics, 
dosing guidelines, and patient compliance estimates with pharmacokinetic (PK), 
pharmacodynamic (PD), and in vitro-in vivo correlation (IVIVC) models to remold 
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quality in terms of risk (Figure 2.1).  The objective was to translate manufacturing and 
drug product attributes into probabilistic risk scores for toxicity and inefficacy.  With 
these estimates, product and process design could then focus on minimizing risk to the 
patient. 
 
Figure 2.1. Schematic of the various model components that comprise the risk simulation platform.  Figure 
adapted from Cogdill, RP; Drennen, JK.  2008.  Risk-based quality by design (QbD): A Taguchi 
perspective on the assessment of product quality, and the quantitative linkage of drug product parameters 
and clinical performance.  Journal of Pharmaceutical Innovation 3 (1): 23 – 29.  Solid arrows represent 
components that are currently linked in the platform, whereas dotted arrows signify components/concepts 
that have yet to be incorporated.  
This work used theophylline as a model drug to illustrate one potential method of 
relating manufacturing characteristics of a solid dosage system to clinical performance in 
simulated asthmatic patients displaying considerable inter-individual variability.  The 
objectives were to (1) describe the structure for harnessing MCS and PRA to estimate 
risks of inefficacy and toxicity and (2) estimate the conditional risk of production 
characteristics on clinical performance for a model solid oral dosage system. 
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2.2 Materials and Methods 
2.2.1 The Weibull Distribution 
 Waloddi Weibull formally introduced what is now referred to as the Weibull 
distribution in a 1939 monograph published by the Royal Swedish Institute for 
Engineering Research.  As Arthur Hallinan, Jr. emphasized, there are (at least) five 
different mathematical formulae used to express the Weibull distribution, all which are 
equivalent following certain transformations.109  It was his opinion that the array of 
formulae most likely created confusion, and, therefore, initial reservation concerning its 
applicability.  Nonetheless, the Weibull distribution has been used to model numerous 
phenomena such as wind speed, failure (or reliability), and dissolution.16,109,110 
Although originally hypothesized as a material function to describe the strength of 
materials subjected to stress, the Weibull distribution is now regarded as a flexible (i.e., 
generalized) statistical distribution.  The distribution was proposed as a three-parameter 
distribution, characterized by a scale parameter (α), a shape parameter (β), and a location 
constant (c), but it is frequently utilized as a two-parameter (c = 0), and, at times, a one-
parameter distribution (α and c = 0).  It should be noted that the symbols used to 
represent these three parameters have varied over time, but these were intentionally 
selected so as to be consistent with the most recent literature.  The following formulae 
will be presented according to the two-parameter functions; a location constant is 
employed to adjust the point at which there is a non-zero probability.  Please refer to the 
article by Arthur Hallinan, Jr. for greater detail regarding the various three-parameter 
Weibull expressions.109   
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The cumulative distribution function (CDF), or the cumulative probability of 
occurrence for a given random variable (V) is described by the two-parameter Weibull 
function  
 ( )
β
α ⎟⎠
⎞⎜⎝
⎛−−=
V
eVf 1  (2.1) 
where V is the vector of points to be modeled (vi ≥ 0), β is the Weibull slope or shape 
parameter (β > 0), and α is the Weibull scale parameter (α > 0).  Similarly, the derivative 
of the CDF describes the probability density function (PDF), which is the probability 
distribution of a continuous random variable.  The PDF is expressed by the equation 
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where V , β, and α are as previously defined.  A random variable is said to be Weibull 
distributed if its CDF or PDF are adequately represented by Equations 2.1 or 2.2 (or the 
equivalent one or three-parameter functions).  Several methods, including the Weibull 
graph technique, least-squares, and maximum likelihood, can be used to estimate the 
parameters.109 
 The Weibull distribution is considered flexible for a number of reasons.  First, it is 
characterized by only 3 (or less) parameters, which is more straightforward than, for 
example, the five-parameter bi-variate normal distribution.  Second, it mirrors the 
Rayleigh distribution and approximates the Gaussian distribution when the shape 
parameter is 2.0 and 3.6, respectively; these distributions can be classified as specific 
cases of the Weibull.  Its ability to assume a range of values for the shape parameter, 
therefore, allows the distribution to more easily compensate for real-world variability.  
Finally, the Weibull distribution provides a reasonable fit to a variety of observed 
 112
distributions, which is evidenced by the assorted phenomena it has been used to model.110  
It was for these reasons that the Weibull distribution was selected to model certain data 
for this work. 
2.2.2 Patient Simulation 
Monte Carlo simulation has been shown to be an effective method for generating 
hypothetical patient populations in situations where it may be unreasonable or unethical 
to utilize humans.64,111  For the work herein, MCS will be used to generate asthmatic 
patients ranging in age from 10 to 90 years; patients outside of this range were not 
modeled due to the lack of data pertaining to the targeted factors.  The most significant 
factors affecting the disposition of theophylline, as determined by Jusko et al.,46 will be 
specified to effectively represent inter-patient variability.  All modeling and MCS 
simulations were performed using routines written in-house (Matlab, version 7.1, The 
MathWorks, Natick, MA ; PLS_Toolbox, version 3.0, Eigenvector Research, Inc., 
Manson, WA).  Initially, data classifying the 2007 United States (US) population by age 
and gender were obtained from the US Census Bureau’s International Data Base,112 and 
statistics summarizing the prevalence of asthma within the US population during 2000 - 
2005 were obtained from the Centers for Disease Control and Prevention (CDC).113  Data 
for the prevalence of asthma specific to individuals older than 65 was not further 
delineated; thus, it was assumed that the prevalence (per 1000 subjects) monotonically 
decreased by 1.0 for each 10-year increment exceeding 70 years.  A new distribution that 
approximated the asthmatic fraction of the total population within each age range was 
generated from the product of the US population and age-specific asthma rates.   
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An MCS routine, utilizing the exclusion method, assigned the age of each 
asthmatic patient based on the aforementioned relative distribution.  The maximum 
number of allowable patients for each age range was determined by multiplying the 
number of desired patients by the relative distribution. To generate an initial estimate of 
age for a given patient, a single pseudo-random value was drawn from a uniform 
distribution generated on the unit scale (i.e., “rand.m” function within Matlab), was 
multiplied by the difference between the upper (i.e., 90) and lower (i.e., 10) age limits, 
and was added to the lower age limit.  The estimate of age was rounded to the nearest 
integer.  The “rand.m” function generates values between the closed interval of [2-53, 1-2-
53] and is theoretically capable of generating 21492 values prior to repeating itself.  If the 
estimate did not fall within the desired age range, the routine continued to generate 
estimations by resampling the uniform distribution until a satisfactory estimate was 
achieved.  Likewise, if the estimate was within an age range where the maximum number 
of allowable patients had already been generated, the routine iterated until an acceptable 
age was attained.  The distribution of age for the 100,000-patient population is 
summarized in Table 2.1.  On average, approximately 375,000 iterations were required to 
assign the ages of the 100,000 patients. 
Once the age of each patient was assigned, the gender of every patient was 
determined.  Gender was resolved by drawing a number from a binomial distribution, 
which was generated using the “binornd.m” function in Matlab.  The success probability 
(p) was set to the fraction of males in a specific age range.112  A value of 1 signified a 
male, whereas 0 represented a female.  The distribution of gender for the 100,000-patient 
population is summarized in Table 2.1.
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Table 2.1. Age and gender distributions for the simulated patient population. 
Age Range 
(years) Males Females 
Combined 
Totals 
Fraction of Total 
Population 
Cumulative Fraction of Total 
Population 
Fraction 
Male 
0 - 4 0 0 0 0.000 0.000 0.000 
5 - 9 0 0 0 0.000 0.000 0.000 
10 - 14 5,324 5,226 10,550 0.106 0.106 0.505 
15 - 19 5,305 4,927 10,232 0.102 0.208 0.518 
20 - 24 4,348 4,247 8,595 0.086 0.294 0.506 
25 - 29 3,781 3,692 7,473 0.075 0.369 0.506 
30 - 34 3,251 3,224 6,475 0.065 0.433 0.502 
35 - 39 3,583 3,410 6,993 0.070 0.503 0.512 
40 - 44 3,728 3,846 7,574 0.076 0.579 0.492 
45 - 49 4,117 4,246 8,363 0.084 0.663 0.492 
50 - 54 3,957 4,088 8,045 0.080 0.743 0.492 
55 - 59 3,443 3,714 7,157 0.072 0.815 0.481 
60 - 64 2,634 2,971 5,605 0.056 0.871 0.470 
65 - 69 1,901 2,153 4,054 0.041 0.911 0.469 
70 - 74 1,420 1,643 3,063 0.031 0.942 0.464 
75 - 79 1,034 1,415 2,449 0.024 0.966 0.422 
80 + 1,187 2,185 3,372 0.034 1.000 0.352 
              
0 - 80 + 49,013 50,987 100,000 1.000 1.000 0.490 
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Anthropometric reference data for the conditional distributions of total body weight (kg) 
and body mass index (BMI) of the US population for all ages during 1999 – 2002 were 
obtained from the National Health and Nutrition Examination Survey (NHANES), 
conducted by the National Center for Health Statistics (NCHS), CDC.114  The weighted 
population means, standard errors of the means, and selected percentiles by sex, race, 
ethnic group, age, or age group were reported in this survey.  Results, categorized by 
gender, are reported per year for individuals 1 to 19 and per decade for subjects 20 years 
and older.  The 5th, 10th, 15th, 25th, 50th, 75th, 85th, 90th, and 95th percentiles (i.e., the value 
in an ordered set of measurements for which x % of the observations lie below) were 
presented provided that the NCHS determined that the estimate was reliable.  Unreliable 
figures were those that had a relative standard error (i.e., ratio of the standard error and 
the mean) greater than 30 %.  The percentiles summarizing each age range for both 
weight and BMI were independently modeled using the two-parameter Weibull function 
(Equation 2.1).  The weight and BMI values for males and females were modeled 
separately and the Weibull parameters were estimated using a least-squares approach.  A 
shape and scale parameter were estimated for each age range modeled; the nominal 
percentiles were predicted using the reference percentile values114 and the corresponding 
Weibull parameters to assess the goodness of fit.  Irrespective of gender, the lowest 
coefficient of determination obtained for any of the individual models for weight or BMI 
was 0.951 and the median value across all models was 0.983.  All anthropometric 
modeling was performed prior to the MCS for generating patients.   
To assign weight and BMI metrics, the appropriate Weibull parameters were 
selected, first for weight and then for BMI, based on a patient’s age and gender.  The age- 
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and gender-categorized shape and scale parameters were used to generate a Weibull 
distribution (i.e., “wblrnd.m function in Matlab), from which a single value, representing 
the patient’s weight or BMI, was extracted at random.  Weight and BMI estimates were 
continually resampled until a value that fell within the restricted weight (20 – 130 kg) or 
BMI (10 – 50) range was obtained. 
With the age, gender, weight, and BMI assigned, the remaining factors affecting 
the disposition of theophylline were specified.  Statistics on cigarette smoking, marijuana 
use, alcohol consumption, and intake of oral contraceptives were obtained from the 2006 
US Health survey conducted by the NCHS, CDC.115  Statistics, reported as percent of 
total population, were taken for the latest recorded year.  Data were (generally) reported 
for the ranges 12 – 13, 14 – 15, 16 – 17, 18 – 25, 26 – 34, and 35 years old and over.  The 
last age bin was modified to include the expanded ranges 35 – 44, 45 – 64, and 65 – 90 
years of age.  Except where noted otherwise, the CDC data for greater than 35 years were 
represented identically in the three expanded age bins.  For heavy alcohol drinkers, which 
was recoded as the percent of those who consumed alcohol, the values for 45 – 64 and 65 
– 90 were adjusted downward (i.e., 8.8 % and 5.9 %, respectively) from the 10.4 % value 
reported for 35+ years based on the assumption that these individuals would pass away 
sooner than those who were not heavy drinkers.  Additionally, the 3.1 % value reported 
for marijuana use for 35+ years was adjusted to 1.5 % for those individuals 65 – 90 years 
of age.  For both marijuana and alcohol use, the percentage of female users was assumed 
to be 50 % of the observed rate for males; the values for heavy alcohol drinkers, however, 
were identical for males and females.  Regarding the intake of oral contraceptives, the 
CDC data reported usage for minors in the range of 15 – 19 years.  Thus, this value was 
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applied to the 16 – 17 age bin, while 0 % and 20 % were assumed for 12 – 13 and 14 – 15 
years old, respectively.  Additionally, a value of 0 % was assumed for the 45 – 64 and 65 
– 90 ranges; oral contraceptive use was not recorded after 44 years.  Regardless of age, a 
value of 0 % for oral contraceptive use was assumed for males.  Data for cigarette 
smoking aligned with the amended age bins; therefore, they were used as reported. 
The probability of suffering from congestive heart failure was modeled using data 
that described the prevalence of heart disease by age, which was obtained from the 
National Heart, Lung, and Blood Institute (NHLBI) Data Fact Sheet.116  These data were 
reproduced from the 1976 – 1980 and 1988 - 1991 NHANES surveys; however, only data 
for 1988 – 1991 were used (Figure 5 of the NHLBI report).  A data tracing program 
written in-house was used to estimate the prevalence (%) for the age-groups sampled.  
For individuals greater than 30 years of age, the probability of experiencing congestive 
heart failure (CHF) was approximated using the equation 
 ( ) ( ) 51.322.01092.3 23 +⋅−⋅≈ − ageagexp  (2.3) 
where p represents the probability of CHF and age is the age (in years) of the patient.  
Based on age- and gender-specific discharge frequencies for CHF cases recorded during 
2004,115 the resultant probability was multiplied by a factor of 0.75 if the patient was 
female.  Additionally, all individuals 30 years of age or younger were automatically 
precluded from having congestive heart failure. 
Sufficient gender- and age-specific data for the general use of barbiturates and 
benzodiazepines were unavailable.  Therefore, inferences for the percent of the total 
population using each class of drug were made based on age and gender.  These data are 
presented in Table 2.2.    
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Table 2.2. Gender- and age-specific data detailing the percent of the total simulated population using 
barbiturates and benzodiazepines. 
  
Age 
Range 
(years) 
12 - 
13 
14 -
15 
16 - 
17 
18 - 
24 
25 - 
34 
35 - 
44 
45 - 
64 
65 - 
90 
Male 0.0 1.0 3.0 4.0 4.0 3.0 2.0 2.0 Barbiturate Use   
(% of total 
population) Female 0.0 0.0 1.0 2.0 3.0 3.0 2.0 2.0 
Male 0.0 2.0 4.0 5.0 7.0 15.0 20.0 15.0 Benzodiazepine 
Use (% of total 
population) Female 0.0 2.0 4.0 5.0 7.0 15.0 20.0 15.0 
 
The likelihood of a patient presenting with any of the remaining factors shown to 
affect theophylline disposition (i.e., cigarette smoking, marijuana use, alcohol 
consumption, congestive heart failure, and intake of oral contraceptives, barbiturates, and 
benzodiazepines) was independently determined by randomly extracting a value from a 
binomial distribution, where p was set to the fraction of the total population that 
presented with a specific factor.  Each factor was categorized based on age and gender, 
and therefore, p was selected based on the patient’s age and sex.  For congestive heart 
failure, p was merely the resultant probability estimated using Equation 2.3.  An output of 
1 from the binomial distribution represented a subject who displayed the given factor, 
whereas 0 indicated a patient who was negative for that factor. 
Once all of the factors were accounted for, theophylline clearance was 
individualized for each patient according to the clearance cascade adapted from Jusko et 
al.46 (Figure 2.2).  It should be noted that the terminal nodes for marijuana use in 
individuals less than 40 years old who did not use oral contraceptives were excluded from 
the clearance cascade model.  Data pertaining to the use of marijuana are subject to 
misrepresentation.  Therefore, eliminating the second split based on marijuana use 
mitigated the uncertainty associated with accurately categorizing patients within the 
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cascade model.  The terminal node on the clearance cascade was determined for each 
patient based on the individualized factors that predispose theophylline disposition.  The 
percentage of the total 100,000-patient population that fell within each node is reported in 
Figure 2.2.  Once it was determined which node best described a given patient, the mean 
and standard deviation of that particular node (Figure 2.2) were used to generate a normal 
distribution (i.e., “normrnd.m” function within Matlab), from which a single value, 
representing the patient’s theophylline clearance, was extracted at random.  Clearance 
estimates were restricted to 5 – 180 mL/hr/kg.  If necessary, the distribution was 
resampled until the estimate was within the constrained range.  The distribution of 
clearance for the 100,000-patient population based on the factors studied is summarized 
in Figure 2.3.  Theophylline clearance was assumed to be constant throughout the course 
of treatment. 
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Figure 2.2. Clearance cascade detailing the average theophylline clearance for individuals classified 
according to numerous factors.  Figure was adapted from Jusko, WJ, Gardner, MJ, Mangione, A, Schentag, 
JJ, Koup, JR, Vance, JW.  1979.  Factors affecting theophylline clearances: Age, tobacco, marijuana, 
cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.  
Journal of Pharmaceutical Sciences 68 (11): 1358 – 1366.  Both the number of individuals in the original 
study by Jusko et al. and the percentage of the 100,000 simulated population that fell within each node are 
indicated.  All terminal nodes are shaded.  0, 1, and 2 signifies the extensiveness  of a given factor as 
delineated in the original study.  MJ = Marijuana; O.C. = Oral Contraceptive; EtOH = Alcohol; CHF = 
Congestive Heart Failure; CIG = Cigarette Smoker; BENZ = Benzodiazepines; BARBS = Barbiturates. 
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Figure 2.3. Frequency histograms of clearance (a) and volume of distribution (b) for the 100,000 simulated 
patients.  The mean, standard deviation (S.D.), and range [ , ] of each parameter are also provided. 
Finally, volume of distribution was assigned by randomly sampling a normal 
distribution defined by a mean volume of distribution of 0.47 L/kg and a standard 
deviation of 0.03 L/kg.  While previous studies have assumed one (constant) average 
volume of distribution for all patients (e.g., 0.45 L/kg),46,56 the author considered this to 
be more representative of the variability that would be encountered in actual patients.  
The volume of distribution values for the 100,000-patient population are summarized in 
Figure 2.3.  Analogous to clearance, the volume of distribution was assumed to be 
constant for each patient during the course of simulated therapy. 
2.2.3 Model Solid Oral Dosage Form 
A solid oral theophylline dosage system that was previously formulated and 
processed at Duquesne University (Pittsburgh, PA) and compacted at a local 
pharmaceutical company was utilized for its estimations of manufacturing variability and 
clinical performance.  The experimental details regarding these tablets have been 
described elsewhere.117  Briefly, three separate manufacturing routes (i.e., direction 
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compression, roller compaction, and wet granulation) were used to produce 300 mg 
standard round bi-convex 3/8” diameter tablets on an 18-station high-speed rotary tablet 
press (model HT-AP1855-U/I, Elizabeth Hata).  Eighteen distinct batches were 
manufactured using the direct compression and roller compaction routes, whereas 12 
batches were produced via wet granulation.  For the direct compression and roller 
compaction (Chilsonator, model IR 220, The Fitzpatrick Company) manufacturing 
methods, various combinations of anhydrous theophylline (BASF), lactose monohydrate 
(316 Fast Flo, Foremost Farms), microcrystalline cellulose (Avicel PH-102, FMC 
Biopolymer), and magnesium stearate (Spectrum Chemical) were processed and tableted.  
Tablets produced using the wet granules (planetary mixer, model 838F, Hobart) consisted 
of anhydrous theophylline, lactose monohydrate, magnesium stearate, and corn starch 
(Spectrum Chemical); a starch paste was used as the binding agent.  For all three 
manufacturing methods, the compaction pressure was adjusted to yield target radial 
tensile strengths of 8, 11, or 14 kiloponds (kp).  The nominal amount of theophylline was 
either 90 or 133 mg.   
USP apparatus 2 (i.e., paddle) dissolution testing was performed using a Distek 
dissolution system (model 2100B) at a paddle speed of 50 revolutions per minute (RPM).  
The dissolution system was equipped with Hewlett-Packard UV-Vis spectrometer (model 
8453) and a closed-loop automated sampler (Distek, Inc.).  All dissolution testing was 
performed using deionized, de-aerated water as the medium in 900 mL Peak™ glass 
vessels at 37±0.1°C.  The absorbance of theophylline was detected at 272 nm in 10 mm 
pathlength quartz flow cells following the construction of a standard curve.  In total, 12 
tablets per batch for each unique manufacturing route were assessed. 
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The Weibull function is often used to describe empirical dissolution data.118  
Dissolution profiles (i.e., percent theophylline released) of tablets produced via the direct 
compression, roller compaction, and wet granulation methods were modeled using the 
two-parameter Weibull function described by Equation 2.1 where V is the vector of 
dissolution time points.  For dissolution modeling, the time constant (α) is often 
represented as T63.2, the time at which 63.2 % of the drug is released.  Once these data are 
fit to a Weibull distribution, the PDF (Equation 2.2) can be used to approximate the 
dissolution rate.  Each dissolution curve was modeled by its reduction to a shape and a 
scale parameter.  The distribution of dissolution shape parameters and dissolution time 
constants for the model system are presented in Figure 2.4.  Two lines were fit to these 
data to represent the approximate maximum and median values for the dissolution shape 
parameter given the range of dissolution time constants (Figure 2.4). 
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Figure 2.4. The distribution of dissolution shape parameters (ß) and dissolution time constants (T63.2) for 
the model theophylline solid oral dosage system.  Two lines were manually fit to these data to represent the 
approximate maximum and median values for the dissolution shape parameter given the range of 
dissolution time constants. 
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Content uniformity testing was also performed on dissolved tablets using a UV-
Vis spectrometer (Hewlett-Packard, model 8453).  Tablets were pulverized and dissolved 
in deionized water.  The absorbance of theophylline was detected at 272 nm in 10 mm 
pathlength cuvettes at 25 °C using a standard curve independent of the one implemented 
for dissolution testing.  Uniformity of tablets produced from all three manufacturing 
routes was assessed.  In total, 10 tablets per batch for each unique manufacturing routine 
were analyzed. 
Dissolution time constants and content uniformity estimates were segregated by 
batch to generate estimates of manufacturing variability.  Intra-batch refers to the 
standard deviation of mean-centered observations within a batch, whereas inter-batch 
denotes the standard deviation of the mean observations across all batches (e.g., content 
uniformity, dissolution time constant).    
2.2.4 IVIVC Model 
Hussein and Friedman modeled the release and absorption characteristics of 
several novel, self-prepared, sustained-release (SR) theophylline formulations in addition 
to two commercial SR products (i.e., Theotrim and Theo-Dur).92  Specific details 
regarding the materials and methods can be obtained from their original publication.  
Briefly, USP apparatus 1 (i.e., rotating basket) dissolution testing was performed at 100 
RPM in 600 mL vessels.  The first 2 hours of testing was conducted in 400 mL of 
simulated gastric fluid containing pepsin, after which, the medium was replaced with 400 
mL of simulated intestinal fluid containing pancreatin and was monitored for an 
additional 10 hours.  Theophylline concentration was subsequently determined by HPLC 
analysis.  Six healthy volunteers were administered each formulation in a crossover study 
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observing a washout period of 3 weeks.  Theophylline plasma concentrations were 
estimated using an HPLC method and the percentage of the theophylline dose absorbed 
was then determined using the Wagner-Nelson method. 
The mean (n = 4) in vitro dissolution percent released and the mean (n = 6) in vivo 
percent absorbed profiles obtained from the volunteers for the said dosage forms were 
used to construct a Level A IVIVC model via a deconvolution approach (refer to section 
1.3.4).  These data correspond to Figures 1 and 3 of their original publication.92  Only the 
values for formulations T-1, T-1-A, T-2-A, and Theotrim were modeled.  A graph tracing 
program was used to extract quantitative data from the figures describing the percent 
released and percent absorbed at the time points sampled.  Subsequently, these data were 
modeled using a two-parameter Weibull function (Equation 2.1); the fitted shape and 
scale parameters were used to estimate the instantaneous rates of release and absorption 
for the in vitro and in vivo data, respectively (Equation 2.2).  Finally, the instantaneous 
dissolution rates were fitted using the Power Law to determine the IVIVC function 
(Figure 2.5).  The resultant nonlinear function for transforming in vitro release to in vivo 
absorption was determined to be 
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Figure 2.5. Plot of the in vivo absorption rate versus the in vitro dissolution release rate.  The IVIVC model 
was fit using a Power Law function. 
 
 
672.0465.0 DB RR ⋅=  (2.4) 
where RB is the in vivo absorption rate, RD is the in vitro dissolution release rate, and 
0.465 and 0.672 are the scale factor (unitless) and Power Law parameter (unitless), 
respectively; the coefficient of determination for this function was 0.943.   
2.2.5 PK Model 
First-order pharmacokinetics by means of a one-compartment open model were 
assumed to adequately describe theophylline plasma concentrations following 
administration of the solid oral dosage form.  Since multiple dosages were administered 
throughout the course of therapy, the principle of superposition was applied.82  
Superposition provides the opportunity to forecast plasma concentration-time curves 
based on the viewpoint that drug levels from successive doses are linearly additive.  The 
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superposition principle assumes that the pharmacokinetics of the drug are not dose-
dependent and that the drug is eliminated by first-order kinetics, which are reasonable 
assumptions for the administration of theophylline (refer to section 1.3.5.2).  The change 
in theophylline plasma concentration as a function of time was modeled using the 
equation 
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where Cp is the theophylline plasma concentration (mg/L), t is the time (hr), S is the 
optional scaling factor (unitless), D is the dose (mg), Vd is the volume of distribution 
(L/kg), W is the patient’s total body weight (kg), β is the Weibull shape parameter 
(unitless), α is the Weibull time constant (hours), A is the IVIVC scale factor (unitless), P 
is the IVIVC Power Law parameter (unitless), and Cl is clearance (ml/kg/hr).  All 
simulations were performed with S at a constant value of 1.0.  This equation was derived 
to characterize the change in theophylline plasma concentration based on the relationship 
between the dissolution and absorptions rates and the individualized patient 
pharmacokinetic parameters.  The output is mg/L/hr of theophylline. 
Similar to the work of Buchwald,83 theophylline input was modeled using 
sigmoidal lag time and cut-off coefficients where absorption was assumed to be 100 % of 
the maximum rate after 0.5 hours (i.e., lag time) and the absorption potential was reduced 
to 50 % after 8 hours (i.e., cut-off) to simulated time-dependent phenomena.  These 
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coefficients were used to adjust the input (I) of theophylline through the following series 
of equations 
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Figure 2.6 shows the lag time and cut-off coefficients for one 12-hour dose.  Equation 
2.5d is analogous to the original PK model with the exception of the lag time and cut-off 
terms.  The numerical solution to Equation 2.5d was obtained via a Matlab-based 
differential equation solver (i.e., ode23). 
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Figure 2.6. Plot illustrating the lag time and cut-off absorption coefficients over a 12-hour window. 
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2.2.6 PD Model 
One or more probabilistic PD models are most desirable for a risk assessment tool 
such as the one described herein.  For example, access to several PD models that 
characterize the probability of efficacy, the probability of multiple adverse events (e.g., 
headache, vomiting, seizure) and the covariance between these observations is optimal.  
More often than not, said models will not be available during the initial stages of risk 
assessment.  Furthermore, efficacy may be characterized by various responses (e.g., 
forced expiratory volume, number of asthmatic attacks, quality of life), further obscuring 
the dose-response relationship and thus, the probability of a given outcome.  Therefore, it 
is necessary to assume an underlying model, which can be replaced, augmented, or 
combined with additional models as the level of understanding increases. 
A probabilistic-based PD model detailing the general efficacy and toxicity of 
theophylline was not readily available.  Therefore, the authors chose to implement a 
model for a hypothetical drug, which also had a therapeutic range of 10 – 20 mg/L 
(labeled Figure 1.7 in the reference).93  Data points were reproduced using the tracing 
program and were fitted using a sigmoid function.  The PD model originally described 
the probability (%) of efficacy and toxicity as a function of drug concentration.  The 
estimated sigmoid functions for efficacy and toxicity are provided in Equations 2.6a and 
2.6b, respectively 
 ( )[ ] 83.31
77.74ˆ
70.996.0 ++= ⋅−− ZE eP   (2.6a) 
 ( )[ ] 77.31
29.74ˆ
40.1940.1 ++= ⋅−− ZT eP   (2.6b) 
 130
where EPˆ and TPˆ are the predicted probabilities (%) for efficacy and toxicity, respectively, 
and Z is the vector of log-transformed theophylline plasma concentrations (mg/L).  The 
PD model was adapted to describe the probability (%) of inefficacy and toxicity as a 
function of theophylline plasma concentration (Figure 2.7).  Inefficacy estimates were 
generated by subtracting the efficacy probabilities from 100 %.  No specific distinctions 
were made between various inefficacious or toxic events; the risk of observing, for 
example, a headache or a seizure was identically weighted. 
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Figure 2.7. Pharmacodynamic model for theophylline describing the probability of observing a toxic or an 
inefficacious event as a function of theophylline plasma concentration.  Figure adapted from DiPiro JT, 
Spruill WJ, Blouin RA, Pruemer JM.  2002.  Concepts in Clinical Pharmacokinetics 3rd ed., New York: 
American Society of Health-System Pharmacists, Inc. (ASHP). p 279. 
2.2.7 Dosing 
Each patient was subjected to an iterative dosing scheme where his/her initial 
dose (D) was estimated using the equation 
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where CT is the target plasma concentration (i.e., the median concentration of the 
therapeutic window, defined as 10 – 20 mg/L), Cl is the individual’s theophylline 
clearance as predicted by the Jusko et al. model (mL/hr/kg),46 W is the patient’s weight 
(kg), Q is the time interval between doses (i.e., 12 hr), and F is the fraction of dose 
absorbed systemically (unitless).  A constant value of 0.8 was assumed for F, which is 
comparable to values reported for other oral theophylline formulations.32  Based on the 
nominal amount of theophylline assumed to be in each tablet (i.e., 100 mg), the number 
of tablets necessary to yield the initial dose was estimated (the number of units was 
rounded to the nearest integer).  Following a period of time assumed to be sufficient to 
reach steady-state (i.e., 5 doses), the patient’s plasma concentration was estimated via the 
PK model (Equation 2.5).  If the dose was found to be inadequate, it was incrementally 
adjusted (either increased or decreased depending on whether it was too low or too high, 
respectively) until the iterative dosing scheme converged on a satisfactory dosage.  If, 
however, the dose was adequate to yield a plasma concentration between the minimum 
effective concentration (MEC) and the minimum toxic concentration (MTC), treatment 
was initiated and the patient was administered the said dose for the duration of the trial 
period.  On average, approximately 1.2 dose adjustments per patient were necessary for a 
given sub-population of 1500 individuals (data from dose adjustment iterations are not 
included in calculation of risk scores). 
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2.2.8 Risk Simulation 
All risk simulations employed a MCS routine independent of that used to generate 
the patients.  The simulation platform was constructed such that the user is able to specify 
the age range of the population to be tested (recall that age is a covariate for all other 
patient factors), as well as the manner in which the simulation terminates.  For this 
option, the user can specify the number of individuals to be included in the sample 
population.  Otherwise, the simulation can be set to iterate until specific convergence 
criteria are reached. All simulations presented in this work were terminated using 
convergence criteria.  The user is also able to specify patient compliance and 
manufacturing variability estimates, as well as details concerning the drug and its 
corresponding therapy.  These were determined or assumed for the model theophylline 
solid oral dosage system tested herein (Table 2.3).   
 
Table 2.3. Summary of the manufacturing variability metrics and the treatment parameters used during 
simulation. 
Manufacturing Metrics 
Intra-Batch RSD of Dissolution Time Constant  0.06 
Inter-Batch RSD of Dissolution Time Constant  0.03 
RSD of Intra-Batch Content Uniformity  0.03 
RSD of Inter-Batch Content Uniformity 0.01 
Simulation Parameters 
Length of Therapy (days) 30 
Time Interval between Doses (hours) 12 
Standard Deviation of Dosing Interval (hours) 1 
Therapeutic Window (mg/L) [10 - 20] 
Rate of Compliance (% of doses taken) 90 
Fraction of Dose Absorbed (unitless) 0.8 
Dissolution Time Constant (hours) 5.0 
Nominal Theophylline Amount (mg) 100.0 
 
Given that one of the principal objectives of this work was to estimate the 
conditional risk of product quality variation on clinical performance, the simulator was 
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assembled such that the user could allow or prohibit the estimates of certain factors to be 
sampled according to their underlying distributions.  These factors included the inter- and 
intra-batch relative standard deviation (RSD) of the dissolution time constants, the inter- 
and intra-batch RSD of content uniformity, the rate of patient compliance, and the 
standard deviation of the dosing interval.  Thus, the risk simulation platform user was 
required to set variability “flags” prior to the start of a simulation that turned the factors 
“on” or “off” to assess their effect on risk.  If a factor was turned off, its estimate was 
consecutively set to the same value, whereas if it was allowed to vary, the estimate was 
influenced by the level of variability (some would refer to this as “quality”) or rate of 
adherence.  For example, the scenario where each tablet contains the same amount of 
active (as per the label claim) represents the highest degree of quality (minimal 
variability) in terms of content uniformity.     
A total of 4 variability flags were to be set by the user: inter- and intra-batch 
dosage variability, patient compliance variability, and dosing variability.  All, none, or a 
combination of these variability flags could have been turned on during the course of a 
given simulation.  When the dosing time interval was subject to variation, each dosing 
time was altered by the addition of a pseudo-random number drawn from a normal 
distribution with zero mean and unit standard deviation (i.e., “randn.m” function within 
Matlab); the random number was multiplied by the standard deviation of the dosing 
interval (Table 2.3) before it was added to the particular dosing time.  Otherwise, doses 
were administered at their scheduled times.  For simulations where patient compliance 
was variable, compliance was modeled using a binomial distribution where the success 
probability was set to the assumed patient compliance (% of doses taken); a value of 0 
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denoted a missed dose.  Patients were prohibited from missing two consecutive doses.  
Noncompliance was prohibited during the patient-specific iterative dosing schedule.  
Otherwise, all doses were assumed to be taken.  
The remaining two variability flags pertain to the dosage form itself.  For 
instances where inter-batch variability was initiated, the initial dose administered to a 
patient (D') was randomly selected from a normal distribution, whose mean was set to D 
(Equation 2.7), and whose standard deviation was set to the inter-batch RSD of content 
uniformity (Table 2.3) multiplied by D.  This estimate then remained the mean nominal 
dosage for that patient throughout the course of treatment (e.g., 30 days).  Additionally, 
the inter-batch variability flag also altered the dissolution time constant; α' was randomly 
selected from a normal distribution whose mean was the nominal time constant (α) and 
whose standard deviation was set as the inter-batch RSD of the dissolution time constant 
multiplied the nominal α (Table 2.3).  Again, α' was held constant for the duration of 
therapy.  When intra-batch variability was prompted, each dose administered to a given 
patient was adjusted from the nominal amount (either D or D', depending on whether or 
not inter-batch variability was triggered) to reflect the level of variability around the 
mean for the current batch.  This was accomplished by randomly selecting the current 
dose from a normal distribution of mean D or D' and standard deviation of D or D' 
multiplied by the intra-batch RSD of content uniformity (Table 2.3).  Additionally, the 
intra-batch variability flag also altered the dissolution time constant for each dose; it was 
randomly selected from a normal distribution whose mean was the nominal time constant 
(α or α', depending on whether or not inter-batch variability was triggered) and whose 
standard deviation was set as the intra-batch RSD of the dissolution time constant 
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multiplied by α or α'.  Otherwise, the dose estimated using Equation 2.7 was successively 
administered assuming a constant dissolution time constant when dosage form variability 
was not assessed.  The simulation assumed that the one-month drug supply (for each 
patient) was drawn from a single batch. 
The final parameter that needed to be addressed was β.  The Weibull shape 
parameter was estimated for each dose using the linear relationships describing the 
approximate median and maximum values of β as a function of α (Figure 2.4).  
Specifically, β was randomly selected from a normal distribution.  The mean of the 
normal distribution was set as the median value of β and the standard deviation was set to 
the standard deviation of β, which was estimated using the 99.9 % confidence interval for 
a normal distribution and the difference between the maximum and median shape 
parameters for a given time constant.  The minimum allowable value for β was 1.01. 
With all of the parameters set, the program commenced by first excluding those 
patients not meeting the age criteria, that is if  the criteria differed from 10 – 90 years.  
Each patient was randomly selected from the sub-population and dosed accordingly.  
Once the appropriate dose was determined for each patient, he/she was administered 
treatment.  Throughout the course of the therapy, a patient’s theophylline plasma 
concentration was monitored by integrating Equation 2.5.  Plasma concentrations were 
estimated 6 times per hour.  These data were stored and superimposed over the course of 
treatment.  A frequency histogram summarizing theophylline plasma levels was 
generated for each patient; responses were segregated (i.e., binned) into 0.25 mg/L 
intervals.   
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Probabilistic estimates of observing inefficacious and toxic events were 
predetermined for theophylline concentrations ranging from 0 to 100 mg/L at 0.25 mg/L 
increments using the PD sigmoid functions (Equations 2.6a and 2.6b).  Using these 
concentration-based likelihoods, risk estimates (or scores) were generated after each 
patient was treated.  First, the plasma concentration histograms were aggregated (i.e., 
data within each concentration bin were amassed for all patients tested).  Next, the 
aggregated plasma concentration data was transformed into a CDF.  Provided that both 
the PD functions and the pooled CDF were generated using the same concentration axis, 
plots of the inefficacy risk scores versus the aggregated CDF data and the toxicity risk 
scores versus the aggregated CDF data were generated.  These plots were used to 
interpret the percentage of the population that had a risk score at or below a given value 
(i.e., the likelihood of observing an adverse event within a sample population given the 
observed plasma concentrations).  Example plots for inefficacy and toxicity are shown in 
Figure 2.8a and Figure 2.8b, respectively.  These plots illustrate that 95 % of the sample 
population had an inefficacy risk score less than or equal to 25.62 % and a toxicity risk 
score of less than or equal to 8.01 % for the given trial simulation.  In other words, 95 % 
of the population was treated such that there was a maximum likelihood of 25.62 % and 
8.01 % for observing an inefficacious or toxic event, respectively.   
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Figure 2.8. Plots of inefficacy (a) and toxicity (b) risk scores versus the fraction of observations for the 
sample population tested.  These data were interpolated (solid lines) to determine the percentage of the 
sample population (95 %) that had a risk score less than or equal to a given value.  The sample population 
was treated such that there was a maximum likelihood of 25.62 % and 8.01 % for observing an 
inefficacious or toxic event, respectively. 
Rather than reporting multiple risk scores for both inefficacy and toxicity, it was 
desirable to summarize the risk to a sample population with a single risk score for each 
adverse event.  Thus, the empirical CDF/PD function plots were interpolated to yield a 
single risk score corresponding to a CDF probability of 0.95 for both inefficacy and 
toxicity.  A risk score summarizing those tested was generated for each addition of a 
patient.  The number of iterations conducted was not fixed; rather, the risk simulator 
continued to test additional patients until the risk scores for inefficacy and toxicity both 
stabilized below a certain oscillation threshold.  Stability of risk assessments was 
assessed by calculating the absolute fractional change of the median risk score (Δ) 
observed by adding one additional patient to the sample population using the equation 
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where RS indicates the risk score for the ith observation and n represents the number of 
patients assessed.  Patients were consecutively tested until the variability of the risk 
estimates for both inefficacy and toxicity were below the difference threshold of 10-4.  
Furthermore, the absolute change was required to retain a value below the threshold for 
250 consecutive patients before the simulator converged on the risk estimates; these 
criteria were required for both inefficacy and toxicity.  Therefore, two risk scores, one for 
inefficacy and one for toxicity, were generated for each trial simulation.       
2.2.9 Experimental Design 
A 2x2x2x2x2x2 full factorial design was generated in Matlab using the 
“fullfact.m” function to assess the effects of manufacturing variability and patient 
compliance on clinical performance (Table 2.4).  Two levels for each factor were tested, 
which corresponded to the presence or absence of variability (i.e., factor on or off, 
respectively).  The six factors assessed were the inter- and intra-batch RSD of the 
dissolution time constants, the inter- and intra-batch RSD of content uniformity, the rate 
of patient compliance, and the standard deviation of the dosing interval.  A value of 1 
signified the presence of variability, whereas 0 represented its absence.  Each row in the 
design represents an independent risk simulation trail.  The full factorial experimental 
design was performed in triplicate, which required a total of 192 simulations.  The 
simulation run order for each replicate of the design matrix was randomized.  The age 
range for patient inclusion was not altered from that of the general population. 
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Table 2.4.  Summary of the 2x2x2x2x2x2 full factorial experimental design.  A value of 1 signifies the 
presence of variability, whereas 0 represents its absence.   
Trial 
Number 
Intra-
Batch β 
Inter-
Batch β 
Intra-
Batch 
Content 
Uniformity
Inter-
Batch 
Content 
Uniformity
Patient 
Compliance
Standard 
Deviation 
of Dosing 
Time 
Interval 
1 0 0 0 0 0 0 
2 1 0 0 0 0 0 
3 0 1 0 0 0 0 
4 1 1 0 0 0 0 
5 0 0 1 0 0 0 
6 1 0 1 0 0 0 
7 0 1 1 0 0 0 
8 1 1 1 0 0 0 
9 0 0 0 1 0 0 
10 1 0 0 1 0 0 
11 0 1 0 1 0 0 
12 1 1 0 1 0 0 
13 0 0 1 1 0 0 
14 1 0 1 1 0 0 
15 0 1 1 1 0 0 
16 1 1 1 1 0 0 
17 0 0 0 0 1 0 
18 1 0 0 0 1 0 
19 0 1 0 0 1 0 
20 1 1 0 0 1 0 
21 0 0 1 0 1 0 
22 1 0 1 0 1 0 
23 0 1 1 0 1 0 
24 1 1 1 0 1 0 
25 0 0 0 1 1 0 
26 1 0 0 1 1 0 
27 0 1 0 1 1 0 
28 1 1 0 1 1 0 
29 0 0 1 1 1 0 
30 1 0 1 1 1 0 
31 0 1 1 1 1 0 
32 1 1 1 1 1 0 
33 0 0 0 0 0 1 
34 1 0 0 0 0 1 
35 0 1 0 0 0 1 
36 1 1 0 0 0 1 
37 0 0 1 0 0 1 
38 1 0 1 0 0 1 
39 0 1 1 0 0 1 
40 1 1 1 0 0 1 
41 0 0 0 1 0 1 
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Trial 
Number 
Intra-
Batch β 
Inter-
Batch β 
Intra-
Batch 
Content 
Uniformity
Inter-
Batch 
Content 
Uniformity
Patient 
Compliance
Standard 
Deviation 
of Dosing 
Time 
Interval 
42 1 0 0 1 0 1 
43 0 1 0 1 0 1 
44 1 1 0 1 0 1 
45 0 0 1 1 0 1 
46 1 0 1 1 0 1 
47 0 1 1 1 0 1 
48 1 1 1 1 0 1 
49 0 0 0 0 1 1 
50 1 0 0 0 1 1 
51 0 1 0 0 1 1 
52 1 1 0 0 1 1 
53 0 0 1 0 1 1 
54 1 0 1 0 1 1 
55 0 1 1 0 1 1 
56 1 1 1 0 1 1 
57 0 0 0 1 1 1 
58 1 0 0 1 1 1 
59 0 1 0 1 1 1 
60 1 1 0 1 1 1 
61 0 0 1 1 1 1 
62 1 0 1 1 1 1 
63 0 1 1 1 1 1 
64 1 1 1 1 1 1 
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A 2x2x2x2 full factorial design was also generated to assess the effects of 
manufacturing variability excluding all influences from patient compliance and dosing 
time variability (Table 2.5).  Again, two levels for each factor were tested where a value 
of 1 signified the presence of variability and 0 represented its absence.  The four factors 
assessed were the inter- and intra-batch RSD of the dissolution time constants, and the 
inter- and intra-batch RSD of content uniformity.  All runs were performed in triplicate, 
which required a total of 48 simulations.  The simulation run order for each replicate of 
the design matrix was randomized.  The age range for patient inclusion was not altered 
from that of the general population. 
 
Table 2.5. Summary of the 2x2x2x2 full factorial experimental design. 
Trial 
Number 
Intra-
Batch β 
Inter-
Batch β 
Intra-
Batch 
Content 
Uniformity
Inter-
Batch 
Content 
Uniformity
1 0 0 0 0 
2 1 0 0 0 
3 0 1 0 0 
4 1 1 0 0 
5 0 0 1 0 
6 1 0 1 0 
7 0 1 1 0 
8 1 1 1 0 
9 0 0 0 1 
10 1 0 0 1 
11 0 1 0 1 
12 1 1 0 1 
13 0 0 1 1 
14 1 0 1 1 
15 0 1 1 1 
16 1 1 1 1 
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2.2.10 Statistical Analyses 
Sensitivity analyses were conducted on the results of the two DOEs using 
standard least-squares regression and an effects screening approach to determine the 
factors that had a significant influence on the risk to inefficacy and toxicity.  This 
approach calculated the type III sums of squares.  The inputs (Tables 2.4 and 2.5) were 
coded as nominal and the responses were coded as continuous.  A full factorial model 
was initially generated to consider all potential interactions.  Thereafter, fractional 
factorial models were assessed.  Standard least-squares regression was also used to 
determine the final models for inefficacy and toxicity; both the inputs and responses were 
coded continuous.  The significance level (α, not to be confused with the Weibull scale 
parameter) for all analyses was 0.05.  All statistical analyses were conducted in Matlab 
(version 7.1, The MathWorks, Natick, MA) or JMP (version 8.0.1, SAS Institute Inc., 
Cary, NC).  The risk scores for inefficacy and toxicity were analyzed independently.     
2.3 Results and Discussion 
2.3.1 Relationship between Toxicity and Inefficacy 
 It is important to understand the underlying relationship between inefficacy and 
toxicity in view of the fact that one of the fundamental objectives of the drug 
development process is to minimize the incidence of both adverse events.  This can be 
accomplished using the PD model(s).  Figure 2.9 illustrates the probabilistic relationship 
between inefficacy and toxicity, both of which are functions of theophylline 
concentration; Figure 2.9 is merely a 3-dimensional representation of the PD data that 
appear in Figure 2.7.  As might be expected, the likelihoods for inefficacy and toxicity 
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are invariant at concentrations well below the MEC; the probability of experiencing an 
inefficacious event is high at low concentrations, whereas the probability associated with 
toxic events is minimal.  As theophylline levels approach that which has been reported to 
have clinical effects (~ 5 mg/L), however, the probability of inefficacy sharply declines 
and does not begin to stabilize until roughly the mid-point of the therapeutic range.  
Conversely, the probability for toxic events is relatively constant until the middle of the 
therapeutic window, at which point the likelihood dramatically increases.  The 
probability of inefficacy is nearly at its lowest value beyond the middle of the therapeutic 
range, indicating that patients continue to experience clinical outcomes (e.g., 
bronchodilation) while enduring the adverse event(s).  The PD model also reveals that the 
probability of inefficacy will never be below approximately 22 %, which suggests that 
the drug will not offer clinical benefits for certain patients.                 
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Figure 2.9. Plot of toxicity probability versus inefficacy probability versus theophylline concentration. 
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 Figure 2.9 also illustrates that there are concentration ranges for which the two 
adverse events are inversely related to one anther.  In particular, the probabilities for 
inefficacy and toxicity are linearly related with a correlation coefficient of –0.976 over 20 
– 25 mg/L.  Comparable negative correlations can be found locally over other 
concentration ranges.  This is important since, depending on where patients are dosed, the 
interpretation of risk, for example, in a sensitivity analysis, has the potential to be 
analyzed in terms of either outcome without consideration of the other.  Indeed, this 
should be verified before one of the two metrics is disregarded.  While it is generally 
desirable to dose patients midway between the MEC and MTC, drug levels may 
consistently reside more close to one or the other.  In this instance, a comparable change 
in both metrics may have more clinical relevance for one adverse event than it does for 
the other; this is more likely when the drug levels are near concentrations for which the 
relationship between inefficacy and toxicity deviates from linearity.      
2.3.2 Dissolution Time Constant Optimization 
The theophylline tablets produced from the three manufacturing routes resulted in 
various dissolution profiles.  Thus, it was necessary to select an appropriate dissolution 
time constant that characterized the release of theophylline for the model dosage form 
prior to determining the conditional risk of product quality on clinical performance.  
Dissolution time constants ranging from 1 to 7 hours were assessed at 0.5 hour intervals 
since the majority of the tablets modeled yielded dissolution time constants in this range 
(Figure 2.4).  Variability in the six manufacturing and patient compliance factors was 
prohibited during these trials.  Each time constant was assessed in triplicate and the risk 
scores for inefficacy and toxicity are shown in Figure 2.10a and Figure 2.10b, 
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respectively.  Ultimately, a dissolution time constant that minimized the risk to inefficacy 
and toxicity was desirable.  Due to the local inverse relationship between inefficacy and 
toxicity, the minimum risk for inefficacy occurred at a time constant where risk of 
toxicity was the greatest.  Therefore, a time constant of 5.0 hours was selected to 
characterize the model theophylline dosage form as this value favorably reduced the 
likelihood of toxic events observed at shorter time constants and concurrently minimized 
the increase in inefficacious events observed at longer time constants.  These risk scores 
effectively represented the baseline risk from which variations in clinical performance 
were assessed.  The remaining simulations were run using the parameter values indicated 
in Table 2.3 according to the experimental designs illustrated in Tables 2.4 and 2.5. 
 
Figure 2.10. Plots of inefficacy (a) and toxicity (b) risk scores versus various dissolution time constants 
tested in different age-restricted sample populations. 
2.3.3 2x2x2x2x2x2 Full Factorial Experimental Design 
 The following screening and modeling efforts utilized standard-least squares 
regression.  The general approach to linear modeling assumes that the response is 
continuous over the range of negative infinity to positive infinity.  This assumption can 
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be particularly problematic for proportional responses (e.g., probabilities), since, due to 
model error, the predictions can be outside of the anticipated range (e.g., 0 to 1 or 0 to 
100).  Therefore, the estimates and standard errors were examined for consistency and 
accuracy to substantiate the use of linear regression.  The validity of the other 
assumptions of linear regression (e.g., homoscedasticity, linearity, normality) was also 
verified.  Additionally, predictor variables were analyzed for multicollinearity. 
The resultant inefficacy and toxicity risk scores for the 2x2x2x2x2x2 full factorial 
experimental design are summarized in Figure 2.11; quantile and other statistical metrics 
are also presented in Table 2.6.  Risk scores for both inefficacy and toxicity were 
approximately unimodally distributed; the assumption of normality, therefore, is not 
unreasonable.  Accordingly, transformations were deemed to be unnecessary.  Simple 
linear regression revealed that the scores for inefficacy and toxicity were negatively 
correlated (r = -0.997).  The inverse relationship was a direct result of the PD model and 
the dosing regimen; 95 % of the patients were dosed such that the CDF was consistently 
interpolated at theophylline concentrations of 20 – 25 mg/L (recall the inverse 
relationship of the PD model in this concentration range, which is illustrated in Figure 
2.9).  Given their inverse relationship, the discussion is predominately focused on 
toxicity.  The corresponding inverse statistical relationships for inefficacy were 
confirmed.  
 147
 
Figure 2.11. Frequency histograms of the resultant inefficacy (a) and toxicity (b) risk scores for the 
2x2x2x2x2x2 full factorial experimental design (n = 192).  The mean, standard deviation (S.D.), and range 
[ , ] of each adverse event are also provided. 
 
Table 2.6. Summary statistics for the 2x2x2x2x2x2 full factorial experimental design. 
Inefficacy 
Percentile Metric Probability (%)  Metric 
100.0% maximum 26.461  Mean (%) 25.962 
99.5%   26.461  Std Dev (%) 0.236 
97.5%   26.369  Std Err Mean (%) 0.017 
90.0%   26.281  Upper 95% Mean (%) 25.996 
75.0% quartile 26.135  Lower 95% Mean (%) 25.928 
50.0% median 25.979  Number of Observations 192 
25.0% quartile 25.785      
10.0%   25.629      
2.5%   25.538      
0.5%   25.468      
0.0% minimum 25.468      
Toxicity 
Percentile Metric Probability (%)  Metric 
100.0% maximum 8.336  Mean (%) 7.428 
99.5%   8.336  Std Dev (%) 0.387 
97.5%   8.184  Std Err Mean (%) 0.028 
90.0%   7.998  Upper 95% Mean (%) 7.484 
75.0% quartile 7.703  Lower 95% Mean (%) 7.373 
50.0% median 7.373  Number of Observations 192 
25.0% quartile 7.137      
10.0%   6.934      
2.5%   6.820      
0.5%   6.707      
0.0% minimum 6.707      
 
 148
Sensitivity analyses were conducted to determine which factors had a significant 
impact on the risk of an adverse event.  Figure 2.11 illustrates that the ranges of risk 
scores were narrow for both adverse events.  Nevertheless, the full factorial screening 
revealed that three main effects, intra-batch RSD of content uniformity, rate of patient 
compliance, and standard deviation of the dosing interval, significantly influenced 
probability of experiencing a toxic event.  In addition to these main effects, the first-order 
interaction between the rate of patient compliance and the standard deviation of the 
dosing interval was identified as significant.  Two other higher order interactions were 
significant; however, they were determined to be spurious based on the insignificance of 
the other main effects that comprised the interaction terms.  It is important to note that the 
same three main effects were determined to be significant for inefficacy.  The interaction 
between the rate of patient compliance and the standard deviation of the dosing interval, 
however, was not strong enough to significantly alter the likelihood of an inefficacious 
event.  This demonstrates the sensitivity of the risk simulation platform to asymmetric 
risk, a phenomenon that would go undetected with a standard “quality” metric such as 
Cpk, which does not account for clinical outcomes.  Two additional higher order 
interactions were also significant for inefficacy; they were determined to be spurious as 
well.   
Following the full factorial screening exercise, a 2nd degree fractional screening 
was carried out to re-assess the main effects and first-order interactions.  Analogous to 
the previous screening study, three main effects, intra-batch RSD of content uniformity, 
rate of patient compliance, and standard deviation of the dosing interval, as well as the 
first-order interaction between the rate of patient compliance and the standard deviation 
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of the dosing interval significantly influenced the probability of toxicity.  Likewise, intra-
batch RSD of content uniformity, rate of patient compliance, and standard deviation of 
the dosing interval significantly influenced the probability of inefficacy.   
Subsequently, standard least-squares regression was used to compare several 
potential linear models.  Ultimately, the final model for inefficacy included three main 
effects, intra-batch RSD of content uniformity, rate of patient compliance, and standard 
deviation of the dosing interval, while the model for toxicity included these three main 
effects and the first-order interaction between the rate of patient compliance and the 
standard deviation of the dosing interval.  Intra-batch RSD of content uniformity and 
standard deviation of the dosing interval functioned to an increase in the probability of 
toxicity, whereas patient compliance decreased the likelihood of experiencing a toxic 
event.   
Studentized residuals were, where appropriate, analyzed to verify that the 
assumptions of linear regression were valid for these data.  One such plot, studentized 
residuals versus sample number, is provided in Figure 2.12.  Additionally, plots of 
studentized residuals versus the predicted response values were examined, which did not 
suggest that these data were heteroscedastic (plots not shown).  Abnormal patterns were 
not observed in any of the residual plots, which further substantiates the use of linear 
regression.  The studentized residuals were also used to indentify outliers.  The largest 
(absolute value of the) studentized residual for the toxicity model was 2.97, and a total of 
11 residuals were above 2.0.  Likewise, the largest (absolute value of the) studentized 
residual for the inefficacy model was 2.81 and, in all, 11 residuals were above 2.0.  
Therefore, no observations were removed for either model.  The experimental design was 
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intentionally replicated to assess lack of fit.  Testing of both models revealed that the null 
hypothesis, which stated that the model fit these data, could not be rejected.  The final 
models for inefficacy and toxicity are summarized in Tables 2.7 and 2.8, respectively.  
The predicted versus measured plots for the two clinical outcomes, which also illustrate 
the appropriateness of the straight-line model, are shown in Figure 2.13.    
 
 
Figure 2.12. Plots of studentized residuals versus sample number for inefficacy (a) and toxicity (b) for the 
finalized linear models of the 2x2x2x2x2x2 experimental design. 
 
Figure 2.13. Predicted versus measured plots for the inefficacy (a) and toxicity (b) linear models.  The unit 
line is shown in black. 
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Table 2.7. Final model results for inefficacy for the 2x2x2x2x2x2 experimental design. 
Inefficacy 
Summary of Fit       
R2 0.86851       
R2 Adj 0.86641       
Root Mean Square Error 0.086       
Mean of Response 25.962       
Observations 192       
Analysis of Variance 
Source D.F. Sum of Squares 
Mean 
Square F Ratio 
Model 3 9.225 3.075 413.917 
Error 188 1.397 0.007 Prob > F 
Total 191 10.621   1.54E-82 
Lack of Fit 
Source D.F. Sum of Squares 
Mean 
Square F Ratio 
Lack of Fit 4 0.020 0.005 0.664 
Pure Error 184 1.377 0.007 Prob > F 
Total Error 188 1.397   6.17E-01 
        Max Rsq 
        0.87038 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob > |t| 
Intercept 26.059 0.012 2094.647 0.0 
Intra-Batch CU Variability -0.061 0.012 -4.931 1.79E-06 
Patient Compliance 0.234 0.012 18.792 4.97E-45 
S.D. Dosing Time -0.366 0.012 -29.399 3.13E-72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152
Table 2.8. Final model results for toxicity for the 2x2x2x2x2x2 experimental design. 
Toxicity 
Summary of Fit       
R2 0.86239       
R2 Adj 0.85944       
Root Mean Square Error 0.145       
Mean of Response 7.428       
Observations 192       
Analysis of Variance 
Source D.F. 
Sum of 
Squares 
Mean 
Square F Ratio 
Model 4 24.726 6.182 292.969 
Error 187 3.946 0.021 Prob > F 
Total 191 28.672   2.38E-79 
Lack of Fit 
Source D.F. 
Sum of 
Squares 
Mean 
Square F Ratio 
Lack of Fit 3 0.059 0.020 0.926 
Pure Error 184 3.887 0.021 Prob > F 
Total Error 187 3.946   4.29E-01 
        Max Rsq 
        0.86443 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob > |t| 
Intercept 7.270 0.021 346.746 
1.37E-
264 
Intra-Batch CU Variability 0.100 0.021 4.783 3.49E-06 
Patient Compliance -0.381 0.021 -18.160 3.85E-43 
S.D. Dosing Time 0.597 0.021 28.489 6.06E-70 
Patient Compliance x  
S.D. Dosing Time -0.116 0.042 -2.755 6.44E-03 
 
 To further scrutinize the final models, the 95 % confidence intervals for the 
expected mean value were grouped by all possible combinations of the independent 
variables (Table 2.9).  Examination of the mean 95 % confidence intervals revealed that 
no two intervals overlapped across all possible input combinations.  This was the case for 
both inefficacy and toxicity.  Lack of overlap further underscored the significant change 
in risk scores induced by intra-batch RSD of content uniformity, rate of patient 
compliance, and standard deviation of the dosing interval.  The data in Table 2.9 were 
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also used to generate plots of the predicted probabilities for inefficacy and toxicity 
adjusted for intra-batch content uniformity variability, patient compliance, and the 
standard deviation of the dosing interval (Figure 2.14).  The interaction between the rate 
of patient compliance and the standard deviation of the dosing interval for the toxicity 
model is clearly demonstrated by the non-parallel nature of the lines in subplots c and d; 
subplots a and b substantiate the lack of interaction for the inefficacy model.  
 
Figure 2.14. Plots of the predicted mean probabilities for inefficacy (a,b) and toxicity (c,d) adjusted for the 
effects of intra-batch content uniformity variability, patient compliance, and dosing time standard 
deviation.  Asterisks denote the upper and lower values of the mean confidence intervals whereas the open 
circles represent the mid-point of the intervals. 
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Table 2.9. 95 % confidence intervals for the expected mean value grouped by all possible combinations of 
the independent variables.  The acronym CI stands for confidence interval. 
Inefficacy 
Predicted 
Inefficacy 
Mean 95 % CI 
Intra-Batch 
Content 
Uniformity 
Variability 
Patient 
Compliance 
Dosing 
Time 
Standard 
Deviation   Lower Upper 
0 0 0   26.034 26.083 
0 1 0   26.268 26.317 
0 0 1   25.668 25.717 
0 1 1   25.902 25.951 
1 0 0   25.973 26.022 
1 1 0   26.207 26.256 
1 0 1   25.607 25.656 
1 1 1   25.841 25.890 
Toxicity 
Predicted 
Toxicity Mean 
95 % CI 
Intra-Batch 
Content 
Uniformity 
Variability 
Patient 
Compliance 
Dosing 
Time 
Standard 
Deviation 
Patient 
Compliance 
x Dosing 
Time 
Standard 
Deviation Lower Upper 
0 0 0 0 7.195 7.287 
0 1 0 0 6.872 6.964 
0 0 1 0 7.850 7.942 
0 1 1 1 7.411 7.504 
1 0 0 0 7.295 7.387 
1 1 0 0 6.972 7.064 
1 0 1 0 7.950 8.043 
1 1 1 1 7.512 7.604 
 
2.3.4 2x2x2x2 Full Factorial Experimental Design 
 Due to the overpowering variance explained by patient compliance and dosing 
time variability, a second experimental design was executed to evaluate the effects of 
manufacturing variability when patient compliance was 100 % and all doses were 
administered precisely at the scheduled dosing times.  This was done to ensure that the 
two patient factors (at the levels assessed) did not mask subtle, yet important, 
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manufacturing effects.  The resultant inefficacy and toxicity risk scores for the 2x2x2x2 
full factorial experimental design are summarized in Figure 2.15; quantile and other 
statistical metrics are also presented in Table 2.10.  Data were analyzed in a manner 
comparable to that in the 2x2x2x2x2x2 experimental design.  As was observed in the 
2x2x2x2x2x2 experimental design, the scores for inefficacy and toxicity were negatively 
correlated (r = -0.999).  Likewise, the inverse relationship was a direct result of the PD 
model and the dosing regimen; 95 % of the patients were dosed such that the CDF was 
consistently interpolated at theophylline concentrations between 20 and 25 mg/L (recall 
the negative correlation between inefficacy and toxicity within this range).  
Consequently, the discussion is predominately focused on toxicity.  The corresponding 
inverse statistical relationships for inefficacy were confirmed.  
 
Figure 2.15. Frequency histograms of the resultant inefficacy (a) and toxicity (b) risk scores for the 
2x2x2x2 full factorial experimental design (n = 48).  The mean, standard deviation (S.D.), and range [ , ] of 
each adverse event are also provided. 
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Table 2.10. Summary statistics for the 2x2x2x2 full factorial experimental design. 
Inefficacy 
Percentile Metric Probability (%)  Metric 
100.0% maximum 26.200  Mean (%) 26.024 
99.5%   26.200  Std Dev (%) 0.077 
97.5%   26.196  Std Err Mean (%) 0.011 
90.0%   26.125  Upper 95% Mean (%) 26.046 
75.0% quartile 26.086  Lower 95% Mean (%) 26.002 
50.0% median 26.025  Number of Observations 48 
25.0% quartile 25.962      
10.0%   25.911      
2.5%   25.897      
0.5%   25.897      
0.0% minimum 25.897      
Toxicity 
Percentile Metric Probability (%)  Metric 
100.0% maximum 7.507  Mean (%) 7.305 
99.5%   7.507  Std Dev (%) 0.119 
97.5%   7.507  Std Err Mean (%) 0.017 
90.0%   7.483  Upper 95% Mean (%) 7.340 
75.0% quartile 7.401  Lower 95% Mean (%) 7.270 
50.0% median 7.301  Number of Observations 48 
25.0% quartile 7.208      
10.0%   7.151      
2.5%   7.048      
0.5%   7.043      
0.0% minimum 7.043      
 
The results of the 4-factor experimental design were similar to those of the 6-
factor design; intra-batch content uniformity was the only manufacturing factor that 
significantly affected risk of toxicity, even when deviations from the dosing regimen 
were not permitted.  As was observed previously, intra-batch content uniformity was 
positively correlated with the change in toxicity risk scores and negatively correlated with 
inefficacy.  Linear regression, however, did not yield models of considerable predictive 
power (R2 ≈ 0.26), which was most likely a consequence of the large standard deviation 
relative to the narrow range of the resultant risk scores (Table 2.10).  Nonetheless, intra-
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batch content uniformity is important in explaining the variation in inefficacy and toxicity 
risk scores.   
It is important to note that the conditional risk, regardless of whether or not 
patients are compliant, is dependent upon the manufacturing estimates tested.  For 
example, assume that the RSD of content uniformity (both inter- and intra-batch) is 
comparable to the estimates assessed (Table 2.3), but, due to poor control during 
tableting, the estimates for dissolution time variability are worse.  Lack of control during 
tableting could result in highly variable compression pressures, which, in turn, would 
sequentially yield erratic (1) radial tensile strengths, (2) dissolution profiles, and (3) 
exposure-response profiles.  These changes would undoubtedly affect the portion of 
variability explained by the inter- and intra-batch dissolution time constant factors.     
 The conditional risk is also expected to vary from product to product.  While 
dissolution variability (at the level tested) did not significantly impact clinical 
performance for the model solid oral dosage system, it may very well significantly 
influence, for example, an immediate release tablet.  For instance, moderate dissolution 
variability could result in sub-therapeutic levels at the critical time period following 
administration (e.g., 30 minutes), which would most likely result in clinical inefficacy.  
These effects were not as pronounced in the model system, most likely because the 
factors were assessed once patients were at steady-state.  Dissolution variability, 
therefore, was not large enough to induce an adverse event.     
 In addition to product-dependence, risk to clinical performance is also dependent 
on the production method.  A substantial change in the manufacturing route, such as from 
direct compression to wet granulation, is likely to considerably alter drug dissolution 
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(Figure 2.4), and, therefore, clinical performance if the change is not optimized with 
respect to the desired QTPP.  The adjustment, however, does not need to be so dramatic 
to have an effect on the patient.  A switch in the blending protocol from a v-blender to a 
bin blender is likely to affect the inter- and intra-batch content uniformity if the PCCPs 
are not optimized with regard to the QTPP.  Likewise, a formulation modification from 
intra- to extra-granular addition of the granulating binder has the potential to alter drug 
dissolution, and ultimately, inefficacy or toxicity.  For these very reasons, changes in the 
manufacturing protocol should be investigated with regard to their impact on clinical 
performance.  This can be accomplished by directly linking the process to clinical 
performance via a design space.   
2.3.5 Risk Simulation: A Piece of the Modernization Puzzle 
The risk simulations were conducted at the point in time where actual metrics of 
the manufacturing characteristics were available (Table 2.3).  Nonetheless, this was not 
designed to imply that a risk assessment can only be initiated once the manufacturing 
variability metrics are accessible.  Given an approach such as the one described herein, a 
risk assessor has the opportunity to assume values for parameters and/or attributes he/she 
believes have the potential to influence risk.  Since these are approximations, uncertainty 
can then be propagated through the platform to gain a better understanding of which 
factors significantly affect risk.  As the actual values become available, they can be 
incorporated, and the risk assessment can then be repeated.   
 Similarly, finalized/optimized components of the risk simulation platform (Figure 
2.1) are not necessary to conduct the assessment.  This work was completed using a 
hypothetical PD model.  That does not mean, however, that the additional assessments 
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cannot be carried out once a legitimate probabilistic PD model of theophylline is 
generated.  Moreover, gender- and age-specific estimates for the usage of barbiturates 
and benzodiazepines were assumed.  As actual data become available, the patient 
population can be re-generated, at which point the risk simulations can be repeated.  
Components, whether they are as substantial as the PK or PD model, or as small as a 
single coefficient in a model, can be replaced as better estimates, or the finalized 
elements, are arrived at.  The risk simulation platform was constructed to be modular to 
provide this flexibility.  This iterative procedure can be implemented throughout the drug 
development process to enhance product and process understanding. 
One of the objectives of the Critical Path Initiative is to accelerate the time-to-
market of innovative, safe, and effective medical products by changing the approach to 
product development.  Sponsors are encouraged to utilize innovative techniques to 
investigate the manufacturability, safety, and efficacy of candidate molecules and/or drug 
products.9  This objective can certainly be expanded to include approaches that examine 
the impact that changes, such as those instituted through comparability protocols, have on 
the manufacturability, safety, and efficacy of currently marketed products.  The 
multivariate risk simulation platform used in this work provides the opportunity to 
simultaneously study the effects of manufacturing, compliance, and physiologic and 
pathophysiologic states on the safety and efficacy of drug delivery systems.  This is true 
for new chemical entities and previously marketed drugs alike. 
 The multivariate risk simulation platform also serves as a resource allocation tool, 
which can help fulfill the public health objective of offering affordable medications.  For 
example, analysis of the model drug system revealed that intra-batch content uniformity 
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was the only manufacturing factor assessed that significantly influenced the probability 
of an adverse event.  Risk simulation, therefore, identified intra-batch content uniformity 
as a CQA.  While the other factors are not to be disregarded (beyond the range 
evaluated), it would be unreasonable to a invest large sum of resources into further 
reducing the precision of manufacturing such that dissolution variability consistently 
passed strict specifications seeing as how the current level of variability did not 
significantly alter clinical performance.  Such an investment would needlessly inflate the 
overall product cost.  The manufacturer should still be cognizant of the insignificant 
factors, however, since additional levels of variability in one or more of the 
inconsequential variables could elicit a significant change in clinical performance.  This 
could be accomplished by monitoring and controlling their variability within the limits of 
acceptable risk to clinical performance (i.e., quality, as it is redefined).  Resources 
should, on the other hand, be devoted to understanding and controlling the PCCPs for 
intra-batch content uniformity such that risk of adverse events is minimized.       
 Up to this point, the utility of the risk simulation platform has largely been 
couched on harnessing explicit patient and product knowledge to evaluate clinical 
performance (i.e., quality) as it relates to pharmaceutical production.  As was discussed in 
the literature survey (refer to section 1.3.3.2), simulation has played an important role in 
clinical trials.  A risk simulation approach such as this one also has the potential to 
contribute greatly in this area.  Despite the fact that conditional risk was investigated 
using the general population, the risk simulation platform can also delineate sub-
populations that display disparate risk levels (Figure 2.10).  This supports the selection of 
participants for inclusion in clinical trials, with the ultimate objective of reducing the 
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likelihood of the drug being toxic or ineffective.  Although drugs that are capable of 
being safely and effectively administered to the general population are desirable, certain 
patient factors often preclude individuals from taking a given medication.  These sub-
populations must be quickly identified so as to allow safe treatment.  The gamut of 
patient factors that interact to affect drug action will not always be available initially; 
however, data from drugs of the same class or defensible estimates can be used as starting 
points.  Subsequent clinical trial data can then be integrated within the simulation 
platform to better understand the conditions that predispose patients to adverse clinical 
outcomes.  Once validated, these data can then be used to carefully market the product.   
 Whether launching a clinical trial or beginning treatment in a doctor’s office, the 
risk simulation platform can facilitate arriving at a safe and effective individualized dose 
based on the volunteer/patient’s ascertainable factors (e.g., age, gender, BMI, smoking 
and drinking status, known concomitant drugs).  Together with the acting physician’s 
expertise, the likelihood of adverse events can be minimized before the individual is ever 
administered the drug.  With the appropriate data, this methodology would eliminate the 
oftentimes cyclic dose (by weight or some other dosing nomogram), monitor 
(serum/plasma levels), and adjust (as needed) approach which unquestionably jeopardizes 
the health of the individual if the first attempt is inaccurate.  Admittedly, any uncertainty 
present in the risk simulation platform would also endanger the individuals.  The 
platform, however, could be validated through a randomized clinical trial (simulation 
supervised versus unsupervised dosing) thereby mitigating the effects of unmodeled 
variance. 
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 Thus far, the inter-relationship of the risk simulation components was utilized 
none other than to generate risk scores.  These links are illustrated by the solid arrows in 
Figure 2.1.  The risk scores, however, can be harnessed to oversee and/or optimize certain 
components (dotted arrows).  For example, the dosing guidelines (whether for the general 
population or select sub-populations) can be adjusted to minimize the risk of adverse 
events.  Furthermore, feedforward and feedback manufacturing controls can be instituted 
(via process and control models) to control PCCPs such that the desired level of clinical 
performance is attainted.  Similarly, raw material variability can be integrated such that 
the process can be adjusted to compensate for risk imparted by incoming components.  
Chapter 3 uses the risk simulation platform to generate a design space for the model solid 
oral dosage system that is bounded by risk scores.  Once the design space has been 
created, control models can be developed to ensure that production is maintained at a 
level of acceptable risk.  Since risk scores are continuous, one or more acceptance 
thresholds must be arrived at.  This should be a multidisciplinary decision that weighs 
factors such as feasibility, cost to the consumer, and risk-to-benefit ratios.        
2.4 Conclusions 
 A risk simulation platform that integrated population statistics, drug delivery 
system characteristics, dosing guidelines, patient compliance estimates, production 
metrics, and PK, PD, and IVIVC models to investigate the impact of manufacturing 
variability on clinical performance of a model theophylline solid oral dosage system was 
described.  This work was predicated on requests to re-define pharmaceutical quality in 
terms of risk by linking production characteristics to clinical attributes.  Manufacturing 
precision was characterized by inter- and intra-batch content uniformity and dissolution 
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variability metrics, while clinical performance was described by a probabilistic PD model 
that expressed the probability of inefficacy and toxicity as a function of theophylline 
plasma concentrations.  At the levels assessed, both patient compliance variables, percent 
of doses taken and dosing time variability, significantly impacted risk of inefficacy and 
toxicity.  In addition to these factors, intra-batch content uniformity variability elicited a 
significant change in risk scores for the two adverse events, and, therefore, was identified 
as a CQA.  This is the first in a series of chapters that demonstrate how pharmaceutical 
quality can be recast to explicitly communicate risk as it relates to clinical performance.  
Future research will focus on constructing a design space that directly links critical 
process parameters to quantitative estimates of inefficacy and toxicity risk.  Thereafter, 
control models can be developed to supervise production such that clinical performance 
of the final product is within the hyperspace.  
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Chapter 3: Performance-Based Quality Specifications: The 
Relationship between Process Critical Control Parameters, Critical 
Quality Attributes, and Clinical Performance 
 
3.1 Introduction 
The quality of pharmaceutical products is currently evaluated through a series of 
independent tests (e.g., USP <711> and <905>) that do not explicitly communicate the 
clinical consequences of product variability.  Univariate specifications disregard potential 
multivariate and nonlinear interactions that affect risk of clinical performance.20  For 
example, a clinical inter-dependence between API content and drug release is expected to 
exist for solid oral dosage systems.  Super-potent tablets with elevated release rates 
compromise patient safety due to increased drug levels in the blood.  Furthermore, such 
product poses a specific (toxic) risk to patients whose drug clearance rates are suppressed 
(e.g., alcoholics with severe liver damage).  Therefore, under the current testing 
paradigm, it is conceivable that in-specification (i.e., passing) product could, in certain 
patients, pose a greater clinical risk than product determined to be out-of-specification 
(Figure 3.1).  If quality were to be redefined by linking production characteristics to 
clinical attributes, however, specifications for product release could be then be 
established on the basis of clinical risk.   
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Figure 3.1. Schematic illustrating final product release testing with USP <905> and <711>.  Given the 
specifications, only tablet A would pass the release tests, despite the fact it may very well pose a greater 
risk than tablet B.  OOS stands for out-of-specification.  Figure reproduced from the work of Cogdill and 
Drennen. 
 Besides failing to directly communicate clinical consequences, these tests 
dichotomize quality as satisfactory or unacceptable, despite the fact that the unit-to-unit 
quality can be disparate in a passing lot.  While equally weighting the risk of all samples 
in and of itself diminishes their utility, the validity of these very tests, which are used to 
gauge the quality of pharmaceutical products, is now being questioned.  A recently 
published article evaluated the sensitivity of the USP <905> test for content 
uniformity.119  To conduct the investigation, lots containing varying degrees of non-
conforming material were simulated in silico.  Lots of different distributions (i.e., normal, 
log normal, bimodal, and uniform) were also tested.  The authors concluded that USP 
<905> “is relatively insensitive to detecting non-conforming material.”  Furthermore, 
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despite that fact that the simulated lots contained considerable portions of out-of-
specification material, the test did not consistently fail these lots until the percentage of 
defects was in excess of 20 %.  This underscores the potential ineffectiveness of the USP 
<905> and the corresponding final product specifications in gauging quality.  Similar 
arguments, such as the one framed by Tsong et al.,120 have also questioned the sensitivity 
of USP <711> for detecting lots where considerable portions of the tablets are out-of-
specification.   
Under the current (empirical) paradigm for product development, specifications 
are often established on the basis of achievable levels of process reproducibility long 
after the production method is selected from feasibility and profitability criteria.  For 
instance, a particular production facility might be equipped for, and decidedly 
experienced in (and, therefore, biased towards) wet granulation methods.  The drug-
specific process would have been inevitably transferred from R&D to production, at 
which point a considerable level of process understanding is available.  The final product 
specifications would more than likely be set in parallel with (or following) the scale-up 
efforts.  These specifications seek to maximize production yield while concurrently 
minimizing foreseeable undesirable outcomes (e.g., product recalls, adverse patient 
reactions).  Since the majority of these outcomes have profound direct (rework costs, 
legal fees) and indirect (brand image) monetary connotations, companies often prefer to 
impose excessively strict specifications to mitigate the effects of process and/or product 
uncertainty (i.e., their effect on clinical performance).  Thus, there exists a need to 
directly link process and product variability to clinical performance to maximize safety, 
effectiveness, and affordability.      
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In contrast to the empirical paradigm, a first-principles approach to product 
development would determine the acceptable limits of clinical performance before 
consideration of the production method.  Process development would commence only 
after the performance-based quality specifications were defined.  In other words, 
production would be tailored to achieve the clinical specifications without prior 
knowledge of process reproducibility.  The idea of a first-principles approach might be 
further extended to begin with a particular disease state and a preliminary understanding 
of the patients with said condition.  Next, a pharmacophore would be optimized for a 
specific receptor, which collectively elicit pharmacologic action.  Using available patient, 
PK, and PD knowledge, acceptable levels of clinical performance would then be 
proposed, but should be flexible to integrate incoming clinical data (i.e., uncertainty in 
initial knowledge).  The tolerable limits for clinical performance will then be used to 
condition the manufacturing process and evaluate product quality.  Ideally, a drug 
delivery system and its associated manufacturing process would be selected on its ability 
to achieve the highest levels of clinical performance; however, companies may very well 
be restricted by prior investments (e.g., purchase of specific production equipment).  The 
process, irrespective of the delivery system ultimately implemented, can be optimized 
with respect to clinical performance.  Once the delivery system has been identified, the 
CQAs, or the physical, chemical, biological, or microbiological properties or 
characteristics that affect clinical performance (i.e., quality), can then be identified.  
Thereafter, the process variables that ultimately impact clinical performance (i.e., PCCPs) 
can be isolated.  The first-principles approach to product development is summarized in 
Figure 3.2. 
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Figure 3.2. Schematic diagram illustrating the first-principles approach for product development. 
Design space has assumed a predominant role in the pharmaceutical industry.  It 
is, therefore, appropriate to discuss the impact that recasting quality in terms of clinical 
performance has on components associated with the idea of design space.  In its current 
form, design space is considered “the multidimensional combination and interaction of 
input variables (e.g., material attributes) and process parameters that have been 
demonstrated to provide assurance of quality.”12  As the appendices in ICH Q8R1 
illustrate, the hyperspace is defined by PCCPs, which thereby condition the CQAs.  
Consequently, the design space is specific to a unit operation or a single production 
process.  It defines the operational range of process parameters known to influence 
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(surrogates of) product quality (e.g., dissolution).  Design space can be thought of as the 
link between PCCPs and CQAs (Figure 3.2).  MacGregor and Bruwer recently suggested 
such an architecture where design space would characterized the combination of CQAs 
that offered product whose quality was compliant with specific safety and efficacy 
requirements; however, they did not propose a means to directly connect CQAs and 
clinical performance (i.e., quality).121   
If quality was to be considered in terms of risk by linking production 
characteristics to clinical attributes, design space would be, as MacGregor and Bruwer 
have alluded to, an n-dimensional interaction of inputs that have been demonstrated to 
ensure clinical performance.  CQAs would remain fundamental to the design space; 
however, they would become inputs to, rather than outputs of, the hyperspace.  The 
definition of a CQA would effectively remain unchanged, but the physical, chemical, 
biological, or microbiological properties or characteristics would be directly related to 
clinical performance (e.g., inefficacy or toxicity risk scores) rather than indirectly linked 
via surrogate indicators of quality (e.g., moisture content, dissolution, friability).  The 
identification and utilization of a CQA, therefore, would reflect the re-standardization of 
“quality.”  Likewise, the definition of a PCCP would not need to be amended.  
Conceptually, however, a PCCP would be intimately related to clinical performance 
rather than the surrogate marker.  Performance-based quality specifications (PBQS), 
therefore, are proposed to be the link between CQAs and clinical performance (Figure 
3.2).  As such, they can be used to define a design space centered on quantitative 
estimates of clinical performance.  
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Following the first-principles approach (Figure 3.2), construction of the design 
space would be hierarchical.  At the outset, the underlying relationship between product 
attributes (e.g., API content, drug release rate) and clinical performance would define the 
space.  If the drug delivery system has already been identified (e.g., uncoated tablet), a 
risk simulation platform (reference Chapter 2) could conceivably be used to generate the 
initial hyperspace before a single unit is ever produced.  Nevertheless, once the 
production method has been identified, process and product knowledge, in conjunction 
with experimental design, risk assessment, simulation, and, if desired, PAT, could be 
harnessed to identify the attributes that are critical to clinical performance (i.e., CQAs).  
In contrast to the current design space methodology, a hyperspace that defines the 
relationship between CQAs and clinical performance is extremely powerful since it is not 
specific to a given process.  Theoretically, one of several processes (e.g., direct 
compression, wet granulation, roller compaction) could be integrated within the design 
space since, within reason, the CQAs remain invariant from process to process.  While 
partial transferability between, for example, production lines for an extended release solid 
oral dosage form is feasible, universal transferability (e.g., direct integration of process 
knowledge for a transdermal drug delivery system) would most likely be unachievable 
since different CQAs would be expected to influence clinical performance.  Transfer of 
the process-independent design space to a specific production line would be 
accomplished by identifying the process parameters that affect clinical performance, and, 
subsequently generating process models that effectively serve as transfer functions 
between the PCCPs and CQAs.  The final design space, which would then be subject to 
regulatory discretion, would illustrate the underlying relationship between PCCPs and 
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clinical performance.  Control models could also be integrated to adjust the process (for 
incoming raw material variability, in-process product variability, environmental 
fluctuations, etc.) such that clinical performance of the final product lies within the 
design space.  
 It is apparent that re-defining pharmaceutical quality in terms of risk by relating 
process and patient characteristics to clinical performance is beneficial for the 
manufacturer, the regulator, and the patient alike.  While the revamp is long overdue, 
standardizing such a fundamental concept alters current pharmaceutical quality 
initiatives.  This work addressed the design space modifications that accompany the new 
definition of pharmaceutical quality.  The objectives were to (1) illustrate the potential 
drawbacks of the current paradigm for solid oral dosage form release testing, (2) generate 
artificial design spaces for a model theophylline solid oral dosage system that are 
conditioned on quantitative estimations of inefficacy and toxicity risk, and (3) address the 
potential of a release paradigm where the quality of pharmaceutical products can be 
evaluated with regards to clinical performance.   
3.2 Materials and Methods 
3.2.1 Risk Simulations 
The risk simulator, which has been described previously (refer to Chapter 2), was 
used to conduct in silico studies.  Several modifications were made to the simulator to 
alter its functionality.  However, unless noted otherwise, the theophylline regimen was 
not adjusted.  In the previous studies, the mean Weibull dissolution time constant was 
optimized to minimize global risk.  The underlying Weibull dissolution time constant 
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distribution was then generated using this mean and estimates of the inter- or intra-batch 
RSD.  The resultant distributions were randomly sampled to yield the test parameter for 
the current simulation iteration; a new time constant was sampled for each dose 
administered.  Since the purpose was not to evaluate constrained manufacturing 
scenarios, but rather to perturb the simulation inputs beyond the levels tested in the initial 
risk assessments, particularly for dissolution variability given that it did not have a 
significant impact on clinical performance (reference Chapter 2), the dissolution time 
constants were fixed for each risk simulation trial.   
Additionally, rather than randomly sampling the variability in theophylline 
uniformity from its underlying distributions, deviation from label claim was specified for 
each risk simulation trial.  For a given risk simulation trial, individual patient doses were 
estimated using an iterative dosing scheme (refer to section 2.2.7).  All doses 
administered for a given trial, however, were adjusted to deviate by the same percentage 
from the nominal amount.  Analogous to the previous studies, each simulation trial 
consecutively tested patients until the variability of the risk estimates for both inefficacy 
and toxicity were below the difference threshold of 10-4.  Furthermore, the absolute 
change was required to retain a value below the threshold for 250 successive patients 
before the simulator converged on the risk estimates.  All doses were assumed to be taken 
at their scheduled times; treatment was administered every 12 hours for 30 days.  The age 
range for the general population was not restricted.  A total of 288 independent 
simulation trials were run. 
Data pertaining to 12 distinct wet granulation batches of the model theophylline 
tablets were utilized to conduct these simulations (refer to section 2.2.3).  As was 
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described earlier, 12 and 10 units per batch were sampled for dissolution and content 
uniformity testing, respectively.  Prior to dissolution or content uniformity testing, a 
reflectance spectrum for both sides of each tablet was acquired over the wavelength range 
of 1100 – 2498 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 5000-II, 
Vision version 2.00, FOSS NIRSystems, Inc., Laurel, MD).  Each dissolution profile was 
modeled using a two-parameter Weibull function, which yielded a shape and scale 
parameter.  Data corresponding to tablets that underwent content uniformity testing were 
used to construct calibration models for the prediction of theophylline.  
Calibration models were constructed using NIR reflectance data, expressed in 
absorbance units, of the 120 tablets (240 spectra) and amount of theophylline (%) as 
determined via UV-Vis spectroscopy (refer to section 2.2.3).  Partial least-squares 
regression122 was used via the SIMPLS algorithm123 to relate spectroscopic response to 
theophylline amount.  Preprocessing routines, including standard normal variate (SNV) 
scaling, detrending, derivatives, and combinations of the preceding were tested.124  The 
most favorable data pretreatment method was selected based on a minimization of cross-
validation error.  Contiguous block cross-validation with a block size of 5 was used to 
generate the temporary cross-validation models.  For all preprocessing routine(s) 
employed, spectroscopic data were mean-centered while reference data were scaled to 
zero mean and unit variance.  Model rank was chosen as the point where a rapid decline 
in the incremental variance captured was observed, cognizant of the expected feasible 
limit of dimensionality based on the factors varying within the design.  Detrending (first-
order) was determined to be the optimal data pretreatment method.  Two latent variables 
were necessary to adequately model these NIR absorbance data for the prediction of 
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theophylline.  This calibration model was subsequently applied to the 288 spectra of the 
144 tablets subjected to dissolution testing in order to predict their theophylline levels 
(i.e., testing data set); predicted amounts were compared to the nominal levels for each 
tablet as per the original design.117  Predicted and reference values were used to 
determine the root-mean-standard error (RMSE).  The RMSE for cross-validation 
(RMSECV), calibration (RMSEC), and testing (RMSET) were calculated using the 
formula 
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 (3.1) 
where iy  is the measured amount, iyˆ is the predicted amount, and n is the number of 
samples for the data set under consideration.  Summary statistics for the calibration 
model are provided in Table 3.1. 
 
Table 3.1. Calibration summary statistics for the prediction of theophylline.   
Data Type NIR (Reflectance) 
Method PLS 
Preprocessing First-Order Detrending 
Latent Variables 2 
Component Theophylline 
R2CAL 0.980 
R2CV 0.948 
R2TEST 0.982 
RMSEC (%) 0.96 
RMSECV (%) 1.57 
RMSET (%) 1.04 
BiasCV (%) -0.248 
BiasTEST (%) -0.250 
 
Projection of the spectra of the tablets subjected to dissolution testing onto the 
calibration model provided theophylline amounts.  These data supplement the available 
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information content (i.e., Weibull shape and scale parameters) for these tablets.  Predicted 
theophylline percentages for the same tablet varied slightly due to minor inconsistencies 
(e.g., positioning, heterogeneity, constituent packing) detected between the two tablet 
surfaces.  While the theophylline percentages were unique for a given tablet, the Weibull 
scale and shape parameters were identical for duplicate scans.  Therefore, 288 distinct 
responses were available for the 144 tablets. 
With the percent theophylline and Weibull scale and shape parameter data now 
available, each distinct response was used as an input set for a given risk simulation trial.  
Specifically, predicted theophylline percentages were compared to the nominal values to 
calculate the percent deviation from label claim; this percentage was then used to adjust 
each patient’s dose once it was individualized using the iterative dosing scheme.  The 
Weibull parameters and deviation from label claim were constant throughout a given 
simulation; the inputs were updated with values corresponding to a new tablet (or the 
reverse side of the same tablet) only once the current trial met the convergence criteria.  
Thus, the only element varying within a given trial was the pool of patients tested; all 
patients received tablets that displayed identical content uniformity and dissolution 
characteristics.   
3.2.2 USP Testing 
 Several USP monographs for theophylline products have been published in the 
USP-NF.125  Tests for uniformity and dissolution draw on the general chapters <905> and 
<711>, respectively, where the individual monographs indicate the specifications for 
each test for a particular product.  A monograph for theophylline tablets is available; 
however, it is limited to immediate-release products.  Since the model drug delivery 
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system is an extended-release tablet, specifications were extracted from its closest analog, 
the monograph for extended-release capsules; where appropriate, the specifications for 
products labeled for dosing every 12 hours were used.  This assumption is justified given 
that the specifications outlined in the monograph ought to have been optimized in terms 
of biopharmaceutical performance.  Since theophylline is highly soluble and highly 
permeable, comparable dissolution curves should yield similar safety and efficacy 
profiles for the two delivery systems.  As stated in the monograph, extended-release 
capsules are to contain between 90 and 110 percent of the labeled amount of anhydrous 
theophylline.  All content uniformity analyses were conducted using this criterion.  
Theophylline content was determined using the aforementioned calibration model.  Given 
that dissolution of the model tablets was conducted in deionized water (refer to section 
2.2.3), dissolution profiles were evaluated using Test 10; none of the other 9 tests are 
applicable.126  Acceptance criteria for the percentage of label claim dissolved at the 
specified times are summarized in Table 3.2.  All dissolution testing was conducted using 
these criteria according to USP <711>.80      
 
Table 3.2. Acceptance criteria for the percent label claim of theophylline dissolved at the specified times 
according to USP Test 10 for 12-hour extended-release capsules. 
Time 
(hours) 
Amount Dissolved 
(% Label Claim) Designation 
1 6 - 27 Q1 
2 25 - 50 Q2 
4 65 - 85 Q4 
8 > 80 Q8 
 
 Dissolution profiles (% theophylline released versus time) of the 144 tablets 
manufactured via the wet granulation method were evaluated according to the criteria 
outlined in Table 3.2 using a program written in-house.  The program determined the 
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percent theophylline dissolved (i.e., Q1, Q2, Q4, and Q8) at the specified times (i.e., 1, 2, 
4, and 8 hours) for each tablet.  Once these data were available, each tablet was evaluated 
according to USP <711> under the assumption that the one tablet was representative of a 
uniform lot (i.e., all tablets within the given lot had identical Q1, Q2, Q4, and Q8 values).  
Level once acceptance criteria for extended-release dosage forms states that all Q values 
for each unit tested must fall within the stated ranges.  Furthermore, all units tested must 
have a Q value greater than the amount specified for the final test time.80  Since the lots 
are assumed to be uniform, proceeding to level two testing upon failure of level one or 
level three upon failure of level two will not alter the test outcome.  Thus, the tablets 
were only subjected to level one testing according to the criteria outlined in Table 3.2.   
Given that the risk simulator was constructed to process Weibull parameters 
estimates rather than Q values, least-squares regression was used to relate the dissolution 
time constants (T63.2) of the 144 tablets manufactured via the wet granulation method to 
Q1, Q2, Q4, and Q8; linear as well as polynomial fits were evaluated.  The predictive 
models for Q1, Q2, Q4, and Q8 are summarized in Table 3.3; RMSEC was determined 
using Equation 3.1.  Since T63.2 is a reasonable surrogate for Q1, Q2, Q4, and Q8, at least 
inasmuch as the scenarios tested, USP <711> results for the model system were displayed 
in terms of T63.2.  Reported specifications for T63.2 only encompass tablets (lots) that 
passed USP <711> according to the criteria outlined in Table 3.2. 
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Table 3.3. Summary of the predictive models for Q1, Q2, Q4, and Q8 with T63.2 as the predictor. 
Dissolution Time 
(hours) Designation Transformation Equation 
RMSEC 
(%) R2CAL 
1 Q1 1/Q1 1/Q1 = 0.00017*T63.23 - 0.0031*T63.22 + 0.026*T63.2 – 0.0030 2.58 0.874 
2 Q2 None Q2 = -0.34*T63.23 + 6.65*T63.22 - 45.58*T63.2 + 129.75 1.91 0.987 
4 Q4 1/Q4 
1/Q4 = 1.68x10-5*T63.24 - 0.00037*T63.23 + 0.0028*T63.22 – 0.0054*T63.2 
+ 0.013 1.80 0.993 
8 Q8 None Q8 = 0.28*T63.23 - 4.60*T63.22 + 15.88*T63.2 + 84.53 1.29 0.987 
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3.3 Results and Discussion 
3.3.1 USP <905> and <711> ‘Testing’ 
The scores for inefficacy and toxicity for the 288 trials were negatively correlated 
(r = -0.8785), which is not as strong as that which was observed in the risk assessments 
(reference Chapter 2).  The reduction in covariance between inefficacy and toxicity is a 
consequence of assuming uniform production; lots which deviate to a greater extent from 
nominal result in theophylline plasma concentrations that are consistently off-target, and, 
therefore, outside the concentration range where inefficacy and toxicity are inversely 
related.  Due to the lack of (complete) correspondence, results were depicted for both 
adverse events.  
While it would have been straightforward to assign artificial values for 
theophylline content and the Weibull dissolution parameters, it was particularly desirable 
to ascertain the true relationship between these factors seeing as how they are 
confounding.  Thus, to avoid testing a combination of inputs that were potentially 
impractical, production tablets from 12 different batches were used to estimate 
theophylline content and the Weibull parameters.  The 144 tablets manufactured via a wet 
granulation method were delineated into 288 distinct responses where each response 
included percent theophylline (hence, deviation from nominal or label claim), the 
Weibull shape and scale parameters, and Q1, Q2, Q4, and Q8.  These data afford the 
opportunity to evaluate the tablets, which were assumed to each represent a uniform 
production lot, according to the USP tests for content uniformity and dissolution.  
Likewise, these data can be harnessed to investigate the impact that specific 
 180
manufacturing scenarios have on clinical performance.  In other words, the risk simulator 
can be used to project the clinical consequences of producing lots displaying various 
content uniformities and dissolution characteristics.   
 The results of the 288 simulation trials were arranged according to the input 
values for theophylline, expressed as percent deviation from nominal, and the Weibull 
dissolution time constant.  Figure 3.3 displays plots of the resultant inefficacy and 
toxicity risk scores versus API deviation from nominal (synonymous to deviation from 
label claim).  The lower and upper specifications limits for content uniformity, as 
outlined in the individual monograph for extended-release theophylline capsules, are also 
depicted.  All of the 288 lots tested were well within the acceptance limits for content 
uniformity.  Similarly, Figure 3.4 displays plots of the resultant inefficacy and toxicity 
risk scores versus the Weibull dissolution time constant.  The lower and upper 
specification limits for dissolution are also depicted.  For the conditions assessed, tablets 
with dissolution time constants between 3.10 and 3.77 hours resulted in Q1, Q2, Q4, and 
Q8 values that met the acceptance criteria outlined in Table 3.2.  In total, only 62 of the 
288 lots passed USP <711>. 
 
 181
 
Figure 3.3. Plot of risk scores for inefficacy (a) and toxicity (b) versus theophylline amount, expressed as 
percent deviation from nominal (i.e., label claim).  The bold vertical lines indicate the lower and upper 
specification limits for content uniformity analysis as per USP <905>. 
 
Figure 3.4. Plot of risk scores for inefficacy (a) and toxicity (b) versus the Weibull dissolution time 
constant.  The bold vertical lines indicate the lower and upper specification limits for dissolution analysis as 
per USP <711> and the individual monograph for theophylline extended-release capsules. 
 USP tests for content uniformity and dissolution were conducted in sequential 
fashion, which is in line with the current approach for solid oral dosage form release 
testing.  Combining the outputs of the USP tests and the risk simulations exposes one of 
the potential pitfalls of the current system.  As Figure 3.3 illustrates, samples that met the 
criteria for content uniformity, criteria which are intended to ensure the safety and 
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efficacy of the final product, display disparate levels of clinical performance.  The 
maximum risk scores observed in the risk assessments, for which content uniformity was 
identified as a CQA, were 26.46 % and 8.34 % for inefficacy and toxicity, respectively, 
well below many of the scores obtained during these studies.  Despite considerable 
differences in clinical performance, tablets sampled from any of the simulated lots would 
have been taken as acceptable.  It is quite presumptuous to uniformly categorize all 288 
scenarios.  Figure 3.4 offers a similar prospective on the current approach to final product 
testing.  Although the lots which passed USP <711> had relatively low risk scores for 
inefficacy, the toxicity risk scores were exceptionally high, the majority of which were 
above the maximum risk score observed in the risk assessments (reference Chapter 2).  
Albeit an artificial construct, these data emphasize the potential disconnect between final 
product specifications and clinical performance.  This underscores the importance of 
defining quality in terms of risk by linking production characteristics to clinical 
attributes.   
 Another potential shortcoming of the current approach to final product testing lies 
in its univariate approach.  As previously noted, a clinical inter-dependence between API 
content and drug dissolution is likely.  These data support such an interaction.  As Figure 
3.3 illustrates, lots that were low in theophylline content posed a higher risk for 
inefficacy, whereas lots that were in excess of label claim presented a greater likelihood 
of toxicity.  Similarly, Figure 3.4 depicts the clinical impact of various dissolution time 
constants; smaller dissolution time constants (corresponds to faster release rates) result in 
lower probability of being inefficacious, while larger dissolution time constants 
(corresponds to slower release rates) pose a reduced risk of toxicity.  The impact on the 
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risk scores is exacerbated when the effects of content uniformity and dissolution are 
considered simultaneously.  Take, for instance, the group of toxicity risk scores that 
correspond to dissolution time constants between 1 and 2 hours (Figure 3.4b).  Although 
a low dissolution time constant generally yields a high probability of toxicity, time 
constants between 1 and 2 hours resulted in a considerable range in risk scores.  This can 
be explained, at least in part, by the interaction between content uniformity and T63.2; 
super-potent tablets with short dissolution time constants posed a greater toxic risk than 
did sub-potent tablets.  Although this interaction is reflected in the multivariate risk score, 
it is not accounted for in the univariate specifications utilized in USP <905> and <711>.  
This begs the question, how good are the current specifications at ensuring quality? 
It is not entirely appropriate to question the validity of final product specifications 
on the basis of risk score magnitudes without ascribing some level of clinical significance 
to the scores themselves.  While conclusions regarding the clinical significance of a risk 
score should be drawn by a multidisciplinary team comprised of clinicians, scientists, 
process engineers, statisticians, etc., thresholds defining low, medium, and high risk were 
instituted to further underscore the potential drawbacks of assessing final product quality 
under the current paradigm.  Inefficacy risk scores less than or equal to 25.979 %, greater 
than 25.979 % and less than or equal to 26.461 %, and greater than 26.461 % were 
classified as low, medium, and high risk, respectively.  Likewise, toxicity risk scores less 
than or equal to 7.373 %, greater than 7.373 % and less than or equal to 8.336 %, and 
greater than 8.336 % were classified as low, medium, and high risk, respectively.  The 
median risk scores from the 2x2x2x2x2x2 full factorial experimental design (refer to 
Chapter 2) were used to delineate low and medium risk, while the maximum observed 
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risk scores for inefficacy and toxicity were used to distinguish medium and high risk for 
the two adverse events.  Figure 3.5 illustrates the combined effect of theophylline content 
and T63.2 after the scores were categorized according to low, medium, and high risk. The 
acceptance criteria for USP <905> and <711> are also defined.  Figure 3.5a illustrates 
that these criteria are likely much too strict (more so for <711>) when considering 
inefficacy, and are inaccurate for assurance of safety.  The criteria would ideally take into 
consideration both adverse events, and, therefore, would need to be optimized to 
simultaneously mitigate the likelihood of inefficacy and toxicity.  Depending on the risk-
to-benefit ratios determined by the multidisciplinary team, the two adverse events are 
likely to be disproportionally weighted when optimizing the criteria.  For instance, certain 
toxic events (e.g., headache) might be acceptable (to both the clinician and the patient), 
thereby reducing the sensitivity of the test criteria to specific fluctuations in toxicity risk 
scores as a result of the corresponding increase in efficacy.  
 
Figure 3.5. Plots of theophylline content versus Weibull dissolution time constant for inefficacy (a) and 
toxicity (b) with the clinical outcomes categorized according to low, medium, and high risk.  The 
acceptance limits for USP <905> and <711> are indicated by the bold rectangle. 
 185
3.3.2 Design Space 
 In light of the deficiencies which limit assessments of final product quality, risk 
simulation has been used to delineate the relationship between the CQAs of the model 
drug delivery system and its clinical performance (i.e., PBQS).  The relationship between 
theophylline content, T63.2, and inefficacy and toxicity risk is depicted in Figure 3.6.  As 
the following discussion addresses, the PBQS can then be used to generate a design space 
where the incoming CQAs have been conditioned on estimates of inefficacy and toxicity 
risk.  To be consistent with the examples previously shown, clinical thresholds were 
instituted to generate the design spaces.  Inefficacy risk scores less than or equal to 
25.979 %, greater than 25.979 % and less than or equal to 26.461 %, and greater than 
26.461 % were classified as low, medium, and high risk, respectively.  Likewise, toxicity 
risk scores less than or equal to 7.373 %, greater than 7.373 % and less than or equal to 
8.336 %, and greater than 8.336 % were classified as low, medium, and high risk, 
respectively.    
 
Figure 3.6. Contour plots depicting the relationship between theophylline content and the Weibull 
dissolution time constant for inefficacy (a) and toxicity (b).  The color bars represent the ranges of the risk 
scores (%). 
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Two artificial design spaces (independently) conditioned on quantitative estimates of 
inefficacy and toxicity risk are presented in Figure 3.7.  The example design spaces were 
confined to combinations which resulted in low risk scores.  Although the design spaces 
were restricted to three dimensions (projected onto a two-dimensional contour plot) to 
facilitate viewing, the reader should make note that the hyperspace can be n-dimensional.  
The design spaces can be adjusted to reflect a multidisciplinary team’s conclusion 
regarding acceptable risk using the data represented in Figure 3.6.  Validation should 
confirm that design space appropriately discriminates clinical risk.   
 
Figure 3.7. Simulation based design spaces for a model theophylline extended-release tablet conditioned on 
inefficacy (a) and toxicity (b) risk scores.  Dark blue, sea green, and burgundy signify low, medium, and 
high risk, respectively. 
Although dissolution variability was not identified as a CQA during the risk 
assessment, it was included as an input to the design space.  At first glance, it might 
appear as though the results of the risk assessment were discounted in view of the fact 
that T63.2 was an input to the design space.  The results of the risk assessment, however, 
must not be taken at face value.  While dissolution variability was not critical to quality 
(at α = 0.05) within the experimental design, it interacts with content uniformity, which 
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was critical to clinical performance.  If T63.2 were not monitored, it may unknowingly 
drift to a level that would, when combined with the effects of in-specification content 
uniformity, unfavorably impact clinical performance.  Thus, it is imperative that T63.2 be 
included in the design space.  This is true for all non-critical parameters that interact 
(within ranges reasonable for a given process) with CQAs.     
Furthermore, there is no direct penalty (e.g., cost, model complexity) for 
including T63.2 in the design space given that the architecture of the risk simulator (Figure 
2.1) predetermined the mathematical relationship between the T63.2 and inefficacy and 
toxicity risk.  Integration of an attribute not previously studied in the risk assessment 
would, however, invalidate the PBQS.  This underpins the need to combine the 
information gained from the risk assessment with knowledge of the process and product. 
3.3.3 A New Release Paradigm 
 A design space conditioned on probabilistic estimates of clinical performance has 
significant regulatory implications; the advantages currently promoted (e.g., reduced 
comparability protocol reporting) are still applicable.  Although hyperspaces that utilize 
CQAs as inputs are informative, those which directly link PCCPs to clinical performance 
(i.e., those which are specific to a process) are likely to offer the greatest regulatory 
flexibility; this is largely a function of their direct interpretability regarding the process 
itself.  Once the PBQS are established, efforts to generate process models can commence; 
data upon which process models are developed may, in fact, already be available.  These 
models could serve as transfer functions between the PCCPs and CQAs, effectively 
linking a given process to clinical performance.  Control models, therefore, can be 
instituted to oversee process parameters such that clinical performance is maintained 
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within the design space.  Although material attributes (e.g., API particle size distribution) 
were not included in the artificial construct, they are by no means precluded from such an 
approach.  Material attributes can be integrated into the risk assessment as well as the 
process and control models.   
 Thus, a design space constructed from PCCPs (as well as material attributes) and 
estimates of clinical performance can be, coincident with the current intentions of the 
initiative, subjected to regulatory review.  The appropriate validation data, which should 
include actual clinical trial and production data, can be used to demonstrate the predictive 
power of the risk simulator, the process and control models, and, ultimately, the process-
specific design space.  Regulatory approval would, therefore, create a potential platform 
for real-time product release.  In essence, final product conforming to the design space 
need not be re-evaluated for assurance of quality.  The design space, which has its own 
integrated specifications, thereby, serves as the ultimate final product release test.  In 
spite of the best design of experiments, there always exists the potential for introduction 
of unmodeled variance (e.g., change in raw material supplier, shift in production sites).  
Therefore, the design space (and all of its associated models) must be continually 
managed, and updated as necessary.      
3.4 Conclusions 
In silico simulations were conducted to generate inefficacy and toxicity risk 
scores for 288 uniform lots of extended-release theophylline tablets displaying explicit 
content uniformity and dissolution variability.  These data were used to demonstrate 
potential weaknesses of the univariate specifications utilized in USP <905> and <711> 
tests for content uniformity and dissolution, respectively.  The simulated results 
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underscore several potential deficiencies.  First, in-specification product demonstrated a 
large range of quality.  This was especially true for the content uniformity results, where 
all of the 288 uniform lots assessed conformed to the final product specifications.  
Secondly, dissolution testing, which was conducted using criteria outlined in USP <711> 
and the individual monograph for extended-release theophylline capsules, revealed that 
certain out-of-specification lots posed a lower risk of inefficacy and toxicity.  Lastly, the 
relationship between final product specifications and clinical performance was 
obfuscated even further when the specifications for USP <905> and <711> were 
considered simultaneously in the context of acceptable/unacceptable levels of inefficacy 
and toxicity risk.  The simulated results illustrated that the criteria for dissolution testing 
were too strict for inefficacy and were inaccurate for toxicity.  This was related to the 
tests’ inabilities to account for interaction between content uniformity and dissolution 
variability.  
This work also addressed, principally for design space, the consequences of re-
defining pharmaceutical quality in terms of risk by linking production characteristics to 
clinical attributes.  A risk simulator was used to define the underlying relationship 
between quality attributes and clinical performance for the model theophylline extended-
release tablets.  Both critical (i.e., content uniformity) and non-critical (i.e., Weibull 
dissolution time constant) attributes were used as inputs to the design space, which was 
conditioned on quantitative estimates of inefficacy and toxicity risk.  Such a design space 
can then be applied to specific processes using process models, which relate PCCPs to 
the quality attributes, as transfer functions to ultimately link process parameters to 
clinical performance.  The direct link enhances the information content of the design 
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space by omitting quality surrogates (e.g., dissolution, moisture content) that are utilized 
in current design space practices.  Design spaces conditioned on estimates of clinical 
performance may ultimately expedite real-time product release efforts by moderating 
final product testing. 
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Chapter 4: A Near-Infrared Spectrscopic Investigation of Relative 
Density and Crushing Strength in a Four-Component Solid Dosage 
System  
 
The material presented in Chapter 4 was previously published in Short SM, Cogdill RP, 
Wildfong PLD, Drennen III JK, Anderson CA 2009. A near-infrared spectroscopic 
investigation of relative density and crushing strength in four-component compacts. 
Journal of Pharmaceutical Sciences 98(3):1095 - 1109. 
 
4.1 Introduction 
 Near-infrared spectroscopy (NIRS) has demonstrated its utility for the analysis of 
intact pharmaceutical dosage systems.124  Given the quantitative capabilities when used in 
conjunction with multivariate calibration, NIRS is frequently employed for the non-
destructive prediction of constituent concentrations within pharmaceutical compact and 
tablet matrices.  It is well understood, however, that near-infrared (NIR) spectra convey 
information pertaining to both the chemical and physical nature of the samples.127  
Signals related to physical variation (e.g., hardness or crushing strength) are commonly 
treated as interferences in composition calibration models.  Generally, variations in 
physical factors such as relative density (solid fraction) result in a characteristic baseline 
shift,128-133 the effect of which can be suppressed by mathematical treatment.  Two 
common chemometric algorithms used for this purpose are standard normal variate 
(SNV)134 scaling and multiplicative scatter correction (MSC).135  Suppression of these 
physical features usually reduces the number of model factors required to achieve 
optimum performance. 
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Beyond chemical quantification, numerous studies have documented the 
modeling of NIR data for the characterization of physical attributes.  One aspect of solid 
oral dosage forms that has been examined using this technology is tablet hardness or 
crushing strength.  Drennen and Lodder pioneered the use of NIRS for the measurement 
of tablet hardness.129,136  Subsequently, numerous publications have demonstrated NIR 
calibrations for crushing strength.128-133,137-149  The majority of these articles suggest that 
an increase in tablet hardness results in a smoother tablet surface, increasing apparent 
NIR absorption (presumably because more light is lost to specular reflectance).  Otsuka 
and Yamane took a unique approach in which they generated calibration models to 
predict the eventual hardness of tablets produced at constant compaction pressure from 
powder mixtures having varying blend times (hence, changing the distribution of 
constituents).138  While the authors were able to generate calibration models having 
significant correlation to tablet hardness, they were unable to relate spectral changes to a 
particular constituent.  The authors suggested that the NIR calibration was detecting not 
only composition, but more subtle factors including porosity, pore structure, and the 
tablet surface and geometry.138  Three other groups have investigated the use of NIRS for 
the analysis of tablet porosity; all determined that NIRS was suitable for the measurement 
of tablet porosity, reporting varying levels of success with the use of different 
mathematical techniques.141,143,149   
The objectives of this work were to demonstrate (1) characteristic absorption 
effects of NIR radiation by compacts of varying relative density and crushing strength, 
(2) the source of spectral variability resulting from varying relative density and crushing 
strength, (3) how multivariate analysis can be used to elucidate the effects of chemical 
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composition upon the physical parameters of pharmaceutical solid oral dosage forms, and 
(4) how calibration experimental design influences spectroscopic variance. Finally, these 
data are used to present a revised rationalization for NIR sensitivity to compact hardness.   
4.2 Materials and Methods  
4.2.1 Compact Production  
 The details regarding the production of the compacts used for this work have been 
described elsewhere.150  Briefly, a fully-balanced, four-constituent mixture design 
consisting of anhydrous theophylline (Lot No. 92577, Knoll AG, Ludwigshafen, 
Germany), Lactose 316 Fast Flo NF Monohydrate (Lot No. 8502113061, Hansen Labs, 
New Berlin, WI), microcrystalline cellulose (MCC, Avicel PH-200, Lot No. M427C, 
FMC BioPolymer, Mechanicsburgh, PA), and soluble starch GR (Lot No. 39362, EMD 
Chemicals Inc., Gibbstown, NJ) was generated.  The approximate median particle size of 
the theophylline, lactose, MCC, and starch (reported by documentation from their 
respective suppliers), was 90, 100, 180, and 17 microns, respectively.  No further 
analyses or operations were performed on the raw materials to determine or alter their 
particle size or distribution.  Twenty-nine design points were chosen to cover a wide 
composition range and to remove any possibility of factor aliasing (Table 4.1).  The 
mixture covariance matrix demonstrates that the design is balanced in all factors, giving 
equal emphasis to all constituents. 
 194
Table 4.1. Concentration design for the 4-component compacts. 
Design 
Point 
Anhydrous 
Theophylline 
(w/w) 
Lactose 
Monohydrate 
(w/w) 
MCC 
(PH200) 
(w/w) 
Soluble 
Starch 
(w/w) 
1 0.600 0.200 0.200 0.000 
2 0.400 0.400 0.200 0.000 
3 0.200 0.600 0.200 0.000 
4 0.400 0.200 0.400 0.000 
5 0.200 0.400 0.400 0.000 
6 0.200 0.200 0.600 0.000 
7 0.600 0.200 0.000 0.200 
8 0.400 0.400 0.000 0.200 
9 0.200 0.600 0.000 0.200 
10 0.600 0.000 0.200 0.200 
11 0.400 0.200 0.200 0.200 
12 0.200 0.400 0.200 0.200 
13 0.000 0.600 0.200 0.200 
14 0.400 0.000 0.401 0.200 
15 0.200 0.200 0.400 0.200 
16 0.000 0.400 0.400 0.200 
17 0.200 0.000 0.600 0.200 
18 0.000 0.200 0.600 0.200 
19 0.400 0.200 0.000 0.400 
20 0.200 0.400 0.000 0.400 
21 0.400 0.000 0.200 0.400 
22 0.200 0.200 0.200 0.399 
23 0.000 0.400 0.200 0.400 
24 0.200 0.000 0.400 0.400 
25 0.000 0.200 0.400 0.400 
26 0.200 0.200 0.000 0.600 
27 0.200 0.000 0.200 0.600 
28 0.000 0.200 0.200 0.600 
29 0.250 0.250 0.250 0.250 
 
Materials for each design point mixture were dispensed by weight (Data Range, 
Model No. AX504DR, Mettler Toledo, Columbus, OH), and subsequently transferred to 
25 mL glass scintillation vials.  In total, 6000 mg of material was weighed out for each 
point, and the nominal weights for all constituents were adjusted to the observed mass 
data to calculate actual concentration.  The vials were mixed for 5 minute cycles by 
placing them on the rotating drive assembly of a Jar Mill (US Stoneware, East Palestine, 
OH, USA).  After each blending period, a NIR reflectance spectrum was acquired 
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through the bottom of each vial (FOSS NIRSystems 5000, FOSS NIRSystems, Inc., 
Laurel, MD), and an ad hoc partial least-squares II (PLS-2) calibration was constructed to 
assess homogeneity.  Mixtures were assumed to be homogeneous when further mixing 
failed to yield an increase in the calibration coefficient of determination.   
The mixtures from each design point were then subdivided and compacted at one 
of 5 pressures (67.0, 117.3, 167.6, 217.8, 268.1 MPa) using a Carver Automatic Tablet 
Press (Model No. 3887.1SD0A00, Wabash, IN) equipped with 13 mm flat-faced punches 
and die.  A dwell time of 10 seconds was employed.  Six compacts weighing 
approximately 800 mg were produced per design point, with the sixth tablet’s compaction 
pressure pseudo-randomly selected from one of the five possible levels, for a total of 174 
compacts.  The compaction order was randomized to minimize heteroscedastic errors.  
Following compaction, the samples were retained in the sealed vials for 15 days prior to 
spectroscopic analysis.  
Compacts consisting of each pure component were produced in a similar manner.  
Approximately 800 mg of each component was compacted at 9 different compaction 
pressures (67.0, 90.5, 117.3, 140.8, 167.6, 191.0, 217.8, 241.3, and 268.1 MPa) using the 
same press and tooling.  Four additional pressures were employed to increase the number 
of data points in each compaction profile.  Three replicate compacts were produced at 
every compaction pressure for each constituent, yielding 27 pure compacts per material.  
The manufacturer’s lot of lactose monohydrate used for the compaction profiles differed 
from that used to make the 4-component compacts (Lot No. 8505010961, Hansen Labs, 
New Berlin, WI); all other materials were from the aforementioned lots.   
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4.2.2 Data Acquisition, Instrumentation, and Software 
       Near-infrared reflectance measurements were acquired for both sides of each 
compact (excludes pure component compacts) using a scanning monochromator 
instrument, equipped with a Rapid Content Sampler, over the wavelength range of 1100 – 
2498 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 5000-II, Vision 
version 2.00, FOSS NIRSystems, Inc., Laurel, MD).  Two ad hoc partial least-squares II 
(PLS-2) calibrations, using the constituent concentrations as reference data, were 
constructed from reflectance spectra corresponding to a specific surface of the tablets.  
Since the coefficients of determination did not differ until the third decimal place, it was 
decided to only consider measurements for one compact face.  
 Transmittance measurements were acquired on a scanning monochromator 
instrument equipped with an InSightTM Tablet Analyzer over the wavelength range of 600 
– 1898 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 6500, Vision 
version 2.00, FOSS NIRSystems, Inc., Laurel, MD).  The wavelength range of the 
transmittance spectra was truncated to 800 – 1400 nm due to limitations imposed by the 
sample pathlength. 
All spectral data were analyzed in the Matlab environment (version 7.1, The 
MathWorks, Natick, MA) using the PLS_Toolbox (version 3.0, Eigenvector Research, 
Inc., Manson, WA) and software developed at Duquesne University.  
4.2.3 Physical Testing 
 Following compaction, the samples were stored in sealed glass scintillation vials 
and were removed only for analysis.  After an approximate 40 day span to allow for 
radial expansion, the compacts were weighed (Data Range, Model No. AX504DR, 
 197
Mettler Toledo, Columbus, OH) and their thicknesses and diameters were measured 
using a digital micrometer (TESA Micromaster, Model No. IP54, Brown & Sharpe, 
North Kingstown, RI).  Assuming a cylindrical geometry, these data were used to 
estimate each compact’s density (ρcomp) according to the formula 
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where m, d, and t are compact mass, diameter, and thickness, respectively.  The pure 
component tablets were allowed to relax for approximately 55 days before their masses 
and dimensions were acquired.  The true density of each constituent was estimated via 
helium pycnometry (Micromeritics Accupyc, Model No. 1330, Particle & Surface 
Sciences Pty. Limited, Gosford, New South Wales, Australia).  The mean of five powder 
sub-samples was used for each constituent (Table 4.2).  The true densities (ρtrue) of each 
compact were estimated using the equation  
Table 4.2. Component true densities as determined by helium pycnometry. 
Component Theophylline Lactose MCC Starch 
True Density (g/cm3) 1.41 1.5063 1.5084 1.477 
True Density (g/cm3) 1.4071 1.5072 1.5084 1.4768 
True Density (g/cm3) 1.4034 1.5072 1.508 1.4766 
True Density (g/cm3) 1.4024 1.5076 1.5053 1.4766 
True Density (g/cm3) 1.4012 1.5074 1.5058 1.4767 
Average True Density (g/cm3) 1.405 1.507 1.507 1.477 
Standard Deviation (g/cm3) 0.0036 0.0005 0.0015 0.0002 
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where Xi and ρtrue,i are the w/w contribution and the true density for the ith component 
within a n-component sample.  For the work herein, n was either 4 or 1 corresponding to 
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the mixture and pure component compacts, respectively. The relative density (D) of each 
mixture and pure component compact was estimated as  
 
true
compD ρ
ρ=   (4.3) 
 The crushing strength of the compacts, reported in kiloponds (kp), was estimated 
for the mixture compacts by a diametric crushing test (Vision Tablet Testing System, 
Model No. ElizaTest 3+, Elizabeth-Hata International, North Huntingdon, PA).  The 
maximum recordable value for this particular instrument was 55.9 kp.  Twelve calibration 
compacts and one test compact were evaluated to have values of (at least) 55.9 kp; one 
other test sample yielded a value of 0.0 kp.  The information pertaining to these 14 
compacts was withheld from the subsequent crushing strength modeling but was included 
in the relative density analyses.      
4.2.4 Regression Analyses  
 Near-infrared reflectance and transmittance spectra were independently modeled 
in an identical manner.  Partial least-squares (PLS) regression122 was used via the 
SIMPLS algorithm123 to relate spectroscopic response to relative density and crushing 
strength.  No spectral preprocessing was employed; data were only transformed to 
absorbance (log (1/R) or log (1/T)) and subsequently mean-centered.  All reference data 
(relative density and crushing strength) were scaled to zero mean and unit variance prior 
to modeling.  Given that the calibrations were intended to model the physical variance 
within the spectra, preprocessing routine(s) were not applied.  Certain applications may 
necessitate spectral preprocessing to suppress interfering signals (e.g., spectrometer drift); 
however, implementation of such methods may reduce the net analyte signal150 of a 
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feature.  For this work, preprocessing routines, including SNV scaling, detrending, 
derivatives, and combinations of the preceding, were tested at the outset;124 all of these 
pretreatments reduced the ability to predict relative density and crushing strength from 
NIR reflectance and transmittance spectra.  
The optimum model was selected based on minimization of “batch-wise” cross-
validation error,151 where the batches in this instance corresponded to the 29 different 
concentration levels.  The root-mean-standard error (RMSE) for cross-validation 
(RMSECV), calibration (RMSEC), and testing (RMSET) were calculated using the 
formula 
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where iy  is the measured parameter, iyˆ is the predicted parameter, and n is the number of 
samples for the data set under consideration.  The testing data set consisted of the sixth 
compact from each design point, whose compaction pressure was pseudo-randomly 
assigned one of the five possible levels.  While this does not constitute a truly 
independent dataset for model validation (i.e., for use in process control), the course of 
action is suitable for exploratory analyses such as this. 
4.3 Results and Discussion 
4.3.1 Optical Effects of Varying Compaction Pressure 
  The optical effects of varying compaction pressure, which elicits change in the 
physical parameters of the samples, are difficult to visualize amongst the broad chemical 
variation built into the design.  Thus, Figure 4.1a and Figure 4.1b display the 
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characteristic baseline shifts for reflectance and transmittance spectra associated with 
changes in tablet density when the percent contributions of the constituents are 
unchanging.  The baseline slope increases with increasing compaction pressure for 
reflectance spectra while the opposite trend is observed for transmittance measurements. 
 
Figure 4.1. Raw NIR absorbance spectra illustrating the spectral effect of compaction pressure when 
concentration is unchanging for reflectance (a) and transmittance (b) measurements.  The design point 
illustrated is 40% theophylline, 40% lactose, 20% MCC, and 0% starch.  The intensity recorded at the first 
wavelength of each scan was subtracted from all remaining wavelengths to facilitate viewing. 
The characteristic increase in measured absorbance as a result of an increase in 
compaction pressure for NIR reflectance spectra (Figure 4.1a) is consistent with the 
results published over the last fifteen years.128-133,137-149  An increase in compaction 
pressure results in a decrease in reflected intensity.  Without the benefit of corresponding 
transmittance measurements, it is difficult to determine whether the effect is due to 
specular reflectance, absorption, or transmission of the source radiation.  As suggested by 
Cogdill and Drennen,124 Figure 4.1b reveals that the latter may well be true; as 
compaction pressure increases, transmission also increases. 
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Otsuka et al. recently published the results of a detailed scientific study of this 
effect.152  The authors cite a light penetration model based on time-of-flight analysis of 
wood chips, where the transmittance of NIR radiation can be ascribed to the pore 
structure of the sample.  It was shown that as the tablet porosity decreases, the solid/solid 
boundary surface area increases, resulting in less scattered light and more transmitted 
light.  On the other hand, as the porosity increases, the air/solid boundary surface area 
increases, and scattering predominates.  As for reflectance of NIR radiation, the authors 
hypothesize that for a tablet having low porosity, the light penetrates deep into the sample 
and is consequently absorbed between the matrices.  Conversely, reflectance intensity is 
higher in a highly porous tablet due to scattering at the air/solid boundaries, which 
precludes the radiation from penetrating deep into the sample.152  
These results dispel a commonly held explanation for NIR reflectance sensitivity 
in the presence of varying compact density (often referred to as tablet hardness).  
Therefore, the notion that a more dense compact scatters less and absorbs more may not 
be entirely accurate.  While it is not feasible to generalize these conclusions to all 
compact systems, it is expected that these results are generally applicable to most 
compacted pharmaceutical powders.  Based on the results of this work, the authors 
speculate that a reduction in compact porosity or void fraction increases the forward 
promotion of scattered photons, which is consistent with the phenomena observed in 
Figure 4.1.  
4.3.2 Relative Density Modeling 
It was determined that three latent variables (PLS factors) were required to 
adequately model the effect of relative density variation on reflectance and transmittance 
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spectra based on the minimization of RMSECV.  The use of three latent variables is 
reasonable considering the number of degrees of freedom in the experimental design.  A 
summary of the calibration statistics is provided in Table 4.3.  Calibration and test set 
prediction plots for both reflectance and transmittance are shown in Figure 4.2.  The 
comparison of predicted and reference relative density values suggest a non-linear 
relationship; a potential explanation for this is the non-linear relationship between 
relative density and compaction pressure (Figure 4.3a). 
 
Table 4.3. Calibration statistics for the prediction of relative density and crushing strength for NIR 
reflectance and transmittance geometries.   
Reflectance Geometry 
Data Type Relative Density Crushing Strength 
Method SIMPLS 
Preprocessing Raw Spectra Raw Spectra 
Latent Variables 3 3 
RMSECV [unitless, kp] 0.013 4.640 
RMSEC [unitless, kp] 0.013 4.182 
RMSET [unitless, kp] 0.017 4.739 
R2CV 0.922 0.832 
R2CAL 0.928 0.864 
R2TEST 0.906 0.856 
BiasCV [unitless, kp] 1.141E-04 5.301E-02 
BiasTEST [unitless, kp] 2.921E-03 -1.437E-01 
Transmittance Geometry 
Data Type Relative Density Crushing Strength 
Method SIMPLS 
Preprocessing Raw Spectra Raw Spectra 
Latent Variables 3 5 
RMSECV [unitless, kp] 0.018 3.678 
RMSEC [unitless, kp] 0.017 3.257 
RMSET [unitless, kp] 0.013 3.187 
R2CV 0.850 0.895 
R2CAL 0.868 0.917 
R2TEST 0.936 0.938 
BiasCV [unitless, kp] 1.402E-04 9.543E-02 
BiasTEST [unitless, kp] -5.263E-04 -5.638E-01 
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Figure 4.2. Predicted versus measured relative density plots for the calibration (a,c) and test (b,d) data sets 
for reflectance (a,b) and transmittance (c,d) geometries. 
 
 
Figure 4.3. Plots of relative density (a) and crushing strength (b) versus compaction pressure.  Only 
calibration samples are plotted. 
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The PLS loadings, scores, and regression vectors from the optimized calibration models 
were studied to evaluate the potential link between the physical data modeled and the 
chemical composition of the compacts.  The calibration samples were grouped into 
different datasets based on constituent concentration and compaction level prior to 
modeling.  Figure 4.4a and Figure 4.4b display the score values on the second versus the 
first latent variables for transmittance and reflectance geometries, respectively.  The 
majority of the variance (89.07 and 85.69%) associated with the first latent variable is 
attributable to compaction pressure.  This is expected as compaction pressure was one of 
the independent factors varied in the design; changing compaction pressure results in 
different relative densities.   
 
Figure 4.4. Plot of PLS scores for relative density on latent variable two versus latent variable one for 
reflectance (a) and transmittance (b) where the anhydrous theophylline concentration calibration samples 
were grouped into the following classes: red-triangle = 0.0 w/w, green-asterisk = 0.2 w/w, blue-square = 
0.25 w/w, cyan-plus = 0.4 w/w, and black-diamond = 0.6 w/w. 
Similar to differing compaction pressures, changes to constituent concentrations 
result in varying compressibilities.  When the calibration samples were grouped based on 
theophylline concentration (Figure 4.4), a pronounced separation in score space was 
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evident along the second latent variable (8.89 and 8.27% variance).  This pattern suggests 
the influence of theophylline on the modeling of relative density as a function of 
compaction pressure.  Its influence was also demonstrated by the second loading that 
weighted wavelength regions associated with features in the pure component spectrum of 
anhydrous theophylline (second loading vector not shown).  No separation was observed 
in reflectance or transmittance for the other components among all possible combinations 
of the first three latent variables. 
 The PLS regression vectors used for the prediction of relative density appear in 
Figure 4.5a and Figure 4.5b for reflectance and transmittance geometries, respectively.  
The regression vectors also have several features correlated to the pure component 
spectra of anhydrous theophylline, which is not unexpected.  A slightly greater 
correlation was observed between the regression vectors and the pure component 
spectrum for the reflectance data.  The regression vectors further convey the importance 
of anhydrous theophylline for the prediction of relative density via NIR reflectance and 
transmittance spectra.   
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Figure 4.5. PLS regression vectors for relative density (solid) and crushing strength (dotted) and the pure 
component spectrum of anhydrous theophylline (dashdot) for reflectance (a) and transmittance (b) 
geometries.  All vectors were scaled to the range of 0 to 1 to facilitate viewing. 
Pure component compacts were produced to assess which component (1) 
produced compacts having the highest relative densities at a given compaction pressure 
and (2) was most susceptible to changes in relative density upon compaction.  The pure 
component compaction profiles evaluating relative density versus compaction pressure 
for all four constituents after production are shown in Figure 4.6.  The trend did not 
change following the approximately 55 day relaxation period (plot not shown).  Of the 
four components, anhydrous theophylline consistently produced pure component 
compacts with the highest values.  Relative density can also be used to estimate the 
porosity (ε) of a cylindrical compact from the equation  
 
 207
50 100 150 200 250 300
0.8
0.82
0.84
0.86
0.88
0.9
0.92
0.94
0.96
0.98
1
Compaction Pressure (MPa)
R
el
at
iv
e 
D
en
si
ty
 (u
ni
tle
ss
)
 
 
Anhydrous Theophylline
Lactose Monohydrate
MCC (PH200)
Soluble Starch
 
Figure 4.6. Relative density versus compaction pressure profiles for anhydrous theophylline (squares), 
lactose monohydrate (triangles), MCC (diamonds), and soluble starch (circles) immediately after 
production. 
 
true
comp
ρ
ρε −= 1  (4.5) 
 
where ρcomp and ρtrue are the same as previously defined.  Applying Equation 4.5 to 
consider the results shown in Figure 4.6 in terms of porosity (void fraction), anhydrous 
theophylline consistently produced the least porous pure component compacts.  As far as 
the gross change in porosity is concerned, MCC displayed the largest change in porosity 
over the compaction range tested.  This is not unexpected considering the microstructure 
and propensity of MCC to deform under mechanical stress.153,154  It was expected that 
MCC would have a large influence (leverage) on the spectroscopic analyses; however, 
this affect was not observed.  This may be explained by the spectroscopic signals of each 
constituent.   
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The pure component spectrum of anhydrous theophylline is more orthogonal to 
the interfering factors; there was much greater collinearity between lactose monohydrate, 
MCC, and soluble starch (Figure 4.7).  This orthogonality enhances the net analyte signal 
for anhydrous theophylline, which inherently augments the sensitivity of the method to 
this material.  Therefore, the wide anhydrous theophylline concentration range tested 
(Table 4.1) most likely overwhelmed the signal attributable to the other three 
constituents. 
 
Figure 4.7. Pure component spectra for transmittance (a) and reflectance (b) geometries.  Individual vectors 
appear as the mean spectrum of twenty-seven pure-component compacts varying over the compaction 
pressure range of 67.0 - 268.1 MPa. 
4.3.3 Crushing Strength Modeling 
 Based on the minimization of RMSECV, it was determined that three latent 
variables were required to adequately model the crushing strength variation for 
reflectance data while five were required for transmittance measurements; this result was 
independent from relative density modeling.  A summary of the calibration statistics is 
provided in Table 4.3.  These data demonstrate that there was sufficient sensitivity in 
both the NIR reflectance and transmittance data to model crushing strength as observed 
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in the relative density analyses.  This can be observed in the predicted versus measured 
crushing strength plots for the calibration and testing data sets (Figure 4.8).  It should be 
noted that the inclusion of the samples reading 55.9 kp would not have considerably 
altered the results shown in Figure 4.8 and Table 4.3.  These data were excluded as they 
were at the limit of the testing instrumentation.   
 
Figure 4.8. Predicted versus measured crushing strength plots for the calibration (a,c) and test (b,d) data 
sets for reflectance (a,b) and transmittance (c,d) geometries. 
 Comparing the plots in Figure 4.8 with those in Figure 4.2, it is apparent that the 
predicted versus measured plots for crushing strength demonstrate a more linear 
relationship than was observed for relative density.  However, there is an apparent 
reduction in model accuracy, which may be attributed to the reduced precision of the 
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reference measurements.  The crushing strength calibration may be more linear than the 
relative density model because the measurement is more closely analogous to the 
structural factors affecting photon propagation, namely particle-particle interaction.  If 
the tensile strength of an object at zero porosity is defined as the intrinsic strength of the 
material(s) multiplied by the area normal to the applied force, then greater compaction 
pressures must increase the effective area of particle-to-particle contact, even as compact 
volume is reduced.  As more and more particles fuse together, the effective path-length of 
photons through the material is enhanced, decreasing the reflectance and increasing the 
transmittance intensities of the samples.  It is important to note that an increase in particle 
fusion will also enhance (to a certain extent, although the enhancement is ultimately 
limited by the material’s crystallographic density) the relative density of a sample, having 
an analogous effect on the reflectance and transmittance intensities.   
Subsequent to model optimization, the PLS scores, loadings, and regression 
vectors were analyzed for a relationship between physical and chemical information 
within the spectra.  In a similar manner, the calibration samples were grouped according 
to compaction and concentration levels.  Separation of the samples by compaction 
pressure demonstrated that the variance associated with the first latent variable is most 
likely due to consolidation.  The separation among different compaction levels was not as 
clear for the crushing strength analysis.  This may be explained by the relatively lower 
precision of diametric compression testing; note the tighter distribution of data points 
around the unity line for relative density (Figure 4.2 and Figure 4.8).  This uncertainty 
effectively reduces the covariance between the NIR spectra and the reference data, which 
decreases the likelihood of separation in scores space.  Ultimately, this reduction in 
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covariance deflates the signal-to-noise ratio, causing the data for adjacent compaction 
levels to blur together, perhaps because of increased rotational ambiguity during solution 
of the factor structure. 
As was previously observed in the relative density analyses, a division in score 
space is evident when the calibration samples are grouped according to anhydrous 
theophylline concentration for both reflectance and transmittance data (Figure 4.9a and 
Figure 4.9b, respectively).  This separation indicates the influence of anhydrous 
theophylline (on the calibration model) for the prediction of crushing strength.  The 
influence of anhydrous theophylline is further demonstrated by the second loading vector 
that tracked the loss of theophylline (observed for both sensing geometries).  Several 
segments of the vectors corresponded to features in the pure component spectrum of 
anhydrous theophylline (loading vector not shown).  No discernible patterns were 
observed for the remaining components among all possible combinations of the first three 
and five latent variables for reflectance and transmittance geometries, respectively.  
 
Figure 4.9. Plot of PLS scores for crushing strength on latent variable two versus latent variable one for 
reflectance (a) and latent variable three versus latent variable two for transmittance (b) where the 
calibration samples were grouped into classes (see Figure 4.4 caption) based on anhydrous theophylline 
concentration. 
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 The crushing strength regression vectors have several features related to the pure 
component spectrum of anhydrous theophylline (as observed in the relative density 
analyses).  The PLS regression vectors used for the prediction of crushing strength appear 
in Figure 4.5.  Once again, the correlations between the regression vectors and anhydrous 
theophylline were slightly less intense for the transmittance data.   
While models employing baseline fitting algorithms have proven effective in the 
presence of both chemical and physical variation,130 PLS regression was used due to the 
extended concentration range (0 – 60% w/w for all constituents).  When composition was 
held constant (by selecting sub-sets of the calibration data), baseline fitting methods 
performed comparably with PLS regression (results not shown).  Additionally, this 
regression method was implemented based on its tangible outputs (e.g., scores, loadings, 
and full-spectrum regression vectors), which can be used to better understand the effects 
of chemical variation on physical parameters of pharmaceutical compacts.   
To assess the effect of concentration variation, 29 sub-calibrations where 
constructed using linear regression to relate the standard deviation of each spectrum to 
relative density or crushing strength.   In order to mitigate concentration’s leverage, a 
sub-calibration was built at each experimental design point (Table 4.1); only calibration 
samples corresponding to the above models were used.  For the prediction of relative 
density, the mean, median, and standard deviation of the sub-calibrations’ coefficient of 
determinations were (0.954, 0.957, 0.027, n = 29) and (0.529, 0.578, 0.333, n = 29) for 
reflectance and transmittance geometries, respectively.  The ability to model relative 
density as a function of the standard deviation of the spectrum is compromised in the 
presence of the extended concentration range as evidenced by the reduction in R2 when 
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all 145 calibration samples are assessed simultaneously (0.840 and 0.189 for reflectance 
and transmittance geometries, respectively). 
The ability to predict crushing strength as a function of the standard deviation of 
each spectrum is compromised in the presence of concentration variation when all 133 
calibration samples are modeled (R2 = 0.511 and 0.005 for reflectance and transmittance 
geometries, respectively).  For the prediction of crushing strength, the mean, median, and 
standard deviation of the sub-calibrations’ coefficient of determinations were (0.945, 
0.970, 0.079, n = 29) and (0.436, 0.337, 0.358, n = 29) for reflectance and transmittance 
geometries, respectively.   
When concentration is held constant, both relative density and crushing strength 
are modeled well by the standard deviation of the log (1/R) spectra.  The authors suggest 
that the thickness of the compacts (mean = 4.387 mm, median = 4.307 mm, standard 
deviation = 0.237 mm, n = 174) in conjunction with tablet positioning error155 may have 
compromised the integrity of the transmittance results due to nonlinearity.  
4.3.4 Rationalization of NIR Sensitivity to Compact Density 
It is proposed that NIR sensitivity to variation in compact density is attributed to 
changes in the distribution of forward and back photon propagation.  It is well understood 
that scattering events occur only where there is a transition in refractive index.156  In the 
absence of a transition, an impinging photon will tend to be transmitted without a change 
of direction.  Similarly, when the transition is small (e.g., between particles of different 
materials having similar refractive indices), the change in photon direction will be small.  
Particle-particle interfaces present a smaller refractive index change relative to air-
particle interfaces.   
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When contrasting the photon path in highly porous and highly dense compacts, 
the latter present fewer air-particle interfaces, and more particle-particle interfaces.  
Consequently, photons incident on less porous compacts encounter fewer scattering 
opportunities per unit of pathlength, and tend to exhibit enhanced forward propagation 
due to increased particle-particle transmission.  It is understood that individual 
constituents have different optical properties, and therefore, each would be expected to 
exhibit a unique optical response to varying porosity.  This argument is similar to that 
posed by Isaksson, Miller, and Naes, where they investigated the spectral effects of 
laminate films covering homogenized meat.157  The authors found that the addition of the 
laminate, whose refractive index is more similar to that of the meat than the air, reduced 
the specular scattering observed at the laminate-meat interface (as opposed to the air-
meat interface).  Ultimately, the addition of the laminate film decreased the diffuse 
reflectance intensity and increased the transmitted light intensity.   
As noted above, an increase in compaction pressure (alternatively, relative density 
and crushing strength) resulted in higher amounts of transmitted radiation.  For the 
compacts studied, increasing density did not lead to higher absorbance intensities as has 
been previously asserted.128,130-132,141  While the data necessary to definitively state the 
reason(s) why this occurs have yet to be published, the theory of large-particle (e.g., Mie) 
scattering may offer a plausible first approximation.156,158   
For large-particle scattering, intensity can be viewed in terms of its forward and 
back distribution (or transmission and remission), where for particles larger than 
wavelength of the impinging radiation, interference is such that the forward direction is 
favored.156,158  If we can assume that, as porosity decreases, the average size of scattering 
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centers (e.g., particle size) within the compact increases, Mie theory would predict a 
greater propensity for scatter in the forward direction.  Moreover, as the void fraction 
decreases, the relative area of low refractive index (particle-particle) transitions in 
comparison to high refractive index (air-particle) transitions increases, resulting in 
scattering (refraction) angles favoring forward propagation.156,158  Forward scatter does 
not necessarily favor additional scatter more so than absorption; however, the reduction 
of scattering in the reverse direction would ostensibly reduce the reflectance intensity 
while increasing the transmittance intensity.  Moreover, this would lead to increased 
pathlength for diffuse reflectance measurements, and reduced pathlength for (diffuse) 
transmittance measurements.  The specific application of Mie theory to consolidated 
pharmaceutical powders, however, violates many of the underlying assumptions (e.g., 
isolated particles, spherical particles, single scattering events). 156,158 
Taking into consideration the anisotropy of both pharmaceutical solid materials 
and the composites formed by their compaction, it is reasonable to consider alternative 
methods which are valid for particles having non-spherical shape and contact with other 
particles.  Grundy, Douté, and Schmitt proposed a model based on ray tracing and Monte 
Carlo simulation of the linear polarization and scattering by anisotropic particles of sizes 
much larger than the wavelength of incident light.159  While this reference dealt 
exclusively with individual particles, their S-Scat model yielded results similar to those 
predicted by Mie theory.  Additionally, the authors observed that for irregular particles, 
scattering in the forward direction (larger phase angles) was favored.159  Utilizing models 
with the ability to compensate for the anisotropy of pharmaceutical solids (e.g., S-Scat) 
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may help to clarify the spectroscopic intricacies observed during the modeling of relative 
density and crushing strength.   
Additional research is required to address concomitant issues such as variation in 
raw material particle shape, size, etc. to understand how photons interact with compacts 
of varying density and composition.  Future research will be focused on developing 
comprehensive NIR photon migration simulation algorithms to address these issues.   
4.4 Conclusions 
Calibration models were constructed using PLS regression to relate NIR 
reflectance and transmittance spectra to compact relative density and crushing strength 
values.  Both reflectance and transmittance data had adequate sensitivity to model both 
physical characteristics.  Second to compaction pressure, anhydrous theophylline was 
most influential on the spectral analyses of relative density and crushing strength, which 
was mainly a function of the experimental design and the enhanced chemical sensitivity 
to this particular component.  Additionally, the calibration models for relative density and 
crushing strength demonstrated that the latter was more linear but less accurate in 
prediction.  This study also demonstrated that, in contrast to the existing interpretations, 
increasing tablet density does not necessarily reduce scattering or increase absorbance of 
NIR radiation.  The optical interactions are a function of changing compact porosity, 
which promotes greater scattering in the forward direction.  Propagation of light in the 
forward direction is detected as an increase in transmitted intensity.  Future studies will 
focus on using empirical data combined with in silico simulations to discern what 
happens to source photons as they interact with compacted pharmaceutical powders of 
varying relative densities.   
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Chapter 5: Determination of Figures of Merit for Near-Infrared and 
Raman Spectrometry by Net Analyte Signal Analysis for a Four 
Component Solid Dosage System 
 
The material presented in Chapter 5 was previously published in Short SM, Cogdill RP, 
Anderson CA 2007. Determination of figures of merit for near-infrared and raman 
spectrometry by net analyte signal analysis for a 4-component solid dosage system. 
AAPS PharmSciTech 8(4):Article 96. DOI: 10.1208/pt0804096.   
 
5.1 Introduction 
A number of technologies may be suitable for a given analytical measurement 
application.  Ultimately, a decision must be made as to which device will be deployed.  
Common methods for comparison of instruments based upon different fundamental 
principles are not well established.  While there are multiple considerations upon which 
instrument selection is based (cost, performance, infrastructure, etc.), this work will focus 
only on method performance characterization for two sample technologies. 
The advent of the Process Analytical Technology (PAT) initiative6 has increased 
the performance demands upon, and the need for understanding of, analytical methods.  
In a PAT environment, sensors are controlling processes (as opposed to advising).  
Pharmaceutical literature often gives the impression that a multivariate sensor is 
generally applicable for in-, on-, and at-line process monitoring applications.  These 
applications typically require chemometric modeling/calibration160 to transform 
instrument signal into useable information.  Multivariate calibration provides a platform 
for data driven analyzer selection.       
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Process analytic measurement applications in pharmaceutical science include 
qualitative and quantitative identification of compounds, examination of phase 
transformations and polymorphs, and investigations of manufacturing and process 
development. Near-infrared (NIR) and Raman spectroscopy are both sensitive to, and 
capable of accurately predicting, these phenomena.124,161  As NIR is based on optical 
absorption and Raman on the measurement of inelastic scattering, comparison of the 
parallel performance of these two classes of instrumentation is indirect.  More often than 
not, the instrument eventually deployed is selected based on limited criteria which do not 
consider all aspects of performance.   
Calibrations are frequently evaluated using the coefficient of determination (R2) 
and/or estimation of prediction error. 162-166  Neither of these measures directly consider 
issues such as precision164,165 and signal-to-noise (S/N) ratio.167,168  While these are 
important statistics, they should not be considered independently; rather, the effectiveness 
of a method should be judged based on a complete assemblage of indicators which 
describe all aspects of performance and are generalized across technological platforms.  
Net analyte signal (NAS) theory provides a mechanism for determining figures of merit 
indicative of an instrument’s utility. 
Net analyte signal theory is the concept of separating relevant signals for a 
particular component of interest from the remaining interfering elements present within 
the spectra.169  Lorber170 is widely acknowledged as the originator of multivariate NAS 
theory;  Brown,171 however, makes the clarification that Morgan172 published on a similar 
topic prior to Lorber, although the work “contains some errors.”171  Net analyte signal 
provides a tool for calculating multivariate figures of merit; prior to Morgan/Lorber, 
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techniques similar to NAS were applied only to data from univariate methods.173 A 
detailed description of univariate calibration and the corresponding determination of 
figures of merit are outside the scope of this work.  For a more detailed discussion, please 
refer to Olivieri et al. and their references.173    
Multivariate NAS was first implemented using pure component projection170 and 
classical regression;174 i.e., constituent concentration was directly related to instrumental 
response vectors.  However, implementation of NAS via pure component or classical 
regression methods is cumbersome in that the spectra or concentrations for all 
contributing species are required.169  The implementation of multivariate NAS was solved 
in terms of inverse regression by Lorber, Faber, and Kowalski, requiring only the 
concentrations for the component(s) of interest to be known.169  For inverse regression, 
concentration is expressed as a function of instrumental response.174  Nonetheless, both 
classical and inverse regression mathematics are suitable for the determination of NAS; 
however, the remaining descriptions and the work herein strictly assume the application 
of inverse regression.   
Mathematically, NAS is defined as the portion of signal unique to the constituent 
being considered and is orthogonal to all other factors present in the data.169,170  NAS, 
therefore, comprises the signal directly useful for quantification.169  A mixture spectrum 
(r) extracted from a spectral matrix containing multiple constituents can be resolved into  
 ⊥+= rrr *  (5.1) 
where r* and r┴ are mutually orthogonal components representing the NAS vector for the 
particular component of interest and the vector of interferences, respectively.169  
However, it is well understood that controllable and uncontrollable errors influence the 
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performance of any analytical technique.  This error (ε), which will be slightly different 
for each sample acquired, can also be partitioned into its respective mutually orthogonal 
components: the part that is orthogonal to the interferences (ε*), and the portion that lies 
within the interference space (ε┴).175  It is important to understand that the estimated r* 
will not lie exactly in the true direction of the NAS vector as a result of ε*.175  The former 
(ε*) is the portion of total stochastic error (ε) which contributes to imprecision. 
Multiple algorithms for calculating NAS have been reported in the literature,176,177 
with the method of computation and resulting output differing.  In this work, the method 
proposed by Bro and Andersen is utilized.178  All equations use X to represent spectral 
matrices; bold characters other than X, e.g., x, y, and NAS, represent vectors; small, 
italicized characters, e.g., x and y, represent scalars.  Additionally, the notation ||x|| 
signifies the Euclidean norm of a vector, the square root of the sum of the squared 
elements.  The superscript T indicates the transpose of a vector. 
Bro and Andersen calculate the net analyte signal vector for a particular 
component of interest by  
 ( ) ( ) TTii bbbbxNAS ⋅⋅⋅⋅= −∧ 1  (5.2) 
where xi is a sample spectrum from matrix X and b is a column vector of the regression 
coefficients for X;178 principal components regression (PCR) or partial least-squares 
(PLS) are common regression techniques used to estimate b.160  It should be noted that X 
is corrected for the mean; thus, outputs from computations employing 
∧
NAS  are mean-
centered.  Results can be rescaled using the vector of means from the centering operation 
of X to the original range.  Net analyte signal can also be expressed in scalar form, with 
no loss in information (but reduced interpretability), by the equation169 
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∧∧ = iiNAS NAS   (5.3) 
As Lorber et al. have noted, the term “NAS” is often interchangeably used to represent 
the NAS vector and the scalar NAS quantity.169  Additional discussion concerning the 
mathematics behind the determination of net analyte signal can be found elsewhere.169-
172,175-181 
5.2 Materials and Methods 
5.2.1 Tablet Production 
 A fully-balanced, four-constituent mixture design comprised of anhydrous 
theophylline (Lot No. 92577, Knoll AG, Ludwigshafen, Germany), Lactose 316 Fast Flo 
NF Monohydrate (Lot No. 8502113061, Hansen Labs, New Berlin, WI), microcrystalline 
cellulose (MCC, Avicel PH 200, Lot No. M427C, FMC BioPolymer, Mechanicsburgh, 
PA), and soluble starch GR (Lot No. 39362, EMD Chemicals Inc., Gibbstown, NJ) was 
generated.  The approximate median particle size of the theophylline, lactose, MCC, and 
starch (reported by documentation from their respective suppliers), was ~90, ~100, ~180, 
and ~17 microns, respectively.  No further analysis or alterations were performed on the 
materials to determine or alter the particle size distribution.  Twenty-nine design points 
were chosen to cover a wide range in all constituents and to remove any possibility of 
factor aliasing (Figure 5.1).  Analysis of the mixture covariance matrix (not shown) 
demonstrated the design is balanced in all directions, giving equal emphasis to all 
constituents.     
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Figure 5.1. Diagram illustrating the concentration design matrix.  The four-component design matrix can be 
viewed in three dimensions, and is in the shape of a tetrahedron because of the constraint imposed by 
concentration closure.  The center of the pyramid represents the point of equal concentration in all 
components and the vertices represent the points of pure constituents.  The solid lines are not labeled for 
their corresponding constituents as they are all equivalent due to the balanced design. 
Materials for each design point mixture were dispensed by weight (Data Range, 
Model No. AX504DR, Mettler Toledo, Columbus, OH) in accordance with the design, 
and were immediately transferred to 25 mL glass scintillation vials.  In total, 6000 mg of 
material was weighed out for each point, and the nominal weights for all constituents 
were adjusted to the observed mass data to calculate actual concentration.  After all 
components were added to each vial, they were tumbled for 5 minute cycles on a rotating 
Jar Mill (US Stoneware, East Palestine, OH, USA).  After every blending period, each 
vial was manually inverted to collect a NIR reflectance spectrum directly through the 
bottom of the glass (FOSS NIRSystems 5000, FOSS NIRSystems, Inc., Laurel, MD).  An 
ad hoc partial least-squares II (PLS-2) calibration, using the constituent concentrations as 
reference data, was constructed after each blending cycle to assess homogeneity.  
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Mixtures were assumed to be homogeneous when further mixing failed to yield an 
increase in the calibration’s coefficient of determination.   
The mixtures from each design point were then subdivided and tableted at 5 levels 
of compaction force (67.0, 117.3, 167.6, 217.8, 268.1 MPa) on a Carver Automatic 
Tablet Press (Model 3887.1SD0A00, Wabash, IN) using flat-faced punches and a 13 mm 
die.  A dwell time of 10 seconds was employed.  Six compacts were produced per design 
point, with the sixth tablet’s compaction force randomly selected from one of the five 
possible levels.  The compaction order was randomized to ensure homoscedasticity of 
experimental error.  In total, 174 compacts were produced with a nominal target weight 
of 800 mg per tablet.  A small arrow was drawn on the perimeter of each tablet (to avoid 
spectroscopic interference) to distinguish between the two flat surfaces.  Tablet 
preparation and compaction occurred over a three day period, after which the compacts 
were left to relax for 15 days prior to spectroscopic analysis to compensate for any radial 
and/or axial tablet expansion.    
5.2.2 Data Acquisition, Instrumentation, and Software  
   Near-infrared reflectance measurements (expressed as log(1/R), or absorbance 
intensity) for both sides of each tablet were acquired over the wavelength range of 1100 – 
2498 nm at a 2 nm increment (FOSS NIR Systems 5000, FOSS NIRSystems, Inc., 
Laurel, MD).  Thirty-two sub-scans were accumulated for each resultant sample 
spectrum.  Prior to scanning, the tablets were precisely centered using the positioning iris 
standard on this particular instrument.  Absorbance data were collected by way of Vision 
data acquisition software (version 2.00, FOSS NIRSystems Inc.) and exported in .NSAS 
file format.  Two ad hoc partial least-squares II (PLS-2) calibrations, using the 
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constituent concentrations as reference data, were constructed from spectra corresponding 
to a specific surface of the tablets.  Since the coefficients of determination did not differ 
until the third decimal place, it was decided to only consider measurements of one tablet 
face (arrow pointing upwards) for both technologies.  
 Raman data were measured using a prototype PhAT System spectrometer with a 
laser excitation wavelength of 785nm and equipped with a fiber-coupled probe head 
(Kaiser Optical Systems, Inc., Ann Arbor, MI).  The PhAT System samples a spot size of 
approximately 6 mm.  Two accumulations were acquired per scan employing an 
integration time of 10 seconds over the range of -64.2 to 1895.7 cm-1 at a 0.3 cm-1 
increment.  A dark scan was subtracted and the cosmic ray filter and intensity calibration 
options were selected.  The tablets used in this study were larger than could be 
accommodated in the tablet holder located in the sample chamber of the PhAT System 
requiring the tablets to be manually positioned such that the laser spot was visually 
centered on the flat face.  Raman intensity data were collected via the HoloGRAMS 
software package (version 4.0, Kaiser Optical Systems, Inc.) and exported in .GRAMS 
file format. 
 The Unscrambler (version 9.0, Camo Software Inc., Woodbridge, NJ) was used to 
convert both .NSAS and .GRAMS files to .mat format to allow further data manipulation.  
All spectral data were analyzed in the Matlab environment (version 7.1, The MathWorks, 
Natick, MA) using the PLS_Toolbox (version 3.0, Eigenvector Research, Inc., Manson, 
WA) and software developed by the Duquesne University Center for Pharmaceutical 
Technology (DCPT).   
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5.2.3 Partial Least-Squares Analysis 
 NIR and Raman data were analyzed separately but in an identical fashion.  The 
NIR spectral range and resolution were not altered; however, the Raman spectral range 
was truncated to 205.5 - 1895.7 cm-1 to remove residual Rayleigh line radiation and to 
reflect the operating range of the analyzer.  Prior to calibration, the Raman data were 
evaluated using a moving-window calibration technique179 with various window widths 
to determine if further wavenumber truncation would be beneficial.  Wavelength 
selection was not shown to enhance calibration performance.  Partial least-squares 
regression122 was used via the SIMPLS algorithm123 to relate spectroscopic response to 
concentration for each constituent on an individual basis.  Since analyte concentration is 
incorporated in the denominator of some figure of merit calculations, samples having a 
corresponding zero concentration for the component being considered were excluded.  
Therefore, samples included in the actual calibration data sets were unique for each 
component.  
Preprocessing routines, including standard normal variate (SNV) scaling, 
detrending, derivatives, and combinations of the preceding were tested.124  The most 
favorable data pretreatment method was selected based on a minimization of “batch-
wise” cross-validation error, where the batches in this instance were the five different 
compaction levels.  During each cross-validation iteration tablets produced at a particular 
compaction force were removed, a calibration was constructed, and the concentrations of 
the excluded samples were predicted via the temporary model.  This procedure was 
continued until all of the samples had been predicted, thereby allowing for the 
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determination of the root-mean-standard error (RMSE).  The RMSE for cross-validation 
(RMSECV) and calibration (RMSEC) were calculated using the formula 
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 (5.4) 
where iy  is the measured concentration, iyˆ is the predicted concentration, and n is the 
number of samples for the data set under consideration.  According to ICH guidelines, 
accuracy expresses the agreeability between reference and predicted values.182  
Therefore, RMSEC and RMSECV are used to report the accuracy of the selected 
calibration.   
5.2.4 Multivariate Figures of Merit  
 The optimal number of latent variables selected during the estimation of each PLS 
regression vector was determined by minimizing RMSECV and RMSEC.  Once 
established, the regression vector was used to determine the NAS according to equations 
(5.2) and (5.3).  Given the number of chemical constituents and physical factors varying 
in this design, it was anticipated that no more than 4 latent variables would be required; 
however, models with greater rank are feasible but would be increasingly difficult to 
justify.  The NAS vector affords the opportunity to calculate numerous figures of merit, 
such as sensitivity, analytical sensitivity, selectivity, and S/N ratio.  Figures of merit can 
be determined for every sample using the following formulae.    
Sensitivity characterizes the extent of signal variation as a function of analyte 
concentration; the higher the sensitivity, the greater the instrumental response to an 
increase in concentration.169,170  Sensitivity is calculated as169,173,177 
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where i
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SEN , i
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NAS , and iy  are the vector of sensitivities for each instrument variable, 
the net analyte signal vector, and the measured concentration for the ith sample, 
respectively.  Sensitivity is reported in units of instrument intensity per concentration.  
Measured concentrations are autoscaled before being utilized in equation (5.5).  It is also 
possible to express sensitivity as a univariate figure of merit by taking the Euclidean 
norm of the sensitivity vector  
 ||||
∧∧ = iiSEN SEN      (5.6) 
where 
∧
iSEN is the univariate measure of sensitivity for the i
th sample.177,180  Sensitivity is 
reported in this document as the mean of the univariate sensitivity values for all samples 
under consideration.   
Sensitivity is only applicable to calibrations constructed on devices operating 
under the same fundamental principles because it incorporates units of instrument signal 
(NIR absorbance intensity and Raman scattering intensity).  The parameter analytical 
sensitivity (γ) was developed to provide an impartial assessment between dissimilar 
analytical techniques.180  Analytical sensitivity is calculated as 
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SEN
δγ
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=  (5.7) 
where 
∧
SEN is the mean of the sensitivity values under consideration found using 
equation (5.6) and δr is a measure of instrumental noise.  This normalization procedure 
allows direct comparison of the measure of sensitivity associated with NIR and Raman 
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data.  Analytical sensitivity has the dimensions concentration-1.  δr was determined as the 
mean standard deviation of iNAS
∧
 (for the component under consideration) of four tablets 
broadly varying in constituent concentrations.  Additionally, this figure of merit allows an 
estimation of the minimum discernible concentration difference given the dynamic range 
modeled180 (γ-1); this is referred to as effective resolution.  
 Predicted values were determined by183 
   bXy ⋅=∧  (5.8) 
where X is the spectral matrix and b is the PLS regression vector, which varies depending 
on the number of latent variables applied.  It should be noted that the concentration data 
have been previously autoscaled; thus, predicted values need to be rescaled using the 
mean and standard deviation of the measured concentrations before the accuracy is 
determined via equation (5.4).   
It is important to observe that all predicted values herein are independent of any 
NAS calculations performed.  Certain NAS techniques allow the determination of 
predicted concentrations using the equation169,177  
 ∧
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where i
∧
NAS , i
∧
SEN , and iyˆ are as defined previously.  Considering equation (5.5) for the 
calculation of the sensitivity vector, the NAS method employed within this paper forbids 
the use of equation (5.9) because it forces ii yy =ˆ .   
 Selectivity is a dimensionless univariate measure of the portion of instrumental 
signal that is not lost due to spectral overlap, in other words the quantity of signal 
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unaffected by interfering factors, restricted to a value between 0 and 1.169  This statistic is 
calculated for each sample by169,181  
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where i
∧
NAS and ix are the NAS vector and the original spectrum for the i
th sample.  The 
magnitude of the selectivity parameter is directly dependent on the degree of spectral 
interference associated with the particular analyte under consideration.  Selectivity is 
reported in this document as the mean of the selectivity values for all samples under 
consideration.   
 Signal-to-noise ratio is one of the most important metrics for general comparison 
of methods.  It is calculated as169  
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where iNAS
∧
 is the scalar representation of the NAS vector, and δr was estimated as the 
mean standard deviation of the predicted concentrations (for the component under 
consideration) of four tablets broadly varying in constituent concentrations (i.e., the same 
four tablets previously used).  Linear regression was performed between measured 
concentration and the univariate NAS values in order to estimate scale (a1) and offset (ao) 
coefficients to transform the NAS value to units of concentration.  This enables S/N to be 
a dimensionless statistic for this four constituent mixture design.   
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Signal-to-noise ratio is reported in this document as the mean of the S/N values for all 
samples under consideration.     
 Given the wide range of concentrations present within the design, limit of 
detection (LOD) is a practical figure of merit.  Limit of detection can be computed as184  
 
m
kLOD Dσ=  (5.12) 
where kD is the statistical confidence factor (here, kD = 3), m is the slope of a univariate 
classical least-squares fit of the predicted and reference data, and σ is defined as δr in 
equation (5.11).  Since the predicted versus measured plot was not significantly different 
from unity, a value of 1.0 was assumed for m in all cases.   
5.2.5 Precision Statistics  
Precision figures of repeatability and intermediate precision were determined in 
accordance with ICH guidelines182, and were reported as the standard deviation of the 
predicted concentration values (equation 5.8) for repeat measurements.  Repeatability and 
intermediate precision values were established using the randomly-chosen design point 
comprised of 20% theophylline, 20% lactose, 0% MCC, and 60% starch, compacted at a 
force of 167.6 MPa.  Repeatability, a measure of short-term sampling error, was 
determined without repositioning of the tablet between successive scans, as well as by 
removing and subsequently re-centering the compact before acquiring the next 
measurement.  Six scans for each type of repeatability test were collected one after the 
other on the same day.  Intermediate precision, which should incorporate typical 
variations such as between analysts and days, was determined by scanning the tablet once 
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a day for six consecutive days.  The same analyst collected these scans and the 
repeatability scans to determine day to day variability of the instruments.  
5.3 Results and Discussion  
5.3.1 Near-Infrared Analysis 
 The RMSEC and RMSECV values were plotted against the number of latent 
variables selected for PLS modeling (Figure 5.2).  Savitsky-Golay first derivative 
preprocessing185 (11 point smoothing and 2nd order polynomial fit) was chosen based on 
the minimization of RMSECV.  It was independently determined that to adequately 
model the NIR absorbance data, theophylline required three latent variables, while four 
were required for lactose, MCC, and starch.  Model rank was chosen as the point where a 
rapid decline in the incremental variance captured was observed, cognizant of the 
expected feasible limit of dimensionality based on the factors varying within the design.  
Without derivative preprocessing, an additional latent variable would have been required 
to compensate for the variation in compact density.  It is speculated that the derivative 
preprocessing most effectively suppressed the physical effect of compaction, which has 
been shown to have a significant effect on the spectral baseline.124,161   
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Figure 5.2. Plot of RMSEC (squares) and RMSECV (triangles) versus the number of PLS factors used to 
model NIR data for theophylline (a), lactose (b), MCC (c), and starch (d), respectively. 
Figure 5.3 displays the regression vectors in addition to the pure component 
spectra for theophylline, lactose, MCC, and starch; note that the pure component spectra 
and the PLS regression vectors were scaled to facilitate viewing.  To gather the pure 
component scans, powder for each constituent was placed in a glass scintillation vial and 
spectra were acquired directly through the bottom of the glass; each pure component 
spectrum represents a mean of three scans.  As expected, each regression vector is highly 
correlated with its associated pure component scan.  The goodness-of-fit seen in the 
predicted versus measured concentration values for the four constituents demonstrates the 
linearity of the PLS models implemented (Figure 5.4a).  
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Figure 5.3. NIR pure component spectra (upper solid lines), PLS regression vectors (lower solid lines), net 
analyte signal (black), and interference (grey) vectors for each calibration sample, for theophylline (a), 
lactose (b), MCC (c), and starch (d), respectively.  Note that the pure component spectra and the PLS 
regression vectors were scaled to facilitate viewing. 
 
Figure 5.4. Predicted versus measured concentration plot for NIR (a) and Raman (b) data.  Circles represent 
the 50th percentile while the upper and lower stars represent the 25th and 75th percentiles, respectively.  
The unity line is shown in black. 
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 Following estimation of the PLS regression vectors for each constituent, the 
portion of the NIR signal related only to the component being analyzed was determined 
for all calibration samples (equation 5.2).  Figure 5.3 exhibits the NAS vector along with 
the corresponding interference spectrum for each calibration sample for theophylline, 
lactose, MCC, and starch.  This unique plotting scheme directly illustrates the contrast 
between analyte and interference signals.  Furthermore, this graphically illustrates the 
ability of multivariate calibration to achieve selectivity.  For example, in Figure 5.3a, a 
great deal of spectral variance can be observed around 1500 nm; however, this variation 
is not attributed to the presence of theophylline, rather, it is the result of the interfering 
components.  This effect is evident by the relatively small range in intensity for the NAS 
spectra in comparison to the larger intensity range for the interference spectra.  
Conversely, much of the spectral variation around 1650 nm is due to the variance in 
theophylline concentration.  Similar phenomena can be seen for the other three 
components (Figure 5.3).   
 5.3.2 Raman Analysis 
 The RMSEC and RMSECV were plotted against the number of PLS latent 
variables modeled in (Figure 5.5).  Savitsky-Golay first derivative preprocessing185 (33 
point smoothing and 2nd order polynomial fit), was also selected based on minimization 
of RMSECV.  Presently, there are no known published reports identifying any consistent 
correlation between variation in Raman spectra and tablet hardness; implying that Raman 
spectra are insensitive to compact hardness variation.  The data collected in this study are 
in agreement with this conclusion; no discernible pattern was observed relating Raman 
intensity and tablet compaction force (Figure 5.6).  Hence, the role of derivative 
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preprocessing was apparently not to mitigate any spectral effect of hardness variation; 
rather, it suppressed the baseline effect present in the spectra.  Theophylline and lactose 
each required four latent variables, while three were required for MCC and starch.   
 
Figure 5.5. Plot of RMSEC (squares) and RMSECV (triangles) versus the number of PLS factors used to 
model Raman data for theophylline (a), lactose (b), MCC (c), and starch (d), respectively. 
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Figure 5.6. NIR (a) and Raman (b) spectra of the same design point (40% theophylline, 40% lactose, 20% 
MCC, and 0% starch) compacted at 67.0, 117.3, 167.6, 217.8, and 268.1 MPa.  For each spectrum, the 
value for the first variable was subtracted to facilitate viewing. 
 Figure 5.7 displays the scaled regression vectors in addition to the scaled pure 
component spectra for theophylline, lactose, MCC, and starch.  Raman pure component 
scans were gathered in the same manner as the NIR.  Again, it was anticipated that the 
PLS regression vectors would include information pertaining to the component, which 
was confirmed by the similarities between the pure component scans and the regression 
vectors for all four constituents.  Less dispersion in predicted values was observed around 
each concentration level, which is in agreement with the higher calibration R2 statistics 
for the Raman calibration (Figure 5.4). 
 237
 
Figure 5.7. Raman pure component spectra (upper solid lines), PLS regression vectors (lower solid lines), 
net analyte signal (black), and interference (grey) vectors for each calibration sample, for theophylline (a), 
lactose (b), MCC (c), and starch (d), respectively.  Note that the pure component spectra and the PLS 
regression vectors were scaled to facilitate viewing. 
Following the construction of the PLS regression vectors for each constituent, the 
i
∧
NAS  was determined for each calibration sample (equation 5.2).  Figure 5.7 depicts the 
NAS vector and the interference spectrum for each calibration sample for theophylline, 
lactose, MCC, and starch.  Although 205.5 - 1895.7 cm-1 was used during calibration, a 
reduced range was plotted to highlight the contrast between NAS and interference 
spectra.  As was observed for NIR, the patterns demonstrate the selectivity of 
multivariate calibration for each component.     
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5.3.3 Figure of Merit Comparison 
Table 5.1 displays the calibration statistics describing the performance of the NIR 
and Raman spectrometers under investigation for this particular four-component solid 
dosage system.  With regard to accuracy, the Raman calibration appears to have an 
advantage relative to NIR; as reflected by the lower RMSE as well as the superior 
coefficient of determination.  Among the four components, theophylline was modeled the 
most accurately by both NIR and Raman.  This is most likely attributable to two factors: 
higher sensitivity and selectivity relative to the other components, which will be 
addressed in greater detail in the following paragraphs. 
 
 239
Table 5.1.  Calibration statistics and figures of merit for Reflectance NIR and Raman as determined for each constituent. 
Data Type NIR (Reflectance) Raman 
Method PLS 
Preprocessing 1st Derivative (11,2,1) 1st Derivative (33,2,1) 
Latent Variables 3 4 4 4 4 4 3 3 
Component Theophylline Lactose MCC Starch Theophylline Lactose MCC Starch 
R2 - Cal 0.962 0.951 0.919 0.952 0.981 0.969 0.958 0.972 
R2 - CV 0.962 0.942 0.902 0.941 0.979 0.962 0.955 0.966 
RMSEC (%) 2.7 3.1 4.0 3.1 1.9 2.5 2.9 2.4 
Accuracy RMSECV (%) 2.8 3.4 4.4 3.4 2.0 2.8 3.0 2.6 
Repeatability - w/o repositioning (%) 0.01 0.16 0.16 0.02 0.28 0.27 0.09 0.04 
Repeatability - w/ repositioning (%) 0.07 0.10 0.36 0.46 0.45 0.46 0.45 0.27 
Precision  Intermediate (%) 0.11 0.16 0.52 0.66 0.35 0.66 0.36 0.26 
Sensitivity (Instrument Intensity / %) 0.02 0.01 0.01 0.01 12768.61 5124.58 3732.26 3265.58 
Analytical Sensitivity (1 / %) 126.36 82.47 37.09 31.18 15.13 17.31 11.85 10.53 
Effective Resolution (%) 0.01 0.01 0.03 0.03 0.07 0.06 0.08 0.09 
Selectivity (unitless) 0.59 0.33 0.24 0.27 0.37 0.24 0.18 0.16 
Signal-to-Noise (unitless) 282.40 189.88 87.23 72.14 34.99 40.69 26.80 23.98 
Limit of Detection (%) 0.33 0.50 1.08 1.31 2.70 2.32 3.53 3.94 
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The ICH guidance on method validation for repeatability182 provides a protocol 
for partitioning sources of variance (i.e., instrumental noise, sample positioning error, 
instrument drift).  In particular, it was noted that repositioning inconsistency was a large 
contributor to total error for both the NIR and Raman calibrations. For the Raman 
analyzer approximate 6 mm of the surface (roughly 46 percent of the tablet surface) is 
sampled; as opposed to the off-line NIR instrument that sampled nearly the entire 
compact face.  Further, NIR has a greater depth of sampling relative to Raman 
spectroscopy.  Therefore, sample heterogeneity and/or sample presentation effects have a 
greater effect on Raman precision.  The impact of sampling heterogeneity is reduced as 
the number of samples analyzed per time period is increased as a result of averaging.  For 
example, if these methods were implemented in an at-line environment, the difference in 
precision between Raman and NIR is expected to decrease.  Additionally, more equitable 
comparisons between these two analyzers could be made by implementing a modified 
sample holder capable of precisely positioning 13 mm tablets, by analyzing tablets of a 
diameter similar to the Raman sampling size, or by averaging multiple locations on either 
side of the tablet.  
In some cases, error statistics were inconsistent with expected trends, as shown in 
Table 5.1.  For example, intermediate precision values calculated using the Raman data 
were actually lower than repeatability figures for both MCC and starch.  This is 
unexpected as intermediate precision includes the additional factor of day-to-day 
instrument drift.  This may be indicative of an incomplete estimate of the variance 
associated with sample repositioning.   
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    While the accuracy and precision data provide a feasible means of comparing 
these two spectrometers, the power of the evaluation can be enhanced by determining 
additional calibration figures of merit.  Sensitivity for both analytical devices was the 
largest for theophylline; an increase in its concentration resulted in the greatest response 
in instrumental intensity.  The relative magnitude of peaks in un-scaled pure component 
spectra (not shown) illustrates this effect.  It is important to note that the sensitivity 
values of individual constituents are not comparable between the two instruments.   
Analytical sensitivity is used to compare sensitivity across different measurement 
technologies.  This normalized statistic quantifies sensitivity with respect to analytical 
precision.  Although both devices exhibited the greatest sensitivity for theophylline, the 
NIR device was more sensitive to all four constituents (in terms of analytical sensitivity).  
Error of repositioning has a direct effect on σ in equation (5.7), which in turn inflated the 
denominator, thereby reducing the analytical sensitivity of Raman.  The constituent 
ordering for highest to lowest sensitivity is not identical between the two instruments.  
This emphasizes the importance of pairing the instrument to the analytical task.  The 
effective resolution results reinforce the results reported for sensitivity.  Despite the 
apparent similarity, this statistic should be considered with respect to quality action 
limits.   
Selectivity is important only when adequate sensitivity is available.  A lack of 
selectivity has the effect of suppressing sensitivity.  If adequate sensitivity is not 
available, improvements of selectivity are futile.  Theophylline, which exhibited high 
relative sensitivity, also exhibited superior selectivity, which is directly attributable to its 
inherent pure component orthogonality.  In contrast, the collinearity among lactose, 
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MCC, and starch (all being carbohydrates) reduced selectivity.  For Raman in particular, 
the sensitivity (equation 5.6) and selectivity are lower for these components.  This is 
manifested in the performance-related figures of merit (LOD, analytical sensitivity, 
effective resolution, and S/N).  An example of the enhanced interference between these 
three components can be seen in the NIR at approximately 1500 nm, where the NAS 
signal is quite large for all three (Figure 5.3).   
From the results discussed thus far, the resulting S/N ratio analysis should be 
straightforward.  The NIR calibration included more useable signal in relation to 
obstructive noise.  In some cases, researchers assume that the coefficient of determination 
is directly predictive of S/N ratio.186  It is for this reason that technology selection criteria 
are often based upon R2 and RMSE, since these statistics are frequently generated during 
calibration, requiring no additional calculations.  The results of this work contradict these 
assumptions.  While Raman outperformed NIR in terms of linearity and accuracy, the 
S/N ratio for NIR measurements was greater.  This occurs because error statistics (R2 or 
RMSE) are heavily influenced by the experimental design, while S/N ratio is inherent to 
the method.  Further studies are planned in which calibrations will be optimized 
according to S/N ratio (as opposed to the traditional method of RMSE); the impetus is to 
address the aforementioned precision issues, while simultaneously enhancing sensitivity, 
selectivity, and LOD.     
It is interesting to note that despite the lower relative precision of the Raman 
measurements, which deflates several of the figures of merit, no negative effect on the 
ability of the SIMPLS algorithm to resolve the covariance structure was observed.  This 
is because inverse least-squares regression is less affected by precision than sample 
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leverage in the estimation of the true solution.  This supports the notion that calibration 
quality is not sufficient to fully describe method performance.  
5.4 Conclusions 
This study demonstrates that multivariate figures of merit (determined from net 
analyte signal theory) can be used to compare calibrations constructed from spectroscopic 
data collected using two analytical instruments detecting different physical phenomena.  
The observed calibration performance statistics demonstrate that NIR and Raman are 
both suitable techniques for the quantitative determination of chemical components 
within this tablet matrix.  Beyond error statistics, multivariate figures of merit provide a 
clearer assessment of the specific factors limiting performance of the methods while 
providing a means for general characterization. Furthermore, figures of merit, such as 
effective resolution and limit of detection, provide an additional mechanism for 
determining the validity and significance of predicted values upon deployment. For all of 
these reasons, figures of merit should take a more prominent place among chemometric 
techniques used in pharmaceutical analytical method development.  
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Chapter 6: Figures of Merit Comparison of Reflectance and 
Transmittance Near-Infrared Methods for the Prediction of 
Constituent Concentrations in Pharmaceutical Compacts 
 
The material presented in Chapter 6 was previously published in Short SM, Cogdill RP, 
Anderson CA 2008. Figures of Merit Comparison of Reflectance and Transmittance 
Near-Infrared Methods for the Prediction of Constituent Concentrations in 
Pharmaceutical Compacts. Journal of Pharmaceutical Innovation 3(1):41 - 50. DOI 
10.1007/s12247-008-9020-8.   
 
 
6.1 Introduction 
The Process Analytical Technology (PAT) initiative6 has increased the 
performance demands upon analytical methods.  In a PAT environment, sensors are 
implemented for control as opposed to inspection.  Process analytical sensors require 
chemometric modeling/calibration160 to transform instrument signal into useable 
information.  Multivariate calibration provides a platform for data driven analyzer 
selection. 
Near-infrared spectroscopy (NIRS) has emerged as a useful analytical technique 
for the nondestructive characterization of solid oral dosage forms.  Technology selection 
is an important early process in method development; following technology selection, the 
choice of the sampling system is critical for method suitability.  Near-infrared (NIR) 
tablet analyzers are constructed to operate in reflectance and/or transmittance modes.   
Measurements of accuracy are often used as the sole discriminating factor in 
selecting spectrometer configuration.157,187-207  All but two pharmaceutically-oriented 
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studies205,207 determined transmittance NIRS to be superior for the analysis of intact 
tablets.  Most suggest that the enhanced accuracy was due to the larger volume of sample 
interrogated with the transmittance mode.201-204  Cogdill et al.207 concluded that, despite 
the enhanced accuracy, the impact of sampling position error was less for the reflectance 
mode.  Mean-squared error and the coefficient of determination assess agreement with a 
reference method; multivariate figures of merit characterize the capability of the 
measurement system.   
Multivariate figure of merit, based on net analyte signal (NAS) theory,170,172 were 
derived from univariate methods (refer to Olivieri et al.173 for additional information).  
Net analyte signal theory involves the extraction of a particular portion of signal from the 
remaining data; it separates information relevant to a particular factor (e.g., chemical 
constituent) from the residual interfering elements.  The NAS is useful for quantification 
because, by definition, it is orthogonal to the remaining factors within the calibration 
data.  Multiple algorithms are available to estimate the NAS.  Comprehensive reviews 
detailing net analyte signal theory and its mathematics can be found elsewhere.150,169-
173,175-181   
For this work, the net analyte signal was calculated using the formula developed 
by Bro and Anderson178  
 ( ) ( ) TTii bbbbxNAS ⋅⋅⋅⋅= −∧ 1  (6.1) 
where, xi is a sample spectrum from matrix X and b is a column vector of the regression 
coefficients for X.  All equations herein use X to represent spectral matrices; bolded 
characters other than X, e.g., y, and NAS, represent vectors, and italicized characters, 
e.g., x and y, represent scalars.  Additionally, the notation ||x|| signifies the Euclidean 
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norm of a vector and the superscript T indicates the transpose of a vector.  Principal 
components regression (PCR) or partial least-squares (PLS) regression are common 
techniques used to estimate b.160  The matrix X is generally corrected for the mean; 
therefore, NAS outputs are mean-centered.  Solutions can be rescaled to their original 
range using the vector of means from the centering operation of X.  Net analyte signal 
can also be represented as a scalar using the equation169 
 
∧∧ = iiNAS NAS   (6.2) 
This operation does not reduce the information contained by the net analyte signal.169  
Once the NAS has been determined, multivariate figures of merit can be estimated.   
The objectives of this work were twofold: (1) to assess the utility of net analyte 
signal theory for the determination of figures of merit and (2) to apply NAS theory for 
comparing performance of NIR reflectance and transmittance spectroscopy.   
6.2 Materials and Methods 
6.2.1 Experimental Design 
 A fully-balanced, quaternary mixture design comprised of anhydrous theophylline 
(Lot No. 92577, Knoll AG, Ludwigshafen, Germany), Lactose 316 Fast Flo NF 
Monohydrate (Lot No. 8502113061, Hansen Labs, New Berlin, WI), microcrystalline 
cellulose (MCC, Avicel PH-200, Lot No. M427C, FMC BioPolymer, Mechanicsburgh, 
PA), and soluble starch GR (Lot No. 39362, EMD Chemicals Inc., Gibbstown, NJ) was 
generated.  The approximate median particle size of the theophylline, lactose, MCC, and 
starch (reported by documentation from their respective suppliers), was 90, 100, 180, and 
17 microns, respectively.  No further analyses or operations were performed on the 
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materials to establish or modify the particle size distribution.  Twenty-nine design points 
were chosen to cover a wide range in all constituents and to remove any possibility of 
factor aliasing (Table 6.1).  Analysis of the mixture covariance matrix (not shown) 
demonstrated the design is balanced in all directions, giving equal emphasis to all 
constituents. 
Table 6.1. Composition design.   
Design 
Point 
Anhydrous 
Theophylline 
(w/w) 
Lactose 
Monohydrate 
(w/w) 
MCC 
(PH200) 
(w/w) 
Soluble 
Starch 
(w/w) 
1 0.600 0.200 0.200 0.000 
2 0.400 0.400 0.200 0.000 
3 0.200 0.600 0.200 0.000 
4 0.400 0.200 0.400 0.000 
5 0.200 0.400 0.400 0.000 
6 0.200 0.200 0.600 0.000 
7 0.600 0.200 0.000 0.200 
8 0.400 0.400 0.000 0.200 
9 0.200 0.600 0.000 0.200 
10 0.600 0.000 0.200 0.200 
11 0.400 0.200 0.200 0.200 
12 0.200 0.400 0.200 0.200 
13 0.000 0.600 0.200 0.200 
14 0.400 0.000 0.401 0.200 
15 0.200 0.200 0.400 0.200 
16 0.000 0.400 0.400 0.200 
17 0.200 0.000 0.600 0.200 
18 0.000 0.200 0.600 0.200 
19 0.400 0.200 0.000 0.400 
20 0.200 0.400 0.000 0.400 
21 0.400 0.000 0.200 0.400 
22 0.200 0.200 0.200 0.399 
23 0.000 0.400 0.200 0.400 
24 0.200 0.000 0.400 0.400 
25 0.000 0.200 0.400 0.400 
26 0.200 0.200 0.000 0.600 
27 0.200 0.000 0.200 0.600 
28 0.000 0.200 0.200 0.600 
29 0.250 0.250 0.250 0.250 
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6.2.2 Compact Production 
Materials for each design point mixture were dispensed by weight into 25 mL 
glass scintillation vials (Data Range, Model No. AX504DR, Mettler Toledo, Columbus, 
OH) in accordance with the experimental design.  The materials were mixed for 5 minute 
cycles by placing them on the rotating drive assembly of a Jar Mill (US Stoneware, East 
Palestine, OH, USA).  Following each blending iteration, a NIR reflectance spectrum was 
acquired directly through the bottom of the glass (FOSS NIRSystems 5000, FOSS 
NIRSystems, Inc., Laurel, MD).  Using the constituent concentrations as reference data, 
an ad hoc partial least-squares II (PLS-2) calibration was constructed after each blending 
cycle to evaluate homogeneity.  Mixtures were assumed to be homogeneous when further 
mixing failed to yield an increase in the calibration’s coefficient of determination.   
The mixtures from each design point were then subdivided and compacted at 5 
pressures (67.0, 117.3, 167.6, 217.8, 268.1 MPa) on a Carver Automatic Tablet Press 
(Model 3887.1SD0A00, Wabash, IN) using a 13 mm die and flat-faced punches.  The 
dwell time was set to 10 seconds.  Six compacts were produced per design point, with the 
sixth compact’s compaction pressure randomly chosen from one of the five possible 
levels.  The compaction order was randomized to minimize heteroscedasticity of 
experimental error.  In total, 174 compacts were produced with a nominal target weight 
of 800 mg per compact.  Preparation and compaction occurred over a three day period, 
after which the compacts were kept in sealed scintillation vials for 15 days prior to 
spectroscopic analyses to compensate for any radial and/or axial expansion.    
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6.2.3 Data Acquisition, Instrumentation, and Software 
   Near-infrared reflectance measurements for both sides of each compact were 
acquired using a scanning monochromator instrument, equipped with a Rapid Content 
Sampler, over the wavelength range of 1100 – 2498 nm at a 2 nm increment, averaging 
32 scans (FOSS NIRSystems 5000-II, Vision version 2.00, FOSS NIRSystems, Inc., 
Laurel, MD).  Prior to spectral acquisition, the compacts were positioned via the 
centering iris standard on this instrument.  Two ad hoc partial least-squares II (PLS-2) 
calibrations, using the constituent concentrations as reference data, were constructed from 
reflectance spectra corresponding to a particular surface of the compacts.  Due to the 
subtle differences in calibration accuracy, measurements pertaining to only one side of 
the compacts were used.   
Transmittance measurements were acquired on a scanning monochromator 
instrument equipped with an InSightTM Tablet Analyzer over the wavelength range of 600 
– 1898 nm at a 2 nm increment, averaging 32 scans (FOSS NIRSystems 6500, Vision 
version 2.00, FOSS NIRSystems, Inc., Laurel, MD).  Samples were positioned via a 
tablet holder suited for compacts ~14.5 mm in diameter.  Subsequent to acquisition, the 
wavelength range of the transmittance spectra was truncated to 800 – 1400 nm. 
Reflectance and transmittance data were expressed as log (1/R) and log (1/T), 
respectively.  All spectral data were analyzed in the Matlab environment (version 7.1, 
The MathWorks, Natick, MA) using the PLS_Toolbox (version 3.0, Eigenvector 
Research, Inc., Manson, WA) and software routines developed at Duquesne University 
Center for Pharmaceutical Technology (DCPT).   
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6.2.4 Partial Least-Squares Analysis 
 NIR reflectance and transmittance data were analyzed separately but in an 
identical fashion.  Partial least-squares regression122 was used via the SIMPLS 
algorithm123 to relate spectroscopic response to concentration for each constituent on an 
individual basis.  Compacts lacking the particular constituent being analyzed were 
omitted for the analysis as analyte concentration is incorporated in the denominator of 
some figures of merit calculations.  Thus, the calibration data sets were unique for each 
analysis.   
Preprocessing routines, including standard normal variate (SNV) scaling, 
detrending, derivatives, and combinations of the preceding were tested.124  Assessment of 
the most effective data pretreatment method was made based on a minimization of 
“batch-wise” cross-validation error, where a batch is defined by a compaction level.  
Within each cross-validation iteration, compacts produced at a specific pressure were 
removed, a calibration was constructed, and the concentrations of the omitted samples 
were predicted by the temporary model.  This process was iterated until all of the samples 
had been predicted, thereby allowing for the determination of the root-mean-standard 
error (RMSE).  The RMSE for cross-validation (RMSECV) and calibration (RMSEC) 
were calculated using the formula 
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where iy , iyˆ , and n are the measured concentration, the predicted concentration, and the 
number of samples for the current data set, respectively.  According to ICH guidelines, 
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accuracy expresses the agreeability between reference and predicted values,208 and thus, 
RMSEC and RMSECV indicate the accuracy of the particular calibration.   
6.2.5 Multivariate Figures of Merit 
 Upon determining the optimum calibration model, the PLS regression vector can 
be used to determine the net analyte signal according to equations (6.1) and (6.2).  Net 
analyte signal is the basis for calculation of numerous figures of merit, including 
sensitivity, analytical sensitivity, selectivity, signal-to-noise ratio, and limit of detection 
and are estimated for each sample (compact) according to the following formulae. 
Sensitivity characterizes signal intensity as a function of analyte concentration.  
Larger sensitivities signify an enhanced instrumental response to a given change in 
concentration.169,170  Sensitivity is calculated as169,173,177  
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where i
∧
SEN  is the vector of sensitivities for each instrument variable, i
∧
NAS  is the net 
analyte signal vector, and iy  is the measured concentration for the i
th sample.  Sensitivity 
is reported in units of instrument intensity per concentration.  For the work herein, 
measured concentrations were autoscaled before applying equation (6.4).  It is also 
possible to express sensitivity as a univariate statistic by taking the Euclidean norm of the 
sensitivity vector  
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where 
∧
iSEN is the univariate measure of sensitivity for the i
th sample.177,180  For this 
work, sensitivity is reported as the mean of the univariate sensitivity values for the 
particular data set. 
Given that equation (6.4) utilizes instrument intensity, sensitivity of multiple 
devices is directly comparable only when they operate under the same fundamental 
principles (and units of measure).  Considering this limitation, the statistic analytical 
sensitivity (γ) was developed to provide an impartial assessment between dissimilar 
analytical techniques.180  Analytical sensitivity is calculated as 
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where 
∧
SEN and δr are the mean of the sensitivity values under consideration found using 
equation (6.5) and a measure of instrumental noise, respectively.  Analytical sensitivity is 
reported in units of inverse concentration.  δr was estimated as the mean standard 
deviation of iNAS
∧
 (for the component under consideration) of four compacts widely 
varying in constituent concentrations.  The compacts were scanned once a day for six 
consecutive days.  Additionally, this figure of merit provides a means to estimate the 
minimum discernible concentration difference for the dynamic range modeled (γ-1);180 
this is referred to as effective resolution.  
 Predicted values were determined according to the equation183  
   bXy ⋅=∧  (6.7) 
where X represents the spectral matrix and b is the PLS regression vector, which is 
dependent on the number of latent variables applied and the component being considered.  
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The predicted values were scaled to zero mean and unit variance; consequently, they 
must be rescaled prior to determining accuracy via equation (6.3).  It is important to note 
that all predicted values are independent of any NAS computations.   
 Selectivity is a dimensionless univariate measure of the fraction of instrumental 
signal remaining after accounting for spectral overlap; it is the proportion of signal 
unaffected by the interfering factors.169  This metric is calculated for each sample by169,181    
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where i
∧
NAS and ix are the NAS vector and the original spectrum for the i
th sample, 
respectively.  The magnitude of the selectivity parameter is determined by the degree of 
spectral interference associated with the particular analyte under consideration.  For the 
work herein, selectivity is reported as the mean of the selectivity values for the current 
data set.   
 Signal-to-noise ratio is one of the most important metrics for the general 
comparison of methods and, using net analyte signal theory, is calculated as169 
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where iNAS
∧
 is the scalar representation of the NAS vector, and δr was estimated as the 
mean standard deviation of the predicted concentrations (for the component under 
consideration) of four tablets broadly varying in constituent concentrations (i.e., the same 
four tablets previously used).  Linear regression was performed between measured 
concentration and the univariate NAS values to estimate scale (a1) and offset (ao) 
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coefficients to convert NAS scalars to units of concentration.  Thus, S/N is a 
dimensionless metric specific to the current application. 
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Signal-to-noise ratio is reported in this document as the mean of the S/N values for all 
samples under consideration.     
 Considering the concentration range encompassed by the experimental design, 
limit of detection (LOD) is a valid figure of merit.  Limit of detection can be estimated 
by184    
 
m
kLOD Dσ=  (6.10) 
where kD is the statistical confidence factor (here, kD = 3), m is the slope of a univariate 
classical least-squares fit of the predicted and reference data, and for this work, σ and δr 
were calculated using the same procedure.  A value of 1.0 was assumed for m in all 
computations given that the slopes of the predicted versus measured plots were not 
significantly different from unity.   
6.2.6 Precision Statistics  
Repeatability and intermediate precision were determined according to ICH 
guidelines.208  These statistics function as estimates of precision and were reported as the 
standard deviation of predicted concentrations for the corresponding repeat 
measurements.  Precision statistics were calculated using the randomly-chosen design 
point comprised of 20% theophylline, 20% lactose, 0% MCC, and 60% starch, 
compacted at a pressure of 167.6 MPa.  Repeatability, a measure of short-term sampling 
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error, was determined without repositioning of the compact between successive scans, as 
well as by removing and subsequently re-centering the compact prior to spectral 
acquisition.  Six scans for each repeatability test were collected consecutively on the 
same day.  Intermediate precision, which should incorporate typical variations such as 
between analysts and days, was assessed by scanning the compact once a day for six 
consecutive days.  All precision data were collected by the same analyst. 
6.3 Results and Discussion 
6.3.1 Wavelength Selection Criteria 
 The raw NIR response for all 174 compacts is shown in Figure 6.1 for both the 
reflectance and transmittance geometries.  Mathematical assessment is necessary to 
establish whether or not the entire wavelength range is useful for the prediction of 
constituent concentrations.  While multiple methods for the selection of optimum 
wavelength ranges are available (e.g., moving-window algorithms, manual trial and error 
truncation), this work employed correlation vectors to establish if truncation was 
warranted.  Specifically, the correlation between spectral response and component 
concentration was assessed for each constituent across all wavelengths; only samples 
corresponding to the calibration data sets were considered.  This procedure yields a full-
spectrum correlation vector for each constituent (Figure 6.2).    
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Figure 6.1. Plots of raw reflectance (a) and transmittance (b) spectra for all 174 compacts. 
 
Figure 6.2. Correlation vectors for the reflectance (a) and transmittance (b) instruments illustrating the 
correlation between instrument intensity and concentration at each wavelength. 
 Wavelength regions for calibrations should be carefully selected.  Figure 6.2 
illustrates that the low and high wavelength regions contain meaningful correlations for 
anhydrous theophylline.  Therefore, the entire wavelength range was utilized for the 
reflectance data.  As for the transmittance measurements, Figure 6.2 illustrates that the 
low and high wavelength extremes are not informative.  Furthermore, the transmittance 
spectra in Figure 6.1 appear to be saturated at higher wavelengths, consistent with the 
unstable regions of the correlation vector (~ 1400nm).  Saturation can be attributed to 
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sample thickness (mean = 4.387 mm) in combination with the general increase in 
absorption coefficient that accompanies an increase in wavelength;209 this results in low 
transmittance values.  For these reasons, the transmittance wavelength range was 
truncated to 800 – 1400 nm.   
6.3.2 Model Development 
 All predicted values are independent of any net analyte signal mathematics 
employed.  Savitsky-Golay first-derivative preprocessing185 (eleven point smoothing and 
second-order polynomial) was used for the reflectance spectra, while a combination of 
first-derivative preprocessing (three point smoothing and second-order polynomial) and 
linear detrending was chosen for the transmittance spectra based on the minimization of 
cross validation error.  Model rank was determined (Figure 6.3) using plots of RMSECV 
and RMSEC versus the number of PLS latent factors.  The optimum number of factors 
was selected based on the inflection point of incremental RMSE (or variance) captured, 
also considering the agreement between RMSECV and RMSEC values.  Model 
dimensionality was further justified according to the degrees of freedom varying within 
the experimental design.   
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Figure 6.3. Plot of RMSEC and RMSECV versus the number of PLS factors selected to model anhydrous 
theophylline concentration using reflectance (a) and transmittance (b) spectra. 
For both reflectance and transmittance data, three latent variables were required to 
effectively model anhydrous theophylline concentration, while four latent variables were 
necessary for lactose monohydrate, MCC, and soluble starch.  Calibration is 
demonstrated by the composite constituent concentration plot (Figure 6.4), which 
assesses all components simultaneously.  The specificity of the calibration models is 
assessed by comparing the agreement between the regression vectors and the pure 
component spectra (Figure 6.5).  Comparable correlations were observed for the other 
three constituents (plots not shown). 
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Figure 6.4. Plot of predicted versus measured concentration for reflectance and transmittance data.  Circles 
symbolize the 50th percentile, while the upper and lower asterisks represent the 25th and 75th percentiles, 
respectively.  Transmittance data were offset 10 percent along the ordinate axis to facilitate viewing.  The 
accuracy of all constituents is represented simultaneously. 
 
Figure 6.5. Plots containing the pure component spectrum (upper dashed vector), the PLS regression vector 
(lower bold vector), and the net analyte signal (black) and interference (grey) vectors for each calibration 
sample, for anhydrous theophylline.  Reflectance (a) and transmittance (b) data were scaled to zero mean 
and unit variance, and were offset, to facilitate viewing. 
Subsequent to model selection, the PLS regression vectors were used to determine 
the net analyte signal for each constituent.  The net analyte signal and interference 
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vectors for each calibration sample are plotted in Figure 6.5 for both the reflectance and 
transmittance geometries.  Contributions of spectral variance, whether from the 
constituent itself or the other interfering elements, can be observed with this plotting 
scheme.  Additionally, regions enhancing or suppressing the sensitivities, selectivities, 
and S/N ratios can be examined. 
6.3.3 Comparison of Reflectance and Transmittance Methods 
The calibration statistics detailing the performance of the reflectance and 
transmittance geometries for the quantification of constituent concentrations are provided 
in Table 6.2.  Both geometries offer similar results in terms of accuracy.  Among the four 
constituents, the anhydrous theophylline models were most accurate.  The most probable 
explanation for the enhanced accuracy of anhydrous theophylline is its pure component 
orthogonality, which will be discussed in the following paragraphs.  Additionally, the 
ordering of calibration model accuracy for the different components was identical 
between the two instruments; however, anhydrous theophylline and lactose monohydrate 
were more accurately predicted by the transmittance measurements whereas MCC and 
soluble starch were more accurately assessed by the reflectance measurements.  The 
transmittance method may appear superior, as often times, more importance is placed on 
the prediction on API concentration, which in this system, is anhydrous theophylline.  
The negative consequences of this conclusion will be addressed shortly.  
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Table 6.2. Calibration statistics and figures of merit summarizing method performance for the reflectance and transmittance NIR instruments.   
Data Type Reflectance Transmittance 
Method SIMPLS 
Preprocessing 1st Derivative (11,2,1)a 1st Derivative (3,2,1)a and Detrend 
Latent Variables 3 4 4 4 3 4 4 4 
Component Theophylline Lactose MCC Starch Theophylline Lactose MCC Starch 
R2 - Cal 0.962 0.951 0.919 0.952 0.992 0.952 0.890 0.928 
R2 - CV 0.955 0.942 0.902 0.941 0.992 0.933 0.855 0.909 
RMSEC (%) 2.7 3.1 4.0 3.1 1.2 3.1 4.7 3.8 
Accuracy RMSECV (%) 3.0 3.4 4.4 3.4 1.3 3.7 5.4 4.3 
Repeatability - w/o repositioning (%) 0.01 0.16 0.16 0.02 0.03 0.37 0.34 0.36 
Repeatability - w/ repositioning (%) 0.07 0.10 0.36 0.46 0.11 0.22 0.56 0.80 
Precision  Intermediate (%) 0.11 0.16 0.52 0.66 0.12 0.16 0.58 0.46 
Sensitivity (Instrument Intensity / %) 0.02 0.01 0.01 0.01 0.10 0.03 0.02 0.03 
Analytical Sensitivity (1 / %) 126.36 82.47 37.09 31.18 32.28 39.54 13.34 16.12 
Effective Resolution (%) 0.01 0.01 0.03 0.03 0.03 0.03 0.07 0.06 
Selectivity (unitless) 0.59 0.33 0.24 0.27 0.61 0.23 0.15 0.20 
Signal-to-Noise (unitless) 282.40 189.88 87.23 72.14 74.20 91.32 32.73 36.59 
Limit of Detection (%) 0.33 0.50 1.08 1.31 1.27 1.04 2.89 2.58 
aParanthetical data corresponds to window width, polynomial order, and derivative order, respectively.   
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 Attempts to partition sources of variance, including instrumental noise, sample 
repositioning error, and instrumental drift, were made according to the ICH guidance on 
the validation of analytical procedures.208  The variation in sample repositioning limits 
the performance of both modes.  Issues of sample inhomogeneity amplify the effects of 
sample repositioning error; however, its influence can be suppressed through sample 
averaging.  The data in Table 6.2 suggest that the error associated with sample 
repositioning was not fully captured due to the unanticipated trend in the precision 
statistics.  It is expected that the error of repeatability without repositioning would be 
lower than repeatability with repositioning, which should be lower than intermediate 
precision, as each statistic consecutively includes additional factors that are projected to 
increase precision error.  The inclusion of additional data (e.g., scans, repositions, 
scientists) may help to clarify this issue.  Issues such as this must be adequately addressed 
before comparing methods for possible deployment. 
The conventional accuracy and precision data provide a reasonable means of 
characterizing these two methods; however, this effort can be enhanced with the 
consideration of multivariate figures of merit.  Unlike previous FOM applications where 
sensitivities were not directly comparable due to dissimilar measurement technologies,150 
the sensitivity values reported in Table 6.2 can be compared, because both the reflectance 
and transmittance spectrometers measure sample response in absorbance intensity.  While 
the transmittance measurements were more sensitive for all constituents, the order of 
decreasing sensitivity for both geometries was anhydrous theophylline, lactose 
monohydrate, soluble starch, and MCC.  
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Instrumental noise altered the constituent rank ordering for analytical sensitivity.  
The highest analytical sensitivity for the transmittance method (lactose monohydrate) was 
roughly comparable to the lowest analytical sensitivity for the reflectance data (soluble 
starch).  This illustrates the power of the analytical sensitivity metric, even when the 
instruments operate using the same fundamental principles, as the significance of 
instrumental noise (i.e., sample repositioning) on the transmittance data may have been 
otherwise overlooked.   
The trend for component selectivity mirrors that of sensitivity.  It is expected that 
adequate sensitivity yields acceptable selectivity and equally, inadequate sensitivity 
generates poor selectivity.  In situations where sensitivity is insufficient, attempts to 
enhance selectivity will be ineffective.  The anhydrous theophylline pure component 
spectrum is the most orthogonal to the interfering (spectral) elements (Figure 6.6).  This 
orthogonality is evident in not only the improved sensitivity, but also the selectivity 
statistics.  The inherent collinearity between lactose monohydrate, microcrystalline 
cellulose, and soluble starch most likely resulted in the reduced selectivity. 
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Figure 6.6. Plots of raw reflectance (a) and transmittance (b) pure component spectra.  Each spectrum 
represents the mean response of twenty-seven pure component samples compacted over the range of 67.0 - 
268.1 MPa. 
  The rank order for S/N ratio follows that of analytical sensitivity.  Although the 
transmittance measurements were consistently more selective, the reduction in sample 
repositioning error (analogous to noise) associated with the reflectance method results in 
greater S/N ratios for all constituents.   
While the statistics summarizing the accuracy of the two methods were generally 
similar, the disparate performance between the reflectance and transmittance geometries 
is apparent when considering analytical sensitivity, S/N ratio, and LOD.  Upon 
examination of these statistics, the superiority of the reflectance method for the given 
application is evident.  Although the transmittance method was more accurate and 
selective for anhydrous theophylline, it was outperformed by the reflectance method in 
all other figures of merit.  Considering only the comparable predictive performance of 
lactose monohydrate, microcrystalline cellulose, and soluble starch, one may have 
incorrectly selected the latter method due to its increased accuracy for anhydrous 
theophylline.  The reduction in performance is most likely a consequence of the larger 
sampling position error observed for the transmittance geometry.  It is anticipated that 
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positioning error could be mitigated by obtaining a tablet holder intended for 13 mm 
samples.  At the time of spectral acquisition, an optimized holder was unavailable.  
However, it remains a possibility that the transmittance instrument may be inherently 
noisier (larger δr).   
Multivariate figures of merit provide an additional degree of method 
characterization that cannot be gained from calibration accuracy statistics; however, other 
factors should be taken into account prior to method deployment.  Logistical issues such 
as cost of implementation, compatibility with existing process/production equipment, and 
ease of transferability, may dictate the selection.  Although a particular method may 
outperform another in terms of calibration accuracy, ancillary performance and 
operational issues should be considered when making evaluations.   
6.4 Conclusions 
 The results of this work show that the evaluation of multivariate figures of merit 
provides a rigorous means of comparing the performance of reflectance and transmittance 
NIR spectroscopy for the nondestructive prediction of constituent concentrations within 
compact matrices.  The figures of merit analyses revealed performance factors that 
otherwise may have gone unobserved.  Both reflectance and transmittance geometries 
performed adequately when comparing the calibration accuracy statistics.  The precision 
studies, and more notably the figures of merit, highlight the limitations of the 
transmittance instrument for this specific system.  Performance limitations were most 
likely attributable to sample positioning error, which was present for both spectrometers, 
but was more detrimental to the transmittance method.  This work also emphasizes the 
platform that net analyte signal theory provides for the determination of figures of merit, 
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which are useful for the characterization of calibration performance.  While figures of 
merit are valuable for method characterization, additional logistical factors should be 
taken into consideration.      
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Chapter 7: Integration of Process Analytical Technology with 
Quality by Design to Control the Clinical Performance of a Model 
Drug Delivery System 
 
7.1 Introduction 
 The union between PAT and QbD was conceived some years back when the 
respective initiatives were under development.  Although each has an independent role in 
transitioning from the current to the desired state, the greatest benefits will come from 
synergistic efforts that integrate PAT and QbD.  Together, they are responsible for key 
tasks in establishing, overseeing, and ensuring pharmaceutical quality.   
Recent efforts to remold pharmaceutical quality in terms of risk by relating 
clinical attributes to production characteristics have transformed approaches to QbD 
(refer to Chapter 3).  While this work presented a comprehensive review of the changes 
that are to be expected for design space, little discussion was devoted to PAT or its 
integration within the revised QbD framework.  On-, in-, or at-line multivariate sensors 
are used extensively in a PAT environment, particularly to obtain a greater understanding 
of the process (and its associated components, including raw and in-process materials), 
and to ultimately control characteristics of the final product.  Applications such as these 
typically require chemometric modeling (calibration) to transform instrument signal into 
relevant data (e.g., API/excipient concentration, moisture content, incoming process 
parameter).  Specific information regarding the process (determined via process models) 
can be used adjust the process (via feedforward or feedback control) to obtain a desired 
response.   
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Within the new QbD paradigm, the desired response is final product which 
demonstrates clinical performance as dictated by the design space.  As such, PAT will 
play an integral role in understanding how (explicitly) the process impacts clinical 
performance, and, subsequently, how to control the process such that final product meets 
the safety and efficacy constraints of the design space.  The objective of this study was to 
propose a hypothetical scenario that coupled PAT with QbD such that production could 
be maintained in a low-risk state. 
7.2 Materials and Methods 
 Data pertaining to 12 distinct wet granulation batches of the model theophylline 
tablets were utilized to construct the hypothetical scenario.  In addition to the 12 and 10 
units per batch that were sampled for dissolution and content uniformity testing, 
respectively, the crushing strength of 10 tablets was estimated for each batch by a 
diametric crushing test (ElizaTest 3+ Vision Tablet Testing System, Elizabeth-Hata 
International, North Huntingdon, PA).  A reflectance spectrum for both sides of each 
tablet was acquired before the tablets underwent the relevant destructive analyses.  
Reflectance was measured over the wavelength range of 1100 – 2498 nm at a 2 nm 
increment, averaging 32 scans (FOSS NIRSystems 5000-II, Vision version 2.00, FOSS 
NIRSystems, Inc., Laurel, MD).   
 Calibration models were constructed using NIR reflectance data, expressed in 
absorbance units, of the 120 tablets (240 spectra) and the crushing strength measurements 
(MPa).  Partial least-squares regression122 was used via the SIMPLS algorithm123 to relate 
spectroscopic response to crushing strength.  Preprocessing routines, including standard 
normal variate (SNV) scaling, detrending, derivatives, and combinations of the preceding 
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were tested.124  The optimal calibration model was selected based on a minimization of 
cross-validation error.  Contiguous block cross-validation with a block size of 5 was used 
to generate the temporary cross-validation models.  Irrespective of the preprocessing 
routine(s) employed, spectroscopic data were mean-centered while reference data were 
scaled to zero mean and unit variance.  Model rank was chosen as the point where a rapid 
decline in the incremental variance captured was observed, cognizant of the expected 
feasible limit of dimensionality based on the factors varying within the design.  
Calibration efforts revealed that no data pretreatment was necessary.  Two latent 
variables were necessary to adequately model these NIR absorbance data for the 
prediction of tablet crushing strength.  The 288 spectra of the 144 tablets subjected to 
dissolution testing were projected onto the calibration model to predict their crushing 
strengths (i.e., testing data set); predictions were compared to the nominal values for each 
tablet as specified in the original design.117  Predicted and reference values were used to 
determine the root-mean-standard error (RMSE).  The RMSE for cross-validation 
(RMSECV), calibration (RMSEC), and testing (RMSET) were calculated using the 
formula 
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where iy  is the measured crushing strength, iyˆ is the predicted crushing strength, and n is 
the number of samples for the data set under consideration.  The calibration model is 
summarized in Table 7.1.   
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Table 7.1. Calibration summary statistics for the prediction of crushing strength.   
Data Type NIR (Reflectance) 
Method PLS 
Preprocessing Raw Spectra 
Latent Variables 2 
Component Crushing Strength 
R2CAL 0.836 
R2CV 0.770 
R2TEST 0.926 
RMSEC (MPa) 0.30 
RMSECV (MPa) 0.37 
RMSET (MPa) 0.20 
BiasCV (MPa) 0.043 
BiasTEST (MPa) -0.038 
 
 These data augment the available information content (i.e., Weibull shape and 
scale parameters, theophylline content) for the same tablets used in previous studies.  As 
a result of minor spectroscopic differences detected between the two tablet surfaces, the 
predicted crushing strengths varied slightly for the same tablet.  Thus, 288 distinct 
responses were available for the 144 tablets.  These data were then used to determine if 
an underlying relationship existed between crushing strength and T63.2.  Modeling efforts 
utilized standard least-squares regression.  Transformations to both the predictor 
(crushing strength) and the predicted (T63.2) variables were explored.     
7.3 Results and Discussion 
7.3.1 Relationship between Crushing Strength and the Weibull Scale Parameter 
 Standard least-squares regression revealed a weak correlation between crushing 
strength and T63.2 when all 288 responses were considered simultaneously (r = -0.3217).  
As previous work has demonstrated,210 however, varying constituent concentrations, as 
dictated by the experimental design, can mask (spectroscopically and non-
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spectroscopically) underlying relationships involving crushing strength (see Chapter 4).  
When the relationship was re-evaluated with the relative contributions of each component 
held constant, a much stronger correlation was observed (r = 0.9188); this was 
determined using 72 of the 288 responses.  This was equivalent to assessing one 
formulation, which was tableted with the distinct purpose of obtaining several target 
crushing strength values.  The function describing the relationship between these two 
variables was determined to be 
 ( ) 043.052.02.63 −⋅= StrengthCrushingT  (7.2)  
7.3.2 Integration of PAT with QbD 
 Simulation revealed that both inefficacy and toxicity risk concerning the model 
solid oral dosage system were a function of, among other factors, content uniformity and 
dissolution variability (refer to Chapters 2 and 3).  This knowledge was used to generate 
process-independent design spaces for the model system, which explicitly defined the 
clinically acceptable combinations of theophylline (% nominal) and T63.2 (hours).  Based 
on the findings of the previous studies, the following discussion focuses on integrating 
PAT at several strategic stages prior to final product release.    
 Given the relationship between content uniformity and risk, blending of the 
formulation presents the first viable opportunity to monitor heterogeneity.  Numerous 
non-invasive analytical techniques have proven useful for evaluating blend uniformity 
(e.g., NIR, Raman).  Although uniformity, at least so much as in USP <905>, is solely 
expressed in terms of the API, process modeling can easily be extended to include 
various excipients.   
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 Taking advantage of the correlation between crushing strength and T63.2, 
feedforward control can be used to adjust the crushing strength of the final tablets to 
compensate for the clinical risk associated with various levels of content uniformity.  
Therefore, the PAT sensor(s) informs the control model (via the process model) of the 
content uniformity, which then sends a set-point(s) to adjust the compaction pressure 
(and other pertinent process variables) to modify the release profile and ultimately 
regulate clinical performance.  Since other downstream unit operations have the potential 
to affect the content uniformity estimated during blending (e.g., wet granulation, milling, 
tableting) additional calibrations can be deployed to monitor uniformity and/or crushing 
strength of the product post-tableting.  These data can be used to update or even adjust (in 
real-time) the process and/or control models, as necessary.  Various factors, including 
spectrometer drift, machinery and/or tooling deterioration, or a change in raw materials, 
could render the use of feedback control invaluable.  Ideally, however, the majority of 
these factors would be accounted for prior to model deployment.  The PAT system, 
therefore, monitors and controls the attributes which are critical-to-quality to ensure that 
the final product lies within the design space.  The integration of PAT and QbD is 
depicted in Figure 7.1.   
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Figure 7.1. Schematic illustrating the integration of PAT with QbD to control clinical performance. 
7.4 Conclusions 
PAT is an important component of QbD applications.  The methodologies 
developed in the previous phases of this dissertation were used as the basis to propose a 
hypothetical scenario that coupled PAT with QbD such that production could be 
maintained in a low-risk state.  PAT can be integrated to monitor and control production 
to ultimately ensure that the critical-to-quality attributes of the final product lay within 
the design space bounded by clinical risk.  Feedfoward control is proposed to adjust 
tableting such that dissolution would compensate for risk imparted by various levels of 
content uniformity imposed by upstream processing.  Additionally, feedback control 
could be utilized to retrospectively update or modify the process and/or control models, 
as needed.  Multivariate modeling is an indispensible component of PAT.  Future studies 
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should focus on the effects of model uncertainty and how it propagates through QbD 
methodologies to ultimately impact estimates of clinical performance.   
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Chapter 8: Summary 
 Despite recent advances, the pharmaceutical industry has failed to adequately 
integrate innovative approaches into its drug discovery and development programs.  A 
2003 Wall Street Journal article declared that the “pharmaceutical industry has a little 
secret: Even as it invents futuristic new drugs, its manufacturing techniques lag far 
behind those of potato-chip and laundry-soap makers.”  “To the FDA, with its mission of 
protecting patient safety, it seemed more important to manufacture drugs precisely to 
specification, using tried-and-true systems, than to latch on to the latest in manufacturing 
trends.”  Furthermore, “in other industries, manufacturers constantly fiddle with their 
production lines to find improvements.  But FDA regulations leave drug-manufacturing 
processes virtually frozen in time.”211  The FDA has since stepped forward to accept 
partial responsibility for the current state of affairs and introduced or endorsed numerous 
regulatory initiatives, reports and guidances intended to modernize the Agency’s as well 
as manufacturers’ approach to drug discovery and development.  This new approach is 
centered on risk-based decisions. 
 While the new documents were a colossal step in the right direction, multiple 
definitions and ambiguous interpretations of “pharmaceutical quality,” an element 
fundamental to every facet of the regulatory, pharmaceutical, and consumer industries, 
were at odds with the modernization efforts.  Mindful of the misnomer, requests were 
made by a few pioneering individuals to re-define pharmaceutical quality in terms of risk 
by relating clinical attributes to production characteristics.  This work was predicated on 
this very concept.     
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 The predominant focus of this dissertation was to assemble a platform capable of 
evaluating the effects of product and patient variability on clinical performance in silico.  
To the best of the author’s knowledge, this is the first tool of its kind.  Theophylline was 
selected as the model drug for these studies on the basis of its narrow-therapeutic index 
and the preponderance of available literature data detailing this compound.  Population 
data specifying asthma rates, anthropometric measurements, and other physiological, 
pathophysiological and behavioral factors known to influence treatment with 
theophylline were accrued and used to generate a hypothetical asthmatic patient 
population.  Concurrently, in vitro-in vivo correlation, pharmacokinetic, and 
pharmacodynamic data/models for theophylline were amassed and used to define the 
architecture of the risk simulation platform. 
 Specifics regarding the structure of the risk simulation platform were described in 
great detail.  Its framework utilized Monte Carlo simulation and probabilistic risk 
assessment to evaluate the impact that manufacturing variability had on the clinical 
performance of model extended-release theophylline tablets.  Clinical performance was 
evaluated through quantitative risk scores for inefficacy and toxicity, which was made 
possible by utilizing a probabilistic pharmacodynamic model that expressed the 
probabilities of each adverse event as a function of theophylline plasma concentration. 
 Production data for a solid oral theophylline dosage system that was formulated, 
processed, and compacted prior to the conception of this work was used to generate 
estimates of inter- and intra-batch content uniformity and dissolution variability.  These, 
along with estimates of patient compliance (both percentage of doses consumed and 
adherence to the dosing regimen), were used to evaluate their impact on clinical 
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performance in the simulated asthmatic population.  A total of 6 factors were studied via 
two full factorial experimental designs to determine which factor(s) posed a significant 
risk of inefficacy or toxicity.  Sensitivity analyses revealed that patient compliance and 
intra-batch content uniformity had a significant impact on inefficacy and toxicity risk 
scores.  Intra-batch content uniformity, therefore, was identified as a critical quality 
attribute.  The results of these initial risk simulations demonstrated the conditional risk of 
manufacturing variability on the clinical performance of the model drug delivery system.    
 With the framework of the risk simulator solidified and the relationship between 
product attributes and risk established, the next phase of this research explored the 
regulatory undertones of re-defining quality.  This research initially addressed the 
potential limitations of the final product specifications utilized in the USP <711> and 
<905> methods for dissolution and content uniformity, respectively.  A series of risk 
simulations were conducted to highlight the fact that the univariate specifications, upon 
which the USP methods are centered, disregard potential multivariate and nonlinear 
interactions that affect clinical performance.  The simulations revealed that in-
specification product demonstrated an extensive range of inefficacy and toxicity risk 
scores, magnitudes of which were in excess of those determined to be significant in the 
sensitivity analyses.  Furthermore, the specifications were not consistently sensitive to the 
lots which offered the utmost safety and efficacy.  These results suggested that the final 
product release tests were unable to adequately appraise final product quality as it related 
to clinical performance of the model drug delivery system.   
 The same series of risk simulations were also used to examine the implications 
that re-casting quality might have on design space initiatives.  Contrary to the current 
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approach to constructing a design space, re-defining quality in terms of risk by relating 
clinical attributes to production characteristics offers the ability to generate a hyperspace 
that is explicitly bounded by estimates of clinical performance.  Given the new approach 
to design space, performance-based quality specifications were proposed to be the link 
between critical quality attributes and clinical performance.  The performance-based 
quality specifications, which are delineated via the risk simulation platform, define a 
process-independent design space.  Design spaces that were conditioned on quantitative 
estimations of inefficacy and toxicity risk were generated for the model system.  
Although critical-to-quality attributes are compulsory inputs to a design space, attributes 
which interact with those determined to be critical should also be included.  A design 
space that defines the relationship between quality attributes and clinical performance can 
then be applied to specific processes using process models as transfer functions to 
ultimately link process parameters to clinical performance. 
 The last segment of this research briefly addressed the role that Process Analytical 
Technology will play in implementing performance-based quality specifications.  
Multivariate data analysis has been and will continue to be a key factor in coupling 
Process Analytical Technology and Quality by Design.  Portions of this dissertation 
explored routines for evaluating the performance of predictive models, particularly 
calibrations developed using on-, in-, or at-line multivariate sensors.  As these types of 
models undoubtedly will be used to identify, predict, and control elements fundamental to 
linking manufacturing to clinical performance, their adequacy in terms of predictive 
performance must be accounted for.  Future research should be conducted to investigate 
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the impact that model uncertainty has on the generation of performance-based quality 
specifications. 
 This work described within this dissertation is significant in that it facilitates the 
transition of the pharmaceutical industry to the desired state.  The proposed concepts not 
only embrace the Process Analytical Technology and Quality by Design initiatives, they 
support the objectives of the Critical Path Initiative by adopting an innovative approach 
to pharmaceutical product development.  With a direct emphasis on clinical performance, 
manufacturers and regulators can more easily focus on controlling manufacturing in a 
manner commensurate with patient risk. 
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